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5ABSTRACT
Introduction: Combination antiretroviral 
therapy (cART) has decreased morbidity 
and mortality rates of individuals infected 
with human immunodeficiency virus type 
1 (HIV-1). Its use, however, is associated 
with severe metabolic adverse effects which 
increase the patients’ risk of conditions 
such as diabetes and coronary heart 
disease. Perhaps the most stigmatizing 
side effect of cART is lipodystrophy, i.e., 
the loss of subcutaneous adipose tissue 
(SAT) in the face, limbs and abdomen 
with concurrent accumulation of adipose 
tissue in the intra-abdominal and 
dorsocervical regions. The pathogenesis 
of cART-associated lipodystrophy remains 
unclear with a number of antiretroviral 
agents associated with its development, 
and a variety of mechanisms proposed 
to date. For example, nucleoside reverse 
transcriptase inhibitors (NRTI) have been 
suggested to induce lipoatrophy through 
mitochondrial toxicity. At present, there 
is no known effective treatment for 
cART-associated lipodystrophy during 
unchanged cART in humans. Promising in 
vitro data have, however, been published 
showing that uridine can abrogate NRTI-
induced toxicity in adipocytes.
Aims: The present studies were undertaken 
to elucidate whether i) cART as such or 
lipodystrophy associated with its use affect 
arterial stiffness; ii) lipoatrophic abdominal 
SAT is inflamed as compared to non-
lipoatrophic SAT; iii) abdominal SAT from 
patients with as compared to those without 
cART-associated lipoatrophy differs with 
respect to mitochondrial DNA (mtDNA) 
content, adipose tissue inflammation 
and gene expression, and if the NRTIs 
stavudine and zidovudine are associated 
with different degrees of lipoatrophic 
change; iv) abdominal SAT (lipoatrophic in 
lipodystrophy) differs from dorsocervical 
SAT (preserved in lipodystrophy) with 
respect to mtDNA content, adipose tissue 
inflammation and gene expression in 
patients with and without cART-associated 
lipodystrophy and v) oral uridine 
supplementation can revert lipoatrophy 
and the associated metabolic disturbances 
during ongoing stavudine or zidovudine 
–containing cART.
Subjects and methods: A total of 64 
HIV-1-infected cART-treated patients 
with (n=45) and without lipodystrophy/
-atrophy (n=19) of similar age, gender and 
body mass index were compared in a series 
of cross-sectional studies. A surrogate 
marker of arterial stiffness, heart rate 
–corrected augmentation index (AgIHR), 
was measured by pulse wave analysis. Body 
composition was measured by magnetic 
resonance imaging and dual-energy X-ray 
absorptiometry, and liver fat content by 
proton magnetic resonance spectroscopy. 
Gene expression and copy numbers of 
mtDNA in SAT were assessed by real-time 
reverse transcriptase polymerase chain 
reaction and/or microarray technique. 
Adipose tissue composition as well as 
signs of inflammation were assessed by 
histology and immunohistochemistry. 
Both dorsocervical and abdominal SAT 
were studied. The efficacy and safety 
of uridine for the treatment of cART-
associated lipoatrophy were evaluated 
in a randomized, double-blind, placebo-
controlled 3-month trial in 20 lipoatrophic 
cART-treated patients.
Results: Duration of antiretroviral therapy 
and the cumulative exposure to NRTIs 
and protease inhibitors predicted AgIHR 
independent of age and blood pressure. 
Time since HIV-1 diagnosis, severity of 
immunodeficiency or the presence of cART
-associated lipodystrophy did not affect 
AgIHR. Gene expression of macrophage 
markers and inflammatory cytokines 
was increased in the abdominal SAT of 
lipodystrophic as compared to that of non-
lipodystrophic patients, and was seen to 
correlate with liver fat content. Expression 
of genes involved in adipogenesis, 
triglyceride synthesis and glucose disposal 
was significantly lower and of those 
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6involved in mitochondrial biogenesis, 
apoptosis, inflammation and oxidative 
stress significantly higher in the abdominal 
SAT of patients with as compared to those 
without cART-associated lipoatrophy. 
Most changes were more pronounced in 
stavudine-treated than in zidovudine-
treated patients. Lipoatrophic abdominal 
SAT had significantly lower mtDNA 
content than the abdominal SAT of non-
lipoatrophic cART-treated patients. 
Expression of inflammatory genes was 
significantly lower in dorsocervical as 
compared to abdominal SAT. Neither 
adipose tissue depot had characteristics 
of brown adipose tissue. Despite being 
spared from lipoatrophy, the dorsocervical 
SAT of lipodystrophic cART-treated 
patients had lower mtDNA content than 
the phenotypically similar corresponding 
depot of non-lipodystrophic patients. The 
greatest difference in gene expression 
between dorsocervical and abdominal 
SAT, irrespective of lipodystrophy status, 
was in expression of homeobox genes that 
regulate transcription and cranio-caudal 
localization of organs during embryonal 
development. With regards to the clinical 
trial, uridine supplementation significantly 
increased the absolute amount of limb fat 
as well as its proportion of total fat. Lean 
body mass, liver fat content and markers 
of insulin resistance remained unchanged 
in both uridine and placebo groups. 
Conclusions: Long-term cART is associated 
with increased arterial stiffness and, 
consequently, with higher cardiovascular 
risk. Lipoatrophic abdominal SAT is 
characterized by inflammation, apoptosis 
and mtDNA depletion. However, as mtDNA 
is depleted even in the non-lipoatrophic 
dorsocervical SAT, lipoatrophy is unlikely 
to be caused directly by a decrease in 
cellular mtDNA content. Dorsocervical 
SAT of patients with cART-associated 
lipodystrophy is less inflamed than their 
lipoatrophic abdominal SAT, and does not 
resemble brown adipose tissue. The greatest 
difference in gene expression between 
dorsocervical and abdominal SAT is in 
expression of transcriptional regulators, 
homeobox genes, which might explain the 
differential susceptibility of these adipose 
tissue depots to cART-induced toxicity. 
Uridine supplementation is able to increase 
peripheral SAT in lipoatrophic patients 
during unchanged cART. 
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Introduction
INTRODUCTION
Since the introduction of combination 
antiretroviral therapy (cART) in the 
mid-1990s, morbidity and mortality 
rates of individuals infected with human 
immunodeficiency virus type 1 (HIV-1) have 
markedly decreased (265,307,315,321). 
However, with the spreading use of cART, 
various metabolic adverse effects have 
emerged (47,122). Cumulative exposure 
to cART has been demonstrated to be 
associated with increased incidence 
of myocardial infarction (108,109). 
Interestingly, the increase in relative risk of 
myocardial infarction could only partially 
be explained by conventional risk factors 
(108,109). The augmentation index, a non-
invasively measured surrogate marker 
of systemic arterial stiffness, is known to 
predict cardiovascular events and mortality 
independent of dyslipidemia and other 
confounders in subjects not infected with 
HIV-1 (227,420,421). Its value in explaining 
the increased cardiovascular risk beyond 
that attributable to conventional risk 
factors has not been previously assessed in 
HIV-1-infected patients.
One of the most readily apparent side 
effects of antiretroviral treatment is that 
of cART-associated lipodystrophy. This 
condition is characterized by the loss (i.e., 
lipoatrophy) of subcutaneous adipose 
tissue (SAT) in the face, limbs and trunk, 
with or without concurrent accumulation 
(i.e., hypertrophy) of adipose tissue in the 
intra-abdominal and dorsocervical regions 
(47,122,164,193). These changes in body 
fat distribution are often accompanied 
by other metabolic derangements such 
as hepatic steatosis, insulin resistance 
and dyslipidemia (47,122,164,193). Upon 
its recognition in the late-1990s, it was 
estimated that after a year of exposure 
to cART one out of every two patients 
suffered from at least one physical 
abnormality indicative of lipodystrophy 
(47). At present, despite the increasing 
availability of less toxic antiretroviral 
agents, cART-associated lipodystrophy 
remains the most common form of human 
lipodystrophy (39,114).
In recent years, much interest has been 
focused on unraveling the mystery of cART-
associated lipodystrophy. To date, several 
potential pathogenetic mechanisms have 
been proposed (25,43,53,100,268,422). 
One of the most popular hypotheses has 
been the so-called “mitochondrial toxicity 
theory” (25). This theory states that 
nucleoside reverse transcriptase inhibitors 
(NRTI), a class of antiretroviral drugs, 
inhibit mitochondrial deoxyribonucleic 
acid (DNA) polymerase γ (POLG), an 
enzyme responsible for replication 
of mitochondrial DNA (mtDNA) in 
adipocytes. Inhibition of this enzyme 
decreases mtDNA copy number, resulting 
in depletion of transcripts of mtDNA-
encoded genes such as those involved in 
electron transfer chain and adenosine 
triphosphate (ATP) production. This, 
in turn, leads to decreased lipogenesis, 
and to increased oxidative stress and 
apoptosis in affected adipocytes with the 
end result of adipose tissue inflammation 
and lipoatrophy (71,171,215). While this 
process may contribute to the development 
of lipoatrophy, the “mitochondrial toxicity 
theory” remains insufficient, as it does 
not explain why in cART-associated 
lipodystrophy adipose tissue atrophies 
in some anatomic locations, but remains 
preserved or even hypertrophies in others. 
Furthermore, there are no data comparing 
lipoatrophic and lipohypertrophic SAT 
from the same individual with cART-
associated lipodystrophy. 
Numerous therapeutic interventions, 
including thiazolidinediones (368) and 
leptin (206,275), have been attempted 
in an effort to alleviate cART-associated 
lipodystrophy. Results, however, have 
been disappointing. While modification of 
cART is currently recognized as the best 
choice to halt and revert lipoatrophy (367), 
there is no known effective treatment for 
cART-associated lipodystrophy during 
unchanged cART. Uridine has shown 
promise in vitro by reducing NRTI-
induced toxicity in adipocytes despite the 
15
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continued presence of toxic antiretroviral 
agents (414).
The ensuing review of literature 
will summarize the current knowledge 
of clinical features and pathogenetic 
mechanisms underlying cART-associated 
lipodystrophy, and will contrast the 
pathology inherent to this condition with 
the normal physiology of adipose tissue 
and insulin action in humans. The review 
will also recapitulate the already-explored 
and the yet-promising therapeutic options 
for the treatment of cART-associated 
lipodystrophy.
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Review of the Literature
REVIEW OF THE 
LITERATURE
1.  ADIPOSE TISSUE
1.1. Adipose tissue depots in 
humans
Approximately 10-50% of human body 
mass is composed of adipose tissue 
which can be divided into SAT and intra-
abdominal adipose tissue (IAT). An 
average person with a body mass index 
(BMI) of 20-30 kg/m2 has 10-30 kg of 
SAT and 0.5-4 kg of IAT (385). Women 
have significantly more SAT for a given 
body weight than men (385). There are 
two types of adipose tissue in humans, 
white and brown. White adipose tissue 
(WAT) constitutes the majority of adipose 
tissue within the body (65). Typical white 
adipocytes are unilocular and have few 
mitochondria, while brown adipocytes 
are multilocular and rich in mitochondria 
giving the tissue its typical appearance 
and coloration (65). Besides mature 
adipocytes, adipose tissue also contains 
preadipocytes, macrophages, endothelial 
cells, fibroblasts and leukocytes (432).
The main physiological function of 
WAT is to store free fatty acids (FFA) in the 
form of triglycerides through esterification 
to glycerol in times of energy surplus and 
release thereof via lipolysis during energy 
shortage. WAT also provides mechanical 
support and insulation to other organs. 
Furthermore, WAT is an active endocrine 
and paracrine organ that secrets factors 
involved in adipose tissue development 
and remodeling, regulation of food 
intake, energy expenditure and fat mass 
deposition, insulin sensitivity, lipid and 
cholesterol metabolism, angiogenesis 
and vascular function, as well as pro- and 
anti-inflammatory reactions and immune 
responses (112,316,432). 
In animals, the main function of brown 
adipose tissue (BAT) is thermogenesis, i.e., 
utilization of fat stores for generation of heat 
by uncoupling of ATP production (203). It 
was long believed that in healthy humans 
functional BAT exists only in infancy and 
is mainly located in axillary, deep cervical 
and perirenal sites, whereas interscapular 
depot, typical in rodents, was considered 
quantitatively unimportant (203). 
Recently, however, fluorodeoxyglucose 
positron emission tomography (FDG PET) 
studies in healthy adult humans have 
shown functional BAT to exist in cervico-
supraclavicular, para-aortic, paravertebral 
and suprarenal regions (73,283,399,410). 
In addition, islets of brown adipocytes 
have been found dispersed amid regular 
WAT in healthy adult humans (37,203). 
BAT has also been found in conditions 
such as hibernoma (24), a benign fatty 
tumor of BAT origin, and surrounding the 
capsule of pheochromocytoma (258), a 
neuroendocrine catecholamine-secreting 
adrenal tumor, although there is doubt 
whether the two processes are related or 
simply coincidental (255). The physiologic 
significance of BAT in adult humans 
remains unknown.
All WAT is not the same (8,406). 
Indeed, intra-abdominal adipocytes are 
smaller than subcutaneous ones (316,406). 
This difference could be a consequence 
of decreased FFA uptake following lower 
lipoprotein lipase (LPL) activity and 
triglyceride synthesis in intra-abdominal 
as compared to subcutaneous adipocytes 
(406). Furthermore, the rate of lipolysis is 
higher in IAT than in SAT (8). The intra-
abdominal depot is also more sensitive 
to the lipolytic effect of catecholamines 
and less so to the anti-lipolytic action of 
insulin than the subcutaneous depot (8), 
notwithstanding the similar number of 
adrenergic and insulin receptors in both 
regions (406). Hormone sensitive lipase 
(HSL) does not offer an explanation for 
the increased rate of lipolysis in IAT as 
compared to SAT, as its gene expression 
and protein activity is, if anything, lower 
in IAT than in SAT (406). Gene expression 
of adipose triglyceride lipase is also similar 
in IAT and SAT (17). Interestingly, reduced 
signal transduction through the insulin 
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receptor substrate (IRS) 1 –associated 
phosphatidylinositol-3-kinase (PI-3-kinase) 
pathway has been reported in IAT as 
compared to SAT (452). As insulin is a 
key modulator of gene expression (299), 
its reduced action in IAT is thought to 
affect expression of a number of relevant 
downstream genes. Indeed, mRNA 
concentrations of insulin-regulated 
genes such as glucose transporter protein 
4 (GLUT4), peroxisome proliferator-
activated receptor γ (PPARG) and leptin are 
lower in IAT than in SAT (207). Impaired 
insulin action could also contribute to 
decreased triglyceride synthesis and, thus, 
to small adipocyte size seen in IAT (406). In 
addition, IAT has been found to have higher 
expression of the inflammatory cytokine 
interleukin 6 (IL6), plasminogen activator 
inhibitor 1 (PAI1) and glucocorticoid 
receptors than SAT does (406). Findings 
of differentially regulated adipogenesis, 
increased lipolysis and inflammation in 
IAT compared to SAT have been verified 
by microarrays (30,413). These depot-
specific differences in molecular and 
physiological properties may explain as 
to why excessive IAT, which drains its 
secretions directly into the portal vein, 
appears to be more hazardous than SAT 
in terms of metabolic and cardiovascular 
complications (88,180). It should be noted, 
however, that arguments put forward in 
defense of IAT underscore the fact that 
only correlation, but not causality, has 
been demonstrated between accumulation 
of IAT and metabolic aberrations (105). 
1.2. Adipogenesis 
1.2.1. Adipogenesis of white adipose 
tissue
Molecular events of adipogenesis (Figure 
1) are divided into two main phases, 
determination and terminal differentiation 
(194,304,326). During the determination 
phase, a multipotent mesenchymal stem 
cell becomes preadipocyte, a cell solely 
committed to adipocyte lineage, thereby 
losing its potential to differentiate into 
alternative cell types, e.g., myocytes, 
osteoblasts or chondrocytes (194,304,326). 
In white adipogenesis, determination 
is initiated by bone morphogenetic 
protein 4 (BMP4) and, to some extent, 
bone morphogenetic protein 2 (BMP2) 
(304,390). BMP2 and BMP4 release 
preadipocytes from the suppressive action 
of anti-adipogenic transcription factors, 
e.g., transcription factor homologous 
to CCAAT-enhancer-binding protein 
(CHOP), CCAAT-enhancer-binding 
proteins γ (CEBPG), Klüppel-like factors 
2 and 7 (KLF2 and KLF7), GATA-binding 
factors 2 and 3 (GATA2 and GATA3), 
preadipocyte factor 1 (PREF1) and forkhead 
proteins, thereby allowing the adipogenic 
program to proceed. In addition to BMPs, 
numerous other extracellular modulators, 
both activating (insulin, insulin-like 
growth factor 1, transforming growth 
factor β, fibroblast growth factors) and 
repressing (Wnt family, sonic hedgehog, 
tumor necrosis factor α; TNFA), regulate 
adipogenesis (194,326). Notch signaling 
and the mitogen-activated protein kinase 
pathway may also be involved, although 
the evidence regarding their role is 
inconclusive (194,326). Together, all of 
these master regulators relate information 
about the suitability of extracellular 
conditions for adipocyte differentiation 
and, when appropriate, complement 
the BMPs in suppression of the anti-
adipogenic factors (326).
After determination, committed 
preadipocytes are thought to undergo a 
number of cell divisions known as mitotic 
clonal expansion (194,326), although 
whether this proliferative phase truly 
occurs in human preadipocytes has been 
challenged (304). Finally, preadipocytes 
enter terminal differentiation, wherein 
sequential and partially reciprocal 
activation of pro-adipogenic transcription 
factors CCAAT-enhancer-binding proteins 
α, β and δ (CEBPA, CEBPB and CEBPD), 
sterol regulatory element-binding 
protein   1c (SREBP1C) and PPARG 
further suppresses the anti-adipogenic 
genes and converts preadipocytes 
to mature adipocytes. Once fully 
differentiated, mature adipocytes assume 
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the physiological function of WAT, 
accumulating intracellular triglycerides 
and acquiring machinery for lipid synthesis 
and transport, insulin responsiveness and 
secretion of adipocyte-specific proteins 
(194,304,326). In addition to the main 
transcription factors orchestrating 
terminal differentiation, over 100 co-
factors contributing to regulation of 
adipogenesis have been identified (326). 
These factors act in concert to, directly or 
indirectly, induce expression of adipogenic 
genes like fatty acid synthase (FASN), fatty 
acid-binding proteins (FABPs), insulin 
receptors, GLUT4, leptin and adiponectin 
(194,304,326). Interestingly, not only are 
the key transcription factors of adipogenesis 
such as PPARG and CEBPA, necessary for 
adipogenesis itself, but these factors are 
vital also for maintenance of the functional 
differentiated state of adipocytes. Indeed, 
adipocyte cultures and murine models 
with genetically-induced lack of these 
transcription factors demonstrate loss of 
lipid accumulation and insulin sensitivity, 
and even de-differentiation (326).
1.2.2. Adipogenesis of brown adipose 
tissue
Adipogenesis of BAT features the same 
phases as that of WAT, but some of 
Figure 1. Schematic representation of adipogenesis in white and brown adipocytes. Thick black arrows 
from mature adipocytes indicate proteins produced, but not necessarily secreted, by these cells. Bone 
morphogenetic proteins 2 and 4 (BMP2 and BMP4) and bone morphogenetic protein 7 (BMP7) drive the 
first step of adipogenesis, determination, in white and brown adipogenesis, respectively. They also suppress 
anti-adipogenic factors like CCAAT-enhancer-binding protein γ (CEBPG), transcription factor homologous 
to CCAAT-enhancer-binding protein (CHOP), Klüppel-like factors 2 and 7 (KLF2 and KLF7), GATA-binding 
factors 2 and 3 (GATA2 and GATA3), preadipocyte factor 1 (PREF1), forkhead proteins and necdin allowing 
committed preadipocytes to enter the last phase of adipogenesis, terminal differentiation. Sterol regulatory 
element-binding protein 1c (SREBP1C), CCAAT-enhancer-binding proteins α, β and δ (CEBPA, CEBPB and 
CEBPD) and peroxisome proliferator –activated receptor γ (PPARG) are the main pro-adipogenic transcription 
factors regulating terminal differentiation in both white and brown adipocytes. CEBPB and CEBPD are 
believed to regulate the early stages of terminal differentiation while SREBP1C, PPARG and CEBPA dominate 
the later stages of the process. In preadipocytes committed to brown lineage, BMP7 induces expression of 
PRD1-BF1-RIZ1 homologous domain containing 16 (PRDM16), peroxisome proliferator –activated gamma 
coactivator 1α and 1β (PGC1A and PGC1B) and mitochondrial transcription factor A (TFAM), i.e., genes 
promoting mitochondrial biogenesis. In the end of the adipogenic cascade, mature white adipocytes can finally 
produce proteins characteristic to them: fatty acid synthase (FASN), fatty acid-binding proteins (FABPs), 
glucose transport protein 4 (GLUT4), leptin, adiponectin and many others. Brown adipocytes specialize in 
producing uncoupling protein 1 (UCP1). 
Figure 1.
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the mediators involved differ (Figure 1) 
(390). While BMP2 and BMP4 are the 
main enhancers of determination in 
white adipogenesis (304,390), bone 
morphogenetic protein 7 (BMP7) acts 
exclusively to induce multipotent 
mesenchymal stem cells to become 
committed to brown adipocyte lineage 
(390). BMP7 suppresses expression 
of necdin, a negative modulator of 
brown preadipocyte differentiation, 
and increases that of “traditional” pro-
adipogenic transcription factors (PPARG, 
CEBPA, CEBPB, CEPBD, SREBP1C). In 
addition, BMP7 specifically promotes 
mitochondrial biogenesis and increases 
mitochondrial density in the brown 
preadipocytes by stimulating expression 
of genes like PRD1-BF1-RIZ1 homologous 
domain containing 16 (PRDM16), 
peroxisome proliferator-activated gamma 
coactivator 1α and 1β (PGC1A and PGC1B) 
and mitochondrial transcription factor A 
(TFAM) (390). 
Mature brown adipocytes are 
characterized by expression of 
uncoupling protein 1 (UCP1), a protein 
considered exclusive for mammalian 
BAT (284). UCP1 is located on the inner 
mitochondrial membrane and its function 
is to dissipate cellular energy as heat by 
uncoupling oxidative phosphorylation 
from ATP production in a process called 
non-shivering thermogenesis. UCP1 is 
activated, e.g., by noradrenaline and 
FFAs released in response to external 
stress stimuli such as cold exposure (284). 
There have been reports of UCP1 in WAT 
(280,301). However, the cells expressing 
UCP1 were also reported as having 
morphological appearance of brown 
adipocytes, suggesting that the findings 
represent brown adipocytes dispersed 
within WAT as opposed to WAT itself 
expressing UCP1. 
Interestingly, rodent studies have 
suggested that white and brown adipocytes 
may be able to transdifferentiate into one 
another (65). The exact mechanisms, 
however, remain obscure, and the finding 
has not been verified in cultured human 
adipocytes or human adipose tissue in vivo.
2. INSULIN ACTION
2.1. Insulin action in adipose tissue
Insulin prevents triglyceride breakdown 
and stimulates its storage in adipose tissue 
in vivo (433). Adipose tissue lipolysis is the 
most sensitive of the biological processes 
controlled by insulin being inhibited by 
a much lower concentration of insulin 
(half-maximal effective dose, ED50, for 
suppression of lipolysis measured using 
glycerol infusions is 13 mU/L) (297) than 
is required for inhibition of hepatic glucose 
production (ED50 26 mU/L) (297) or 
stimulation of glucose disposal by skeletal 
muscle (ED50 ~100 mU/L) (443).
Insulin signals through binding 
and autophosphorylation of the insulin 
receptor, followed by sequential tyrosine 
phosphorylation of IRS proteins and 
inositol phosphorylation of PI-3-kinase, 
with consecutive activation of protein kinase 
B and other downstream protein kinases 
(299). Insulin, at least in part assisted by 
SREBP1C, also facilitates intravascular 
lipolysis by stimulating LPL, FFA transport 
and intracellular lipogenesis (299). Insulin 
accomplishes these actions by increasing 
expression of fatty acid transport protein 
(FATP) and acyl-coenzyme A synthase 
(ACS), and by repressing expression of 
genes involved in fatty acid oxidation 
(299). Insulin blocks lipolysis in mature 
adipocytes by suppressing protein 
kinase A-mediated phosphorylation and 
translocation of perilipin (PLIN) 1, a 
protein normally keeping HSL inactive by 
preventing its phosphorylation, thereby 
maintaining a barrier against triglyceride 
hydrolysis in the lipid droplets (433).  
The adipose tissue of obese individuals, 
perhaps due to the presence of hypertrophic 
apoptotic adipocytes (66), harbors vast 
amounts of macrophages that are known 
to be the main source of inflammatory 
cytokines produced by the adipose 
tissue (447). These include monocyte 
chemoattractant protein 1 (protein encoded 
for by chemokine (C-C motif) ligand 2 gene; 
CCL2), macrophage inflammatory protein 
1α (protein encoded for by chemokine (C-C 
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motif) ligand 3; CCL3), TNFA and IL6 
(447). The chronic inflammation in adipose 
tissue is worsened by low expression of 
anti-inflammatory adiponectin and high 
expression of proinflammatory leptin (112). 
Interestingly, a causal link between adipose 
tissue inflammation and insulin resistance 
has been suggested (448). Inflammatory 
cytokines such as TNFA hamper insulin 
signaling in adipocytes by inducing 
serine phosphorylation of the IRSs (331). 
This decreases the capacity of the IRSs 
to undergo phosphorylation on their 
tyrosine residue by the insulin receptor 
(331). This, in turn, leads to a decreased 
activation of their associated downstream 
kinases and opposes the production of 
proteins involved in triglyceride synthesis 
(LPL, FATP, ACS), while at the same time 
increasing lipolysis (331). As a net effect, 
more FFAs are mobilized from the adipose 
tissue and circulating FFA concentration 
increases (331). Increased FFAs, through 
toll-like receptor 4 –mediated activation 
of the nuclear factor κB (NFKB) pathway, 
then trigger adipose tissue-resident 
macrophages to produce auxiliary 
inflammatory mediators (351,448). These 
mediators can further inflame the adipose 
tissue, generating a vicious circle of 
worsening insulin resistance. 
2.2. Insulin action in the liver
In the liver, the physiological action 
of insulin is to suppress endogenous 
glucose production (glycogenolysis and 
gluconeogenesis) in both basal and post-
prandial states (433). Also, under normal 
conditions, insulin suppresses hepatic 
secretion of very-low-density lipoprotein 
(VLDL). This is accomplished via direct 
insulin-induced inhibition of assembly of 
the VLDL particles along with decreased 
availability of FFAs following insulin-
induced inhibition of lipolysis in adipose 
tissue (433). In insulin resistance due 
to conditions such as hepatic steatosis, 
insulin fails to exert these physiological 
effects, leading to hyperglycemia and 
hypertriglyceridemia (441). The lack of 
insulin-stimulated LPL activity decreases 
VLDL catabolism, resulting in further 
worsening of hypertriglyceridemia. The 
latter, in turn, encourages enrichment 
of high-density lipoproteins (HDL) and 
low-density lipoproteins (LDL) with 
triglycerides (441). This renders them 
better substrates for hepatic lipase and 
results in low circulating HDL cholesterol 
concentration and small, dense and 
atherogenic LDL particles (441). Due to 
prevailing hyperglycemia and in an attempt 
to compensate for insulin resistance, 
the pancreatic β-cells increase insulin 
secretion, resulting in hyperinsulinemia 
that, depending on the degree of insulin 
resistance, may or may not be sufficient to 
counteract it (441).         
In obese subjects, adipose tissue –derived 
inflammatory cytokines, such as TNFA 
and IL6, directly blunt insulin signaling 
in the liver (by a mechanism analogous 
to that in adipose tissue), stimulate 
hepatic lipogenesis and aggravate 
hypertriglyceridemia (448). At the same 
time, these cytokines also stimulate adipose 
tissue lipolysis (331), mobilize excessive 
FFAs from inflamed and insulin resistant 
adipose tissue, and increase FFA delivery 
to the liver (441). In the liver, FFAs are 
metabolized into lipid intermediates such as 
ceramides, ceramide-derived gangliosides 
and diacylglycerols (DAG), all of which 
have been proposed to inhibit insulin action 
(223,339,366). Ceramides are thought to 
exert this action via caveolin-mediated 
activation of atypical protein kinase C and/
or protein phosphatase 2A, both of which 
deactivate protein kinase B, rendering it 
unable to transmit normal insulin signaling 
to downstream components (223,366). 
It has been suggested that gangliosides, 
such as ganglioside monosialo 3, 
cause insulin receptor displacement 
from caveolin-rich domains of the cell 
membrane (223). Equally, gangliosides 
may also phosphorylate IRS proteins on 
their serine residue, thereby interfering 
with their ability to react with the insulin 
receptor and to recruit PI-3-kinase with 
the following signaling cascade (223). 
Finally, DAGs are thought to convey 
their insulin-desensitizing effects via 
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phosphorylation of IRS proteins on their 
serine residue, accomplished by activation 
of an isoform of protein kinase C, thereby 
preventing activation of the IRS-associated 
PI-3-kinase pathway (339). Circulating 
inflammatory cytokines promote the 
deleterious accumulation of ceramides 
and their derivatives by supplying the liver 
with adipose tissue –derived FFAs as well 
as by acting directly via toll-like receptor 
4 –mediated activation of enzymes such 
as sphingomyelinase which are involved 
in the synthesis of ceramides (152,223). 
Collectively, these molecular events 
further decrease insulin sensitivity of 
hepatic gluconeogenesis and promote the 
development of hyperglycemia (195,254). 
The degree of hepatic insulin resistance 
is closely associated with the amount of fat 
in the liver (188,332,346). The fatty acids in 
intrahepatocytic triglycerides are derived 
from i) dietary chylomicron remnants, ii) 
FFAs mobilized from adipose tissue, iii) 
post-prandial lipolysis of chylomicrons 
occurring in excess of what can be taken 
up the tissues (FFA spillover) and iv) de 
novo lipogenesis (441). The fatty liver has 
been found to contain increased amounts 
of saturated and decreased amounts of 
unsaturated fatty acids, with concentration 
of DAGs increasing with increasing 
intrahepatocytic triglyceride content 
(189). Intriguingly, de novo lipogenesis 
that yields only saturated fatty acids as a 
product, is increased in insulin resistant 
subjects (441). Ceramides, suggested as 
causative of insulin resistance, in turn, 
are built from saturated fatty acids only 
(223,366). Both increased intracellular 
concentrations of ceramides and of DAGs 
have (vide supra) been proposed to be 
“agents provocateurs” in the pathogenesis 
of insulin resistance (223,339,366).
2.3. Insulin action in skeletal muscle
In skeletal muscle, there are two main 
mechanisms by which insulin stimulates 
glucose uptake, direct and indirect 
(433). Insulin directly stimulates glucose 
transport and phosphorylation as well 
as glycogen synthesis in skeletal muscle 
(433). Insulin promotes glucose uptake 
also indirectly by decreasing FFA 
availability via its anti-lipolytic effect and 
via stimulation of intravascular lipolysis 
(433). In insulin resistant states such 
as obesity, lipolysis in adipose tissue 
is enhanced and FFA transport into 
adipocytes decreased, leading to increased 
circulating FFA concentrations (441). FFAs 
are known to compete with and inhibit 
glucose uptake in skeletal muscle though 
inhibition of glucose transport activity, 
possibly as a consequence of reduced 
IRS-associated PI-3-kinase signaling and 
hampered GLUT4 activity (20).
Another factor possibly contributing to 
increased muscle lipid content is the activity 
of muscular LPL, which is increased rather 
than decreased in insulin resistant states 
(441). Accumulation of intramyocellular 
lipid may, through ceramides (223,366) and 
DAGs (339), interfere with insulin signaling 
at a post-receptor level (vide supra). As a 
result, translocation of GLUT4 to the cell 
membrane and glucose phosphorylation 
via hexokinase II are reduced, and glucose 
uptake impaired (195,254,441). Indeed, 
intramyocellular triglyceride content has 
been shown to closely correlate with insulin 
resistance in skeletal muscle (198,310). 
3. ARTERIAL STIFFNESS
3.1. Definition of arterial stiffness
Arterial stiffness is a term used to describe 
the capacity, or lack thereof, of arteries 
to expand and contract during the 
cardiac cycle (288). In healthy, compliant 
vasculature, contraction of the left 
ventricle during systole increases pressure 
and dilates the arteries (288). The stiffer 
the vessels, the less their caliber changes 
with varying pressure conditions during a 
cardiac cycle, and the faster the pressure 
wave travels along the vessels as its energy 
is no longer dissipated in distending the 
elastic load-bearing elements of arterial 
walls (288). The lack of arterial compliance 
augments systolic blood pressure, resulting 
in increased left ventricular afterload 
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while simultaneously decreasing coronary 
perfusion, thereby aggravating coronary 
artery insufficiency (288).
3.2. Measurement of arterial stiffness
Many methods have been proposed as 
ways to assess arterial stiffness. These 
include sphygmomanometry, ambulatory 
arterial stiffness index, pulse wave velocity, 
ultrasonography and magnetic resonance 
imaging (MRI). Traditional measurement 
of pulse pressure by sphygmomanometry 
is widely available and simple, but prone to 
inaccuracy and human error, and is difficult 
to standardize. Ambulatory arterial stiffness 
index uses a 24-hour blood pressure 
monitoring to produce a stiffness estimate 
(217). While multiple readings taken by 
this approach increase its accuracy, this 
method is laborious and time-consuming. 
Applanation tonometer or even MRI 
techniques can be used to record pulse wave 
velocity (76,231,266). Ultrasonography and 
MRI, in particular, have been developed to 
enable measurements of not only arterial 
diameter and compliance properties, but 
also of thickness of different layers of the 
arterial wall, e.g. intima media (231). These 
methods, however, require expensive 
equipment and skilled personnel to perform. 
Results are also highly user-dependent and 
reproducibility may be of concern.
Pulse wave analysis (PWA) is a technique 
used to assess arterial stiffness by recording 
changes in arterial pressure occurring during 
one cardiac cycle (300). PWA utilizes a 
tonometer to record a pulse wave contour 
from peripheral artery, e.g., radial. In the 
arterial waveform (Figure 2), contraction of 
the left ventricle propelling blood along the 
arteries is seen as the first systolic pressure 
peak. This systolic pulse wave is then 
reflected back from the periphery causing the 
second systolic peak of the pressure wave. 
The stiffer the conducting vessels, the faster 
the pressure wave travels and the faster it is 
reflected back. Consequently, the return wave 
may superimpose with the forward-traveling 
wave, increasing the systolic pressure wave 
and decreasing the diastolic one. The degree 
of augmentation of the systolic pressure, a 
parameter evaluated by pulse wave analysis, 
is defined as the pressure difference between 
the second and the first systolic pressure 
peaks in the aorta. Another important 
parameter analyzed is the augmentation 
index which is defined as the ratio of the 
augmentation and pulse pressure, the latter 
being the difference between systolic and 
diastolic pressure (288,300). 
3.3. Significance of arterial stiffness
In a recent meta-analysis of 18 longitudinal 
studies with a total of 15877 subjects and 
Figure 2.
Figure 2. Representative ascending aortic pulse waveforms during one cardiac cycle of a subject with 
i) compliant vasculature and ii) stiff vasculature. P1 and P2 denote the first and the second systolic pressure 
peaks, respectively. Augmentation is calculated as the difference between P2 and P1. Augmentation index is 
defined as the ratio of augmentation and pulse pressure (PP), the latter being the difference between systolic 
and diastolic pressure. ADP, aortic diastolic pressure; ASP, aortic systolic pressure, equals the highest one of 
the two systolic pressure peaks, P1 or P2. Adapted from Sevastianova et al. Antiviral Therapy 2005; 10:925-35 
(Study I), reproduced with permission of the copyright holder.
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a mean follow-up time ranging from 2.5 
to 19.6 years, arterial stiffness, measured 
by aortic pulse wave velocity, was a 
strong independent predictor of future 
cardiovascular events and of cardiovascular 
and all-cause mortality (411). In studies 
using the aortic augmentation index as a 
marker of arterial stiffness, it has been found 
to predict the risk of future cardiovascular 
events in patients undergoing angiography 
for suspected coronary artery disease 
(420). Furthermore, in a study of 262 
subjects undergoing percutaneous coronary 
intervention, aortic augmentation index 
added prognostic value above and beyond 
clinical risk factors, angiographic variables 
and medication use in a multivariable 
Cox-regression model for the risk of future 
cardiovascular events and mortality (421). 
The augmentation index has also been 
reported to predict cardiovascular death 
independent of age, gender, BMI, blood 
pressure, aortic pulse wave velocity, smoking 
status, lipid profile and other confounders 
in patients with end-stage renal disease 
(227). Most recently,  in a community-
based study involving 1272 participants and 
a 15-year follow up, the augmentation index 
predicted cardiovascular and all-cause 
mortality in men (417).
3.4. Causes of arterial stiffness
 
3.4.1. Age
Arteries stiffen as part of normal aging, 
making age the most important independent 
determinant of arterial stiffness (10,176). 
Arterial stiffening increases systolic blood 
pressure and decreases diastolic blood 
pressure, thereby increasing pulse pressure 
as seen with progressive age (176). There are 
several factors contributing to age-related 
changes in arterial stiffness. The first relates 
to the composition of the extracellular 
matrix, namely to the proportion of rigid 
collagen to extensible elastin within the 
tunica media of the arterial wall. It is known 
that with increasing age this ratio skews 
towards more collagen and less elastin, 
resulting in loss of stretch and in increased 
stiffness (288). It is not only the amount and 
proportion of collagen and elastin, but also 
their disrupted cellular organization that 
makes the arterial wall more rigid (288). 
Other contributors to age-related arterial 
stiffening include progressive endothelial 
dysfunction (featuring decreased release 
of nitric oxide), dysregulation of matrix 
metalloproteases, intimal hyperplasia, 
deposition of calcium within the arterial 
wall, and decreases in vascular endothelial 
growth factors and telomere length, all 
associated with developing senescence 
(282,288).
3.4.2. Genetic factors
Genome-wide association scans have 
identified several loci linked to increased 
arterial stiffness, suggesting its heritability 
(263). Identified candidate genes include 
endothelial nitric oxide synthase, atrial 
natriuretic peptide, as well as several 
genes involved in cell adhesion, cell-cell 
interaction and cellular matrix formation 
(263). The exact pathogenetic mechanism, 
however, remains obscure (263).
3.4.3. Hypertension
While hypertension may be a consequence 
of normal ageing and concomitant arterial 
degeneration (vide supra), it can also 
accelerate arterial degeneration by causing 
overt mechanical strain on the load-bearing 
elastic lamellae of the arterial wall (288). 
Acting much like “accelerated aging”, 
hypertension leads to thinning, splitting, 
fraying, fragmentation and disruption of 
the orderly arrangement of the lamellae of 
the arterial tunica media (288). Indeed, 
hypertension has been documented to be 
associated with increased arterial stiffness 
at any given age indicating its independent 
detrimental impact on vascular health (288).
3.4.4. Dyslipidemia
Hypercholesterolemia due to increased 
LDL cholesterol is as a major risk factor 
for cardiovascular disease, recognized 
by large cohort initiatives such as the 
Framingham Heart Study (426), the 
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Prospective Cardiovascular Munster Study 
(9) and the Interheart Study (446). Thus, 
it can be expected that LDL cholesterol 
concentration correlates with measures 
of systemic arterial stiffness (35). 
Accordingly, in a study with 136 subjects 
with and without hypercholesterolemia, 
concentration of LDL cholesterol, but not 
of triglyceride or HDL cholesterol, was 
identified as an independent predictor 
of the aortic augmentation index despite 
covariates such as age, gender, peripheral 
mean arterial pressure and smoking status 
(425).
3.4.5. Hyperglycemia and hyperinsulinemia
One of the functions of insulin is to 
diminish the stiffness of large arteries and 
induce vasodilatation in the peripheral 
resistance vessels (441). This effect is 
blunted with obesity and other states 
characterized by insulin resistance 
(441). Indeed, perhaps the largest 
study evaluating measures of arterial 
stiffness in the general population (the 
Atherosclerosis Risk in Communities 
Study, n=4701 subjects) has reported both 
fasting glucose and insulin concentrations 
to be strong predictors of arterial stiffness 
in multivariate analyses controlled for 
age, BMI, smoking status, blood pressure 
and total cholesterol concentration 
(336). Moreover, among the non-diabetic 
subjects (~95% of the cohort), fasting 
glucose and insulin concentrations were 
found to correlate, independently and in 
synergy, with increased arterial stiffness 
in both males and females (336). In 
a study assessing arterial stiffness in 
271 diabetic and 285 healthy subjects, 
multiple linear regression analysis 
carried out in all subjects identified the 
presence of type 2 diabetes as a predictor 
of arterial stiffness independent of age, 
gender, BMI, smoking, hypertension and 
dyslipidemia (378). Among the diabetic 
patients only, duration of diabetes was 
the most significant predictor of arterial 
stiffness along with age (378). Several 
other studies have confirmed these 
findings concluding that type 2 diabetes 
is inextricably connected to arterial 
stiffening (208).
3.4.6. Inflammation
Inflammation has been suggested to be 
involved in the development of arterial 
stiffness and the associated cardiovascular 
complications. In particular, circulating 
concentration of high sensitivity 
C-reactive protein (hs-CRP), a marker 
of systemic inflammation and increased 
cardiovascular risk, has been shown to 
be independently related to measures of 
arterial stiffness both in healthy subjects 
(439) and in patients with untreated 
essential hypertension (234). Also other 
inflammatory mediators, such as IL6 and 
TNFA, were found to correlate positively 
with pulse wave velocity and aortic 
augmentation index in hypertensive 
patients (234). Moreover, causal 
relationship between acute inflammation 
and deterioration of arterial compliance 
has been postulated (412).
3.4.7. Smoking
Smoking has been documented to have 
both short-term (95,185,233) and long-
term (219,233) harmful effects on arterial 
compliance. Even passive smoking, both 
in terms of acute (363) and cumulative 
(230) exposure, has been shown to stiffen 
the arteries. In a study assessing arterial 
stiffness in normotensive and hypertensive 
patients, current smoking was found to be 
associated with increased arterial stiffness 
irrespective of blood pressure levels (213). 
In a multivariate analysis of 138 otherwise 
healthy subjects with and without 
dyslipidemia, smoking was associated with 
increased arterial stiffening independent 
of age, gender, lipid profile and peripheral 
blood pressure (425).
3.4.8. Physical inactivity
Regularly performed physical exercise 
is associated with reduced risk of 
cardiovascular disease and even lower 
mortality rate (19). Individuals involved 
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contaminated blood products or through 
mother-to-child transmission that can 
occur in utero, intrapartum or postnatally 
via breast-feeding. As illustrated in 
Figure 3, HIV-1 enters target cells, often 
T-lymphocytes, that express CD4 receptor 
(subsequently referred to as CD4+ T-cells) 
using its envelope glycoprotein complex 
that attaches to CD4 receptors and to 
either chemokine (C-C motif) receptor 
5 (CCR5) or chemokine (C-X-C motif) 
receptor 4 (CXCR4) as a co-receptor (141). 
The virus then releases its single-stranded 
ribonucleic acid (RNA) into the host 
cell’s cytosol, where it is converted into 
double-stranded DNA using viral reverse 
transcriptase enzyme. The viral DNA 
is then transported into the host cell’s 
nucleus, incorporated into the cell’s own 
DNA and replicates by exploiting nuclear 
transcription mechanisms. Viral proteins 
are produced based on the instructions 
provided by the replicated DNA, cleaved 
into active form by viral protease enzyme 
and packed into new virions that are now 
ready to be released from the host cell to 
infect other cells (141).
During the acute viremia (2–4 weeks 
after encountering the virus) most HIV-
1-infected individuals develop symptoms 
of primary infection featuring fever, 
lymphadenopathy, pharyngitis, rash, 
headache, myalgia, arthralgia and malaise 
(150). Initially, there is rapid rise in 
plasma viremia, often to levels in excess 
of 1 000 000 RNA copies/mL (150). This 
usually coincides with a rapid decrease 
in the number of CD4+ T-cells and 
commencement of antibody production 
against HIV-1, i.e., seroconversion (150). 
From this point onwards, circulating virions 
gradually become trapped by the follicular 
dendritic cell network in the lymphoid 
tissue germinal centers and plasma viremia 
subdues (141). HIV-1 infection then enters 
a chronic asymptomatic phase wherein 
the patients remain clinically stable and 
symptom-free for a variable duration of 
time, commonly years, while the virus 
keeps replicating within the lymphoid 
tissue gradually infecting and destroying 
more and more CD4+ T-cells (141). Over 
in endurance sports have been reported 
to have lower aortic pulse wave velocity, 
augmentation index and blood pressure 
than their age-matched sedentary controls 
(376,377,391). Moreover, daily brisk walking 
has been documented to improve arterial 
compliance in previously sedentary men 
(377) and postmenopausal women (269) to 
levels observed in age-matched endurance 
exercise –trained and premenopausal 
peers, respectively, independent of changes 
in body mass, adiposity, arterial blood 
pressure, dietary intake and maximal 
oxygen consumption. This suggests that 
even moderate aerobic exercise may 
produce highly beneficial effects on 
cardiovascular health by minimizing or 
even reverting the age-related structural 
changes in the arterial wall (345). In 
contrast, the effects of resistance exercise 
(i.e., strength training or weight lifting) on 
arteries and cardiovascular health may be 
less favorable (18,264).
4. HIV-1 INFECTION
Since the beginning of the epidemic in 
1981, more than 60 million people have 
been infected with HIV and nearly 30 
million people have died of acquired 
immunodeficiency syndrome (AIDS) 
(428). In 2009, according to the World 
Health Organization, 33 million people 
were estimated to live with HIV, 2.6 
million people were newly infected by 
the virus and, in 2009 alone, 1.8 million 
deaths occurred due to HIV/AIDS (428), 
making it the sixth leading cause of death 
worldwide (427). There are two subtypes 
of HIV, HIV-1 and HIV-2. The latter is 
less virulent than the former and is largely 
restricted to Western Africa. In the rest of 
this review, the focus is set on HIV-1 as it 
is the most prevalent and the most studied 
subtype of HIV.
4.1. Natural course of HIV-1 infection
HIV-1 is transmitted through unprotected 
sexual contact, contaminated needles or 
other injection equipment, transfusion of 
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time, accelerating viral replication and 
advancing immunodeficiency ultimately 
compromise the body’s ability to maintain 
effective immune responses, and patients 
develop non-specific symptoms such 
as fever, fatigue, night sweats, weight 
loss and dermatological or mucosal 
manifestations (141). The term AIDS is 
used to refer to the most advanced stage 
of HIV-1 infection. AIDS is defined by 
the European Centre for Disease Control 
and Prevention as occurrence of any of 
more than 20 opportunistic infections 
(e.g., Pneumocystis jirovecii pneumonia, 
esophageal candidiasis, cytomegalovirus 
retinitis) and neoplasms (e.g., Kaposi’s 
sarcoma) (92).
Before the advent of contemporary 
antiviral medication, prognosis of people 
infected with HIV-1 was bleak - median 
time to development of AIDS was 8-11 
years and median survival was 8-13 years 
from seroconversion (1).
4.2. Treatment of HIV-1 infection
Antiretroviral drugs have been used to 
battle HIV-1 infection since 1987 (98). 
Initially, they were used as mono-/dual/
alternating agent therapy and, although 
reducing morbidity and mortality rates 
of HIV-1-infected patients at a statistical 
level, failed to have a significant impact 
on their life expectancy (149). The break-
through took place in the mid-1990s 
when quantitative measurement of HIV-1 
viremia became possible, enabling better 
evaluation and comparison of efficacy 
of individual drugs and combinations 
thereof. Only then the superiority, 
in terms of viral suppression and 
reversal of immunodeficiency, of triple-
Figure 3. Schematic diagram of life cycle of human immunodeficiency virus type 1 (HIV-1), key enzymes 
in viral replication and the targets of antiretroviral drugs within the host cell. CCR5, chemokine (C-C motif) 
receptor 5; CXCR4, chemokine (C-X-C motif) receptor 4; DNA, deoxyribonucleic acid; RNA, ribonucleic acid.
Figure 3.
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Table 1. Antiretroviral agents available in Finland as of autumn 2011.
Integrase 
inhibitors
raltegravir
Nucleoside 
reverse 
transcriptase 
inhibitors
abacavir
didanosine
emtricitabine
lamividine
tenofovir
stavudine
zidovudine
Non-nucleoside
reverse 
transcriptase 
inhibtors 
efavirenz
etravirine
nevirapine
Protese
inhibitors 
atazanavir
darunavir
fosampenavir
indinavir
lopenavir
ritonavir
saquinavir
tipranavir
Entry
inhibitors 
Fusion
inhibitors
enfuvirtide
CCR5 
inhibitors
maraviroc
CCR5, chemokine (C-C motif) receptor 5.
drug regimens over older therapeutic 
modalities became understood (34,129). 
Triple-drug combinations became known 
as highly active antiretroviral therapy 
(HAART), a term later changed to cART. 
Improved control of viral replication 
lead to gradual increases in CD4+ T-cell 
count, recovery of cell-mediated immunity 
and unprecedented improvements in 
the prognosis of HIV-1-infected patients 
(265,307,315,321). Over time cART 
has evolved to be more effective, better 
tolerated and has been simplified in terms 
of dosing. These therapeutic advances have 
transformed HIV-1 infection from being a 
fatal disease into a chronic condition.
At present, 6 classes of antiretroviral 
drugs are available: nucleoside reverse 
transcriptase inhibitors (NRTI), non-
nucleoside reverse transcriptase inhibitors 
(NNRTI), protease inhibitors (PI), fusion 
inhibitors, CCR5 inhibitors and integrase 
inhibitors (Table 1). NRTIs are structurally 
similar to natural nucleosides that DNA is 
built from. Unlike the natural nucleosides, 
however, NRTIs lack the ability to form a 
phosphodiester linkage with the following 
nucleoside halting the elongation of 
nascent viral DNA. Structurally, NRTIs 
can be divided into two subclasses, 
pyrimidine analogues (e.g., stavudine and 
zidovudine) and purine analogues (e.g., 
didanosine). Both subclasses act against 
HIV-1 in an identical manner in that they 
compete with the natural nucleosides for 
incorporation into the viral DNA and, once 
there, terminate further DNA elongation 
(383). NNRTIs block the same process, 
but act through non-covalent binding 
to a substrate binding site of the reverse 
transcriptase enzyme (27). By altering the 
enzyme’s three-dimensional structure, they 
block its active site and inhibit its action 
in a non-competitive fashion (27). PIs 
prevent cleavage of inactive viral protein 
precursors into their active form, thereby 
decreasing the infectivity of nascent virions 
(99). Entry inhibitors (fusion inhibitors 
and CCR5 inhibitors) block binding of viral 
envelope proteins with their receptors and 
co-receptors on the host cell membrane, 
hampering membrane fusion and entry 
of HIV-1 into the cell (70). The integrase 
enzyme facilitates the insertion of virally 
encoded DNA into the host cell genome. 
Integrase inhibitors target the catalytic 
domain and the ionic cofactors of HIV-1 
integrase enzyme, interfering with merging 
of viral DNA with the host cell DNA (341). 
Schematic representation of the targets of 
action of each antiretroviral drug class is 
depicted in Figure 3.
Albeit highly efficient in preventing 
viral replication and decreasing infectivity, 
no combination of antiretroviral agents 
can eradicate the virus completely. 
Thus, the treatment for HIV-1 is life-
long. While the life-expectancy of HIV-
1-infected patients diagnosed in a timely 
fashion is approaching that of non-
infected individuals (2,226,249,400), 
long-term and cumulative side effects of 
the antiretroviral agents are becoming 
increasingly important. 
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5. cART-ASSOCIATED 
LIPODYSTROPHY
Despite the undisputed positive impact 
that cART has had on the life of HIV-
1-infected patients (265,307,315,321), 
multiple adverse effects have burgeoned 
as the use of cART has increased (47,122). 
Among the most worrisome of these effects 
is a constellation of metabolic disturbances 
(vide infra) collectively termed cART-
associated lipodystrophy, features of which 
were first reported in cART-treated patients 
as early as 1997 (147,148). Originally, 
the prevalence of cART-associated 
lipodystrophy was reported to range from 
2% (322) to 83% (54) depending on the 
characteristics of the cohort (age, gender, 
race), type and duration of antiretroviral 
therapy and diagnostic criteria for the 
condition. Large surveys indicated a 
prevalence of 50% of least one physical 
abnormality after 12-18 months of cART 
(47). Although with the spreading use of 
contemporary, less lipotoxic antiretroviral 
agents, the prevalence of cART-associated 
lipodystrophy seems to be declining 
(142,314), it still remains the most common 
form of human lipodystrophy. Other types 
of human lipodystrophies are extremely 
rare (97,114,340,357) and are summarized 
in Table 2.
5.1. Definition of cART-associated 
lipodystrophy
There are no uniform, universally 
accepted criteria for cART-associated 
lipodystrophy. A case definition (48) and 
a severity grading scale (50) have been 
proposed. These models include variables 
such as age, gender, time since HIV-1 
diagnosis, stage of HIV-1 disease, serum 
HDL cholesterol concentration, anion gap, 
leg fat percentage, waist-to-hip ratio, and 
ratios of IAT-to-SAT and trunk-to-limb 
fat assessed by a single-slice computed 
tomography (CT) at the level of L4 vertebra 
and by dual-energy X-ray absorptiometry 
(DEXA), respectively (48,50). The case 
definition has 79% sensitivity and 80% 
specificity for diagnosis of cART-associated 
lipodystrophy, but requires the use of 
CT and/or DEXA which are not always 
readily available in every day practice (48). 
Additionally, the case definition does not 
differentiate between the different aspects 
of lipodystrophy, i.e., lipoatrophy and 
lipohypertrophy (48). Therefore, the use of 
the proposed definition has been limited, 
and cART-associated lipodystrophy 
continues being diagnosed based on 
clinical assessment encompassing 
patients’ self-reported signs and symptoms 
confirmed by physical examination. The 
concordance between the latter two has 
been reported to be as high as 98% (54). Of 
great clinical importance is to distinguish 
cART-associated lipodystrophy, in which 
adipose tissue is the affected organ and 
skeletal muscle is spared (373), from HIV/
AIDS-related “wasting syndrome” which 
is characterized, predominantly, by loss of 
muscle mass (124).
5.2. Features of cART-associated 
lipodystrophy
 
5.2.1. Adipose tissue 
cART-associated lipodystrophy is 
characterized by the loss of SAT (i.e., 
lipoatrophy) in the face, limbs, buttocks 
and, to a large extent, in the trunk 
(47,122,164,193). Excessive accumulation 
of adipose tissue (i.e., lipohypertrophy) 
may or may not associate with lipoatrophy 
(47,122,164,193). Regions that may 
hypertrophy include the subcutaneous 
dorsocervical fat pad (i.e., “buffalo hump”), 
breasts (both in males and females) and 
IAT (47,122,164,193). Collectively these 
alterations in body fat distribution are 
termed lipodystrophy. 
During the first months following 
initiation of cART amounts of both SAT 
and IAT show an increase (83,239,276). 
This is most likely due to the general 
improvement in health and nutrition 
associated with suppression of HIV-1 
viremia and reversal of the associated 
catabolic state (83,239,276). Subsequently, 
loss of peripheral SAT and accumulation 
of IAT take place (239,276). Initially, both 
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processes occur simultaneously, but over 
time accumulation of IAT plateaus while 
the amount of peripheral SAT continues to 
decrease (239,276) at a approximate rate 
of 0.10 kg of limb fat lost per month (54) 
or ~20% decrease in limb fat after 8-12 
months of cART (83,276). 
5.2.1.1. Adipose tissue composition
Upon comparison with non-lipoatrophic 
adipose tissue under light/electron 
microscope, lipoatrophic adipose tissue 
is characterized by smaller adipocytes 
(12,80,159,224), greater cell size 
variation (12,80,224), disruption of cell 
membranes (224), increased fibrosis 
(159) and vascularization (80,159), 
and signs of apoptosis as assessed 
by immunohistochemistry (80,159). 
Adipocyte size has been reported to be 
similar in aspiration biopsy samples of 
adipose tissue from both lipohypertrophic 
dorsocervical fat pad and lipoatrophic 
SAT in a small group (n=8) of patients 
with cART-associated lipodystrophy 
(165). Other histological parameters 
were not evaluated due to the nature 
of sample acquisition technique. Only 
one other study has addressed the issue 
of morphological differences between 
dorsocervical and abdominal SAT in cART-
associated lipodystrophy using surgical 
biopsy specimens (224). The authors of 
this study reported changes similar to, but 
milder than, those seen in the lipoatrophic 
areas (vide infra) (224). The cited study, 
however, did not specify the location of 
origin of the hypertrophic adipose tissue 
samples and was limited in size (n=4).
5.2.1.2. Adipose tissue inflammation
On histological and immunohistochemical 
analyses, lipoatrophic adipose tissue of 
cART-treated patients is characterized 
by increased macrophage infiltration and 
increased number of lipogranulomata 
(i.e., lipid-laden macrophage clusters 
encircling adipocytes) when compared to 
that of NRTI-naïve (291,292) and HIV-1-
negative subjects (80,159,224,291,292). 
Prior to Studies III and IV, histological 
or immunohistochemical signs of 
inflammation in SAT of similarly treated 
patients with and without cART-associated 
lipodystrophy has not been contrasted.
Adipose tissue macrophages are involved 
in numerous immune functions including 
phagocytosis of cellular debris and foreign 
material as well as triggering immune 
responses via cytokine release and antigen 
presentation (447). Accordingly, profusely 
macrophage-infiltrated abdominal SAT, 
such as occurs in HIV-1-infected patients 
with cART-associated lipodystrophy, 
demonstrates increased gene and protein 
expression of proinflammatory cytokines 
(TNFA, IL6 and IL8) when compared to 
that of HIV-1-infected patients without 
cART-associated lipodystrophy (165,222) 
or HIV-1-negative subjects (12,165). 
Comparative data on dorsocervical and 
abdominal SAT regarding adipose tissue 
inflammation were scarce. Prior to Study IV, 
only two studies on the matter existed and 
both reported that inflammation, as judged 
from mRNA expression of genes such as 
TNFA and CD68 (126) and release of TNFA 
protein (165), is more severe in lipoatrophic 
abdominal than in dorsocervical SAT. 
These studies, however, were limited in size 
(n=8-10) and by nature of the samples. In 
one of the studies, the samples from the 
two adipose tissue depots were not taken 
from the same individuals (126). In the 
other study, adipose tissue was biopsied by 
a needle aspiration technique which does 
not allow assessment at a protein level by 
immunohistochemistry (165). Thus, further 
research of location-dependent differences 
between SAT depots was called for. 
5.2.1.3. Mitochondrial DNA depletion
The mtDNA content has been shown to 
be significantly lower in the lipoatrophic 
SAT from lipodystrophic patients when 
compared to SAT from the corresponding 
location from cART-treated patients 
without lipodystrophy (352,415), HIV-
1-infected cART-naïve (352) and HIV-1-
negative subjects (352,415). Furthermore, 
hyperlactatemia, which is thought to 
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represent a marker of mitochondrial 
dysfunction, has been reported in patients 
with cART-associated lipodystrophy and 
associated with the severity of adipose 
tissue loss (21,50,51). 
One study has characterized 
hypertrophic SAT from the dorsocervical 
depot of cART-treated patients in 
comparison to lipoatrophic abdominal 
SAT from other cART-treated patients 
or SAT from healthy controls (126). This 
study reported mtDNA content to be lower 
in both lipoatrophic and lipohypertrophic 
SAT compared to that of controls (126). 
Furthermore, there was a tendency of the 
dorsocervical SAT to have even greater 
mtDNA depletion than the abdominal 
SAT (126). Prior to Study IV, however, no 
studies had compared the lipoatrophic 
(e.g., abdominal) and the remarkably 
unaffected (e.g., dorsocervical) SAT of the 
same otherwise lipoatrophic cART-treated 
patients.
5.2.2. Liver fat
In case of absence or malfunction of 
specialized energy stores (i.e., adipose 
tissue), triglycerides are deposited 
ectopically in non-adipose tissues such as 
the liver and skeletal muscle (441). This 
phenomenon has been clearly demonstrated 
in non-HIV-1-related lipodystrophies (114). 
In keeping with this, patients with cART-
associated lipodystrophy have also been 
shown to have abnormal transaminase 
concentrations (51,369), higher liver fat 
content (369) and greater prevalence of 
non-alcoholic steatohepatitis (210) when 
compared to HIV-1-infected cART-treated 
patients without lipodystrophy.
5.2.3. Insulin resistance
Insulin resistance is a characteristic feature 
of non-HIV-1-related lipodystrophies 
(114). Patients with cART-associated 
lipodystrophy are no exception having 
higher fasting insulin concentrations than 
non-lipodystrophic cART-treated patients 
(54,369) and HIV-1-negative subjects 
(132). A close correlation between fasting 
insulin concentration and liver fat content 
measured by proton magnetic resonance 
spectroscopy (1H-MRS) has been 
reported in patients with cART-associated 
lipodystrophy (369). In a multivariate 
regression analysis that included 91 patients 
with cART-associated lipodystrophy, 
alanine aminotransferase (ALT) was a 
strong positive predictor of fasting glucose, 
2-hour glucose, fasting insulin and insulin 
area under the curve following oral glucose 
tolerance test (OGTT) (64). These findings 
were maintained even after adjustment for 
confounding factors such as age, gender, 
BMI, use of PIs and co-infection with viral 
hepatitis (64). Furthermore, the ratio of IAT 
to abdominal SAT, both in terms of waist-
to-hip ratio and absolute compartment 
volume measurements by CT, have been 
reported to correlate positively and strongly 
predict fasting hyperinsulinemia and 
insulin area under the curve during OGTT 
in HIV-1-infected men independent of BMI 
(257). Results from OGTTs performed 
in large cohort studies have indicated 
that 7% of patients with cART-associated 
lipodystrophy fulfill the criteria for type 2 
diabetes and up to 35% can be diagnosed 
with some disorder of glucose metabolism 
(impaired fasting glucose, impaired glucose 
tolerance, diabetes) as compared to 0.5% 
and 7%, respectively, in HIV-1-negative 
subjects matched for age, gender and BMI 
(132). Among PI-treated patients, of whom 
83% were lipodystrophic, 7% had type 2 
diabetes and 16% were diagnosed with 
impaired glucose tolerance (54). Peripheral 
lipoatrophy in HIV-1-infected cART-treated 
patients has been reported to correlate 
closely with reduced peripheral insulin 
sensitivity as measured by hyperinsulinemic 
euglycemic clamp technique (279). 
A further study, complementing the 
hyperinsulinemic euglycemic clamp with 
the use of a glucose tracer, found patients 
with cART-associated lipodystrophy to 
have increased post-absorptive glucose 
production, reduced insulin sensitivity of 
peripheral glucose uptake and reduced 
suppression of lipolysis when compared to 
HIV-1-negative non-obese subjects (393). 
Finally, yet another hyperinsulinemic 
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euglycemic clamp study, combining the 
technique with indirect calorimetry, has 
confirmed the aforementioned findings 
and reported lower steady-state glucose 
infusion rate and decreased lipid oxidation 
during hyperinsulinemia in patients with 
as compared to those without cART-
associated lipodystrophy (113).
5.2.4. Dyslipidemia
High triglyceride and low HDL 
concentrations are common features 
of cART-associated lipodystrophy 
(52,122,132,193,259). The severity 
of dyslipidemia, particularly that of 
hypertriglyceridemia, shows a strong 
positive correlation with the severity 
of lipodystrophy (54). The use of PI-
containing therapy is linked with more 
atherogenic changes in lipid profile than 
the use of NRTI-NNRTI-based therapy 
(51,245). It must be remembered, 
however, that considerable differences 
exist between the individual antiretroviral 
agents, even within the same class. Some 
antiretrovirals may even exert a beneficial 
effect on lipid profile. For example, 
NNRTIs, particularly nevirapine, have 
been reported to increase HDL cholesterol 
concentrations (104,395,398).
5.2.5. Cardiovascular complications
Impaired flow-mediated vasodilation, 
indicative of endothelial dysfunction and 
arterial stiffening, has been reported in HIV-
1-infected cART-treated patients to age-
matched HIV-1-negative controls (402). A 
study comparing patients receiving cART 
regimens that include PIs against those 
which did not, found greater evidence of 
the aforementioned vascular anomalies 
among the PI users (364). The prevalence 
of atheromatous plaques, defined as 
thickening of intima media on ultrasound, 
has also been found to be increased in 
HIV-1-infected patients, particularly in 
those taking PIs, as compared to HIV-
1-negative subjects (78,157,232,402). 
These studies, however, did not consider 
cART-associated lipodystrophy as a 
group-defining characteristic, or even a 
factor that could potentially contribute 
to structural or functional atherosclerotic 
changes in the vasculature, despite the 
fact that the incidence of lipodystrophy 
has been strongly associated with the 
use of PIs (52). Of note, prior to Study I, 
PWA had not been used in HIV-1-infected 
patients to assess arterial stiffness. 
Arterial stiffness and hypertension are 
reciprocally regulated processes (287,300). 
Indeed, much like the measures of arterial 
stiffness mentioned above, elevated blood 
pressure has also been associated with the 
use of PIs (63). Both systolic and diastolic 
blood pressure have been reported to 
be higher in patients with as compared 
to those without cART-associated 
lipodystrophy or to controls matched for 
age and gender (338). Lipodystrophy was 
found to be more prevalent among the 
hypertensive HIV-1-infected cART-treated 
patients than among the normotensive 
ones (115). In fact, after family history of 
hypertension and the presence of features 
of the metabolic syndrome, the presence of 
cART-associated lipodystrophy was one of 
the strongest predictors of hypertension in 
these patients (115). It should be pointed 
out, however, that controversial data 
does exist refuting the link between the 
use of cART, or any individual drug class, 
lipodystrophy and hypertension (16,170).
One more feature exacerbating the 
cardiovascular risk burden of patients with 
cART-associated lipodystrophy is that 
of coagulopathy as high concentrations 
of PAI1 and tissue-type plasminogen 
activator, both markers of fibrinolysis, 
have been reported in patients with cART-
associated lipodystrophy (133,444). 
5.3. Pathogenesis of cART-associated
lipodystrophy
The etiology of cART-associated 
lipodystrophy, is unclear, but is likely 
to be multifactorial and to include 
combined effects of antiviral agents, 
HIV-1 infection and host-related factors 
(46,164,193,237,293). While several 
hypotheses regarding the pathophysiology 
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of cART-associated lipodystrophy have 
been put forward (25,43,53,100,268,422), 
none of them provide an exhaustive 
explanation, and some even contradict 
each other. Moreover, none of these 
hypotheses offer an explanation as to why 
adipose tissue atrophies in most anatomic 
locations while in the dorsocervical region 
it remains, at least seemingly, unaffected 
or even hypertrophies.
5.3.1. Antiretroviral agents
It is the current consensus that cART-
associated lipoatrophy is mainly attributed 
to the use of NRTIs (220), particularly 
those with a thymidine-like structure, 
i.e., thymidine analogue NRTIs (tNRTI) 
(138,166,236). Of tNRTIs, stavudine has 
been identified as causing the highest 
prevalence of lipoatrophy (166,236) with 
higher rates of SAT loss when compared to 
regimens containing zidovudine (83,142), 
abacavir (314) or tenofovir (142). With 
regards to mitochondrial toxicity, studies 
of NRTIs in enzyme assays and cell cultures 
have demonstrated the following hierarchy 
of inhibition of the mtDNA-replicating 
POLG protein: zalcitabine > didanosine 
> stavudine > lamivudine > zidovudine > 
abacavir (171). Originally, NNRTIs were 
attributed little role in the development 
of lipodystrophy (46). Recently, however, 
this has been challenged as, irrespective 
of the NRTI backbone, efavirenz was 
reported as causing more limb fat loss 
than ritornavir-boosted lopinavir (142), 
although still less than nelfinavir (83). PIs 
are thought to be associated mainly with the 
development of features of the metabolic 
syndrome (hypertriglyceridemia, low HDL 
cholesterol and insulin resistance) and 
lipohypertrophy (220).
Over time it has become increasingly 
clear that the pathogenesis of cART-
associated lipodystrophy needs to be 
investigated with regards to the impact of 
individual antiretroviral agents rather than 
entire drug classes. The effects of individual 
drugs, however, are difficult to assess in 
HIV-1-infected patients as they are always 
treated with combinations of antiretrovirals. 
Thus, most of the data on the side effects of 
individual agents in vivo in HIV-1-infected 
humans have been produced by large multi-
center cohort studies such as the Data 
Collection on Adverse Events of Anti-HIV 
Drugs (DAD) Study (108). 
5.3.2. Lipoatrophy
In theory, loss of adipose tissue can arise 
through several mechanisms. These 
include decreased differentiation of new 
adipocytes, decreased ability of existing 
adipocytes to store triglycerides leading 
to decreased adipocyte size, increased 
adipocyte loss due to processes such as 
disrupted function of cellular organelles, 
inflammation and apoptosis, or any 
combination of the above.
5.3.2.1. Adipogenesis
Histological analyses of SAT of cART-
treated patients have revealed smaller 
adipocytes, greater cell size variation, 
disruption of cell membranes and signs 
of apoptosis in lipoatrophic as compared 
to non-lipoatrophic SAT (80,159,224). 
Expression of transcription factors 
necessary for adipocyte differentiation, such 
as CEBPA, CEBPB, SREBP1C and PPARG 
(12,159,173), and that of genes involved 
in cellular lipid storage and metabolism 
such as ACS and LPL (159,173), was found 
to be lower in SAT of lipodystrophic as 
compared to that of non-lipodystrophic 
cART-treated patients (173) and HIV-1-
negative subjects (12,159). Furthermore, 
expression of adipogenic genes was 
documented to correlate positively with the 
proportion of small adipocytes, suggesting 
that alterations in gene expression may 
be linked with abnormal differentiation of 
adipocytes in lipoatrophic SAT (12). Based 
on these findings, it can be speculated that in 
cART-associated lipodystrophy adipocyte 
size decreases and SAT is lost as a result of 
at least two processes, possibly occurring 
independent of each other. The first 
process is that of intracellular triglyceride 
depletion due to increased lipolysis, while 
the second is of decreased lipogenesis and 
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poor adipocyte differentiation aggravated 
by concomitant apoptosis. The causal 
relationship between lipoatrophy and 
reduced expression of genes involved in 
adipocyte differentiation and lipid uptake 
has been investigated in a prospective 
in vivo study that showed that the 
aforementioned changes in gene expression 
in SAT from cART-treated patients precede 
visible loss of adipose tissue by several 
months (197). A 6-month interruption of 
cART, on the contrary, has been reported 
to result in significant improvements 
in markers of adipose tissue biogenesis 
and mitochondrial function, as well as in 
decreased adipose tissue inflammation, 
although no visible improvements in body 
fat distribution were recorded (179). 
As PIs were originally thought to be the 
causative agents of lipodystrophy, a large 
number of early in vitro studies explored 
the potential mechanisms by which PIs 
could instigate adipose tissue loss. These 
studies demonstrated that PIs suppress 
the differentiation of preadipocytes and 
reduce lipid accumulation in these cells 
(43,44,81,422,449). PIs were also found to 
inhibit de novo lipogenesis (320), increase 
lipolysis (15,212,320,329) and induce 
apoptosis in cultured mature adipocytes 
(81). A microarray analysis carried 
out in differentiating preadipocytes 
treated with several antiretroviral drugs 
indicated that PIs decrease expression of 
several master adipogenic transcription 
factors, adipokines and genes involved 
in modulation of cell cycle control (306). 
Exposure of HIV-1-negative subjects 
to indinavir for 4 weeks resulted in a 
statistically significant loss of total and 
truncal fat and a borderline significant 
loss of limb fat as measured by DEXA 
(294). Hypotheses contemplating both 
PPARG-dependent (12,43,44,53,81) and 
PPARG-independent (422) mechanisms 
of adipose tissue loss induced by PIs have 
been put forth. Ultimately, however, this 
body of evidence proved to have little 
clinical relevance as the role of PIs in 
causing cART-associated lipodystrophy 
was challenged and greater emphasis was 
set on the effects of NRTIs (220).
NRTIs have been implicated as 
exerting toxicity on adipose tissue both 
independently and in toxic synergy with 
PIs (46,186,236,394). In particular, tNRTIs 
(stavudine, zidovudine), but not other 
NRTIs (didanosine, abacavir, lamivudine, 
tenofovir), have been reported to exert a 
number of adverse effects on adipocytes. 
The effects include promotion of apoptosis 
(42), a decrease in adipocyte lipid content 
(42,200) and a decrease in insulin-induced 
lipogenesis in vitro (42). The latter 
appeared to be due to low expression of 
adipogenic genes such as CEBPA, PPARG, 
FASN, adipocyte lipid binding protein 2 
and acyl-coenzyme A carboxylase (42). In 
line with these data, a 2-week exposure of 
HIV-1-negative subjects to NRTIs has been 
reported to result in decreased PPARG gene 
expression in SAT of these subjects (241). 
5.3.2.2. Mitochondrial toxicity
Clinical trials have demonstrated that 
the absence or presence of tNRTIs in 
the backbone of antiretroviral regimens 
influences the individual’s risk of 
developing lipoatrophy (166). Mechanistic 
studies in vitro have suggested that 
tNRTIs inhibit POLG resulting in impaired 
synthesis of mtDNA (71,171). This results 
in depletion of genes transcribed by it such 
as those involved in the mitochondrial 
respiratory chain and the generation of 
ATP, a major cellular fuel molecule (71,171). 
Impaired synthesis of proteins required 
for such processes as respiratory chain 
function and β-oxidation leads to failure 
of affected mitochondria to meet cells’ 
energy requirements and, consequently 
jeopardizes the viability of these cells (293).
5.3.2.3. Adipose tissue inflammation
Macrophages, present in abundance 
in the lipoatrophic SAT of patients 
with cART-associated lipodystrophy 
(80,159,224,291,292), are known to be 
a source of proinflammatory cytokines 
and chemokines (447). The attraction of 
macrophages to the adipose tissue and 
release of inflammatory mediators by 
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them is stimulated by factors such as the 
presence of apoptotic cells within the 
tissue (447), also a recognized feature 
of cART-associated lipodystrophy (80). 
Endoplasmic reticulum stress caused by, 
e.g., FFA overflow (121) characteristic to 
cART-associated lipodystrophy (130,256), 
can activate the inflammatory pathways 
and cytokine response even further 
(305). Moreover, hypercytokinemia 
has been speculated to result from 
dysregulation of the TNFA system as a 
part of the immune reconstruction that 
follows initiation of cART (205). In a 
setting outside HIV-1, TNFA, the most 
extensively studied cytokine, has been 
found to inhibit expression of genes 
involved in adipogenesis (365), hamper 
LPL activity (106) and increase lipolysis 
by downregulation of PLIN1 (331,433), 
thereby leading to adipocyte apoptosis and 
consequent loss of adipose tissue mass 
(317). These mechanisms of cytokine-
induced lipotoxicity seem to hold true 
also in patients with cART-associated 
lipodystrophy. Indeed, expression of 
TNFA mRNA has been reported to 
correlate inversely with gene expression 
of adipogenic transcription factors in SAT 
(12,159). Furthermore, the loss of limb 
fat has been associated with high serum 
concentrations of soluble TNFA receptors 
(165,279) and IL6 (165) in vivo in humans. 
Finally, the rates of release of TNFA and IL6 
from in cultured human adipocytes have 
been reported to be associated with the loss 
of limb fat (165). It has been hypothesized 
that TNFA and cART may have 
independent and synergistic deleterious 
effects on adipose tissue metabolism, as 
exposure to TNFA of adipocytes cultured 
in the presence of PIs has been reported 
as enhancing the anti-adipogenic effects 
beyond what was seen with PIs alone (267).
5.3.3. Lipohypertrophy
While lipoatrophy has been studied 
extensively, lipohypertrophy remains 
poorly understood. Low circulating growth 
hormone concentrations have been 
reported in HIV-1-infected patients with 
IAT accumulation (324), similar to what 
can be seen outside the HIV-1-setting in 
growth hormone deficiency, a condition 
characterized by abdominal obesity, lipid 
abnormalities and insulin resistance (67). 
Studies of the hypothalamic-pituitary-
adrenal axis prompted by the similarities 
in body fat distribution between cART-
associated lipodystrophy and Cushing’s 
syndrome have ruled out the possibility that 
lipohypertrophy associated with exposure to 
cART is a form of systemic hypercortisolism 
(261,437). It has been suggested, however, 
that local increases in concentrations of 
glucocorticoids and/or their receptors 
could induce regional (dorsocervical, 
intra-abdominal) adiposity by stimulating 
LPL activity (193). In HIV-1-negative 
obese subjects, IAT is known to express 
significantly higher mRNA concentration 
of 11β-hydroxysteroid dehydrogenase, 
an enzyme that catalyzes the conversion 
of cortisol from its inactive metabolite 
cortisone. Furthermore, IAT from these 
subjects has been reported to have greater 
glucocorticoid receptor density than their 
abdominal SAT, perhaps explaining why 
IAT appears to be intrinsically predisposed 
to excessive growth (29). While adipose 
tissue samples from hypertrophic depots of 
patients with cART-associated lipodystrophy 
have never been studied in this regard, 
gene expression of 11β-hydroxysteroid 
dehydrogenase has been reported to be 
significantly higher in the lipoatrophic SAT 
of cART-treated patients than in SAT from 
the non-lipoatrophic ones (371).
Prior to Study IV, no studies had 
performed a comprehensive comparison 
of hypertrophic (e.g., dorsocervical 
depot) to lipoatrophic adipose tissue (e.g., 
abdominal subcutaneous depot) harvested 
from the same individuals. Furthermore, 
no studies had attempted to elucidate 
why the depots behave differently within 
the same individual even though they 
are under the influence of the same 
external factors. A study comparing 
lipohypertrophic and lipoatrophic 
samples from different patients with 
cART-associated lipodystrophy has 
reported hypertrophic SAT to harbor less 
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inflammation than lipoatrophic SAT (126). 
The authors interpreted the relative lack 
of inflammation as a prerequisite for the 
preservation of the dorsocervical region 
unaffected by lipoatrophy (126). A Dutch 
research group utilized a completely 
different approach and generated animal 
models in an attempt to elucidate the 
regional differences in susceptibility to the 
toxic effects of antiretroviral drugs. This 
group suggested that cART-associated 
lipodystrophy results from cART-induced 
selective damage to the autonomic 
innervation of adipose tissue depots, 
leading to variable alterations in hormonal 
signaling and adipose tissue homeostasis 
depending on the region of the body 
affected (100). Interestingly, switch studies 
(both away from PIs and from tNRTIs) 
have generated controversial results. 
These studies reported little to mainly 
no resultant decrease in IAT, provoking 
speculations whether the phenomenon 
of abdominal obesity in cART-treated 
patients may be due more to the currently 
ongoing obesity epidemic in the general 
population than be an actual side effect of 
cART (272). In keeping with this, a 4-week 
exposure of HIV-1-negative subjects to a 
PI indinavir did not increase the amount 
of IAT as measured by MRI (294).
5.3.4. Insulin resistance
Based on in vitro studies using 3T3-L1 
and 3T3-F442A preadipocytes, it has 
been suggested that PIs reduce insulin-
stimulated glucose uptake by selectively 
inhibiting transport activity of GLUT4 
(15,278,329), interfere with protein 
kinase B phosporylation (15,329), and 
decrease mitogen-activated protein 
kinase activation at a downstream step 
in postreceptor insulin signaling (44). 
These findings are supported by the in 
vivo data from HIV-1-negative subjects in 
whom short-term administration of PIs 
indinavir (294,296) and ritonavir-boosted 
lopinavir (295), but not of atazanavir 
(295), decreased insulin-stimulated 
glucose disposal rate as measured by 
hyperinsulinemic euglycemic clamp.
Obesity and lipodystrophy share several 
features that link both conditions to insulin 
resistance despite the differences in their 
phenotype. Liver fat accumulation is 
associated with insulin resistance in both 
conditions (191,369). Hepatic steatosis and 
non-alcoholic steatohepatitis in insulin 
resistant lipodystrophic cART-treated 
patients has been associated with high 
gene expression of SREBP1C and low gene 
expression of PPARG in the liver (210). 
This is in line with the stimulatory effect of 
insulin, typically high in insulin resistant 
subjects with fatty liver, on SREBP1C 
expression (353). Increased expression 
of SREBP1C, in turn, further contributes 
to increased hepatic lipogenesis, thus, 
linking hyperinsulinemia and increased 
SREBP1C expression with high triglyceride 
and low HDL cholesterol concentrations 
seen in cART-associated lipodystrophy 
(268). Reduction of insulin sensitivity of 
lipolysis that accompanies cART-associated 
lipodystrophy, results in high concentrations 
of circulating FFAs (130,256). Accordingly, 
circulating FFA concentrations in these 
patients have been shown to correlate with 
insulin concentrations both in the fasting 
state and in response to a glucose challenge 
(130,256). Moreover, pharmacological 
inhibition of lipolysis and FFA production 
with the anti-lipolytic agent acipimox has 
been demonstrated to improve insulin 
sensitivity in patients with cART-associated 
lipodystrophy (134). These data further 
support the causal relationship between 
increased circulating FFAs and insulin 
resistance in these patients, just as it has 
been described in individuals who are 
not infected with HIV-1 (195,254,441). 
Other features that cART-associated 
lipodystrophy and obesity have in common 
include low concentrations of adiponectin 
mRNA (126,372) and protein (372,387), as 
well as adipose tissue inflammation that has 
been verified histologically (80,159,224), 
immunohistochemically (291,292) and at 
the level of gene and protein expression 
(12,126,165,168,222). Both decreased 
adiponectin (12) and increased adipose 
tissue inflammation (279) have been 
positively correlated with measures of 
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insulin resistance in patients with cART-
associated lipodystrophy (216,448). 
Furthermore, just as in obese subjects 
without HIV-1, these changes are likely to 
contribute to insulin resistance also in HIV-
1-infected cART-treated patients.
In contrast to findings in obesity, leptin 
concentrations have been found to be low 
in SAT of patients with cART-associated 
lipodystrophy (12,52,159,281,369) and 
in other human lipodystrophies (114). 
Nonetheless, leptin does appear to play 
some role in insulin resistance in the 
lipodystrophic patients, as treatment 
of hypoleptinemic HIV-1-negative 
lipodystrophic patients with leptin 
has been seen to mitigate their insulin 
resistance (161,303,311). 
5.3.5. Dyslipidemia
While a certain degree of dyslipidemia 
occurs in HIV-1-infected patients due to 
viral infection per se (125), a randomized, 
double-blind 2-week ritonavir-exposure 
study in HIV-1-negative subjects has 
reported an increase in concentrations of 
triglyceride and VLDL cholesterol, and a 
decrease in concentration HDL cholesterol 
in subjects on ritonavir as compared to those 
on placebo (318). These findings suggest 
that the detrimental effects of PIs on lipids 
can occur independently of HIV-1 infection 
(318). As mentioned in conjunction with 
lipohypertrophy, decreased circulating 
concentration of growth hormone 
documented in patients with cART-
associated lipodystrophy is known to be 
associated with lipid abnormalities (67). 
In vitro studies have reported that PIs 
stimulate the production of triglyceride-
rich particles in murine hepatocytes (211), 
increase lipolysis in mature adipocytes 
(15,212,320,329), perhaps by reducing 
LPL activity (211,320), and inhibit 
proteasome activity, inducing endoplasmic 
reticulum stress (308). Interestingly, all 
these effects are also known to represent 
a link between obesity, insulin resistance 
and dyslipidemia (121,305). Inhibition 
of proteasomal degradation by PIs has 
also been shown to ensue accumulation 
of apolipoprotein B, leading to increased 
VLDL secretion that has been proposed 
as a potential mechanism by which PIs 
may induce dyslipidemia in the setting 
of cART-associated lipodystrophy (218). 
Moreover, patients with cART associated 
lipodystrophy have been reported to have 
fatty liver (369), a condition renown 
for overproduction of VLDL (4) leading 
to high concentrations of circulating 
triglycerides and low HDL cholesterol 
(192). Dyslipidemia in cART-treated 
patients may also be a consequence of 
lipodystrophic changes in the adipose 
tissue rendering it unable to take up 
circulating triglycerides and excessively 
release the stored fatty acids as seen in 
lipodystrophy syndromes unrelated to 
cART (114). 
SREBP1C has also been hypothesized 
to be involved in the pathogenesis of 
dyslipidemia seen in cART-associated 
lipodystrophy as i) treatment of mice with 
PIs increases the abundance of SREBP1C 
protein in the nucleus of their hepatocytes 
and induces hypertriglyceridemia, ii) 
transgenic mice overexpressing nuclear 
SREBP1C in adipose tissue were reported 
to show complete congenital lipoatrophy, 
severe dyslipidemia and insulin 
resistance (354), and iii) single nucleotide 
polymorphism in the SREBP1C gene was 
found to predispose cART-treated patients 
to hypertriglyceridemia (262). However, the 
exact pathogenetic mechanism involving 
SREBP1C remains obscure as controversial 
results of both high (12,286,323) and low 
nuclear SREBP1C protein concentrations 
(43,44) have been reported after exposure 
to PIs in adipocyte cultures, murine 
adipocytes and hepatocytes as well as in 
human adipose tissue in vivo. Attempts to 
explain this controversy have focused on 
functional differences between the SREBP1 
isoforms and non-discrimination between 
them (154,155), as well as on varying cell 
culture protocols (286). Nonetheless, a 
speculative theory linking lipodystrophy, 
dyslipidemia and insulin resistance has 
been proposed based on the assumption of 
elevated concentrations of active SREBP1C 
protein in adipocytes and hepatocytes 
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being the driving force of this constellation 
of abnormalities (268). 
5.3.6. Role of HIV-1 infection
HIV-1 infection itself does not seem to 
bring about lipodystrophic changes in body 
fat as the lipodystrophy syndrome seen in 
HIV-1-infected cART-treated patients has 
never been reported in untreated HIV-1-
infected patients, even in those with a high 
viral load (46). Furthermore, in most cases 
cART-associated peripheral lipoatrophy is 
reversible after changes in cART, without 
changes in HIV-1 RNA load (140). Data 
challenging these arguments, however, 
exist suggesting that HIV-1 infection per 
se initiates reduction of gene expression of 
adipogenic transcription factors (CEBPA, 
PPARG), adipokines (leptin, adiponectin) 
and mitochondrial respiratory chain 
components, making adipose tissue 
vulnerable to the toxic effects of cART (117). 
Moreover, expression of inflammatory 
cytokines such as TNFA has been reported 
to be upregulated in patients with CD4+ 
T-cell count <50 cells/mm3 as compared 
to less immunosuppressed HIV-1-infected 
patients (407). These findings are in 
line with data implicating the severity 
of immunosuppression as a risk factor 
for the development of cART-associated 
lipodystrophy (51).
HIV-1 replication has been documented 
to have a direct, cART-independent 
impact on lipid parameters and glucose 
homeostasis in humans (86). In a study 
involving antiretroviral-naïve HIV-1-
infected patients, higher triglyceride and 
VLDL cholesterol concentrations, lower 
HDL and LDL cholesterol concentrations, 
and decreased insulin sensitivity have been 
associated with lower CD4+ T-cell count 
and higher viremia (86). In another study 
comparing plasma lipids of patient with 
AIDS, latent HIV-1 infection and healthy 
controls, HDL cholesterol concentration 
and triglyceride clearance were lower, 
while triglyceride and FFA concentrations 
seemed unaffected in asymptomatic HIV-
1-infected patients as compared to healthy 
controls (125). Progression to symptomatic 
HIV-1 disease and, subsequently, to AIDS 
was found to lead to a further decline in 
HDL cholesterol concentration and to 
increases in triglyceride, VLDL cholesterol 
and FFA concentrations (125). Increased 
concentration of interferon α, a cytokine 
associated with the progression of HIV-1 
infection, was proposed to contribute to 
high circulating triglyceride concentration 
by decreasing triglyceride clearance (125) 
and increasing hepatic lipogenesis (145). 
Moreover, antiretroviral treatment of 
HIV-1 infection, even with zidovudine 
monotherapy, has been reported as 
reducing both interferon α and triglyceride 
concentrations (124). Disturbances in 
lipid metabolism, thus, may represent a 
non-specific, probably cytokine-mediated, 
response to a chronic infection rather than 
to the HI virus specifically. 
Unlike dyslipidemia, insulin resistance 
and type 2 diabetes were originally 
perceived to be rare in untreated HIV-
1-infected patients (86,178). However, 
when matched for BMI and waist-to-hip 
ratio with HIV-1-negative subjects, HIV-1-
infected antiretroviral-naïve patients were 
found to have up to a 2.2-fold increase in 
the relative risk of diabetes (26). 
5.3.7. Host-related factors 
Several cross-sectional and prospective 
studies have identified host factors that 
place individuals at a greater risk of 
developing lipodystrophic changes while 
on cART (46,122,238). These include 
increasing age and, more controversially, 
female gender, low body weight at the start 
of cART and greater CD4+ T-cell and HIV-1 
RNA responses to commencement of cART 
(46,122,238). Furthermore, dysregulation 
of proinflammatory cytokine homeostasis, 
which can be seen during immune 
reconstruction associated with reversal of 
HIV-1 disease progression, may play a role 
in the development of cART-associated 
lipodystrophy (205,221). As some patients 
get severe side effects from cART and 
some do not, it has been hypothesized that 
genetic factors play a role in predisposition 
to these adverse effects. Indeed, several 
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single nucleotide polymorphisms in 
genes involved in lipid metabolism such 
as SREBP1C (262), apolipoprotein E 
and in the apolipoprotein A1/C3/A4/A5 
cluster (379) have been identified in HIV-
1-infected patients. Enrichment of these 
polymorphisms in certain populations 
might explain why patients of certain 
origin and, thus, genetic background, are 
more/less prone to develop dyslipidemia 
when exposed to cART.
5.4. Significance of cART-associated
lipodystrophy 
5.4.1. Psychological repercussions
Lipodystrophic disfigurement can be 
obvious to the most cursory observation 
and may lead to unwanted disclosure of 
HIV-1 infection and stigmatization (69). 
Lipodystrophy has a profound impact 
on patients’ health-related quality of life 
causing discomfort, erosion of self-image 
and self-esteem, altered social, sexual 
and work-related habits and, at worse, 
can result in social exclusion, depression 
and seclusion (69,128). Together, these 
effects might jeopardize adherence to, and 
even lead to discontinuation of, otherwise 
efficacious antiretroviral therapy (128). 
These considerations, as well as the 
measurable metabolic disturbances, justify 
the ongoing research into pathogenesis and 
potential treatments of cART-associated 
lipodystrophy.
5.4.2. Liver complications
Ectopic accumulation of fat in the liver 
in the absence of excessive alcohol use or 
other underlying conditions and exceeding 
liver triglyceride content of 5.56% (375) is 
termed non-alcoholic fatty liver disease 
(NAFLD). NAFLD is, on one hand, 
associated with insulin resistance and type 
2 diabetes (192) and, on the other hand, 
can progress to more severe conditions 
such as non-alcoholic steatohepatitis, 
cirrhosis and, even, hepatocellular 
carcinoma (253). Both increased liver 
fat (369) and greater prevalence of non-
alcoholic steatohepatitis (210) have been 
reported in lipodystrophic as compared to 
non-lipodystrophic cART-treated patients. 
In HIV-1-infected patients, an additional 
risk factor for the development severe 
liver diseases is the high prevalence of co-
infection with hepatitis viruses B and C 
due to common modes of transmission.
5.4.3. Type 2 diabetes
As cART-associated lipodystrophy 
features accumulation of IAT and liver 
fat as well as development of insulin 
resistance (47,122,164,193), its presence 
increases the risk of developing type 2 
diabetes. While hyperinsulinemia may 
initially compensate for insulin resistance 
and maintain normoglycemia, insulin 
production eventually becomes exhausted 
leading to frank hyperglycemia and 
type 2 diabetes. Indeed, the presence of 
cART-associated lipodystrophy has been 
reported as associated with a 9.1-fold risk of 
impaired glucose tolerance and a 6.5-fold 
risk of type 2 diabetes compared to that of 
HIV-1-negative subjects matched for age, 
gender and BMI, even after adjustment for 
waist-to-hip ratio (132). The prevalence 
and incidence of type 2 diabetes in HIV-
1-infected cART-treated patients have 
been estimated as 2-5 times greater than 
in the general population despite the 
similar prevalence rates of overweight 
and obesity (337). Some of the studies 
included in the cited review, however, 
were carried out in patients on currently 
outdated antiretroviral regimens and, as 
less toxic drugs have become available, 
these prevalence figures may decrease in 
the future. In assessing the prevalence of 
type 2 diabetes in this patient population 
it is also important to keep in mind other 
possible confounders of such analyses, 
e.g., trends in obesity, nutrition, active as 
opposed to sedentary lifestyle and genetic 
predisposition to diabetes.
5.4.4. Cardiovascular disease 
Atherogenic lipid profiles, diabetes, 
hypertension, abdominal obesity, impaired 
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fibrinolysis and a significant prevalence 
of smoking in patients infected with 
HIV-1 as compared to HIV-1-negative 
subjects translate into increased rates of 
cardiovascular morbidity (181,389) and 
mortality (68) in the former group. While 
the aforementioned risk factors, except for 
smoking, are all features of cART-associated 
lipodystrophy, the presence of lipodystrophy 
per se has not been associated with an 
increased cardiovascular risk independent 
of these factors (109). On a positive note, 
the prevalence of cardiovascular risk 
factors, such as smoking and dyslipidemia, 
and the incidence of myocardial infarction, 
seems to be decreasing in HIV-1-infected 
patients over time (119,333).
Antiretroviral drugs may directly 
increase accumulation of cholesteryl 
esters in macrophages and, thus, increase 
the risk of atheroma formation (82) 
independent of their dyslipidemic effects. 
Duration of antiretroviral therapy has 
been documented as increasing the risk 
of cardiovascular events (74,108,110,247), 
with a large DAD Study reporting up to 
a 26% increase in the risk of myocardial 
infarction per each year on cART (109). 
More recently, further analyses of the 
DAD Study have identified specific classes 
of antiretroviral drugs (mostly PIs) (108) 
and individual antiretroviral agents (PIs 
indinavir and ritonavir-boosted lopinavir 
and NRTIs didanosine and abacavir) 
(334,431) as associated with the greatest 
increase in the risk of myocardial infarction. 
As antiretrovirals have detrimental effects 
on cardiovascular health, the Strategies 
for Management of Antiretroviral Therapy 
(SMART) Study was undertaken to explore 
the effects of minimizing exposure to 
antiretroviral agents using intermittent 
therapy (85). Surprisingly, intermittent, 
as compared to continuous, cART 
resulted in a significant increase in the 
incidence of cardiovascular events and 
all-cause mortality, and the study had to 
be terminated early (85). The exploratory 
analyses that followed SMART revealed 
that intermittent, but not continuous, 
cART resulted in a decrease in total, large, 
medium and small HDL particles, and in an 
increase in concentrations of hs-CRP, IL6 
and D-dimer (84). These markers were all 
associated with higher cardiovascular risk 
status and correlated with an increase of 
HIV-1 RNA that followed cART interruption 
(84). Thus, increased cardiovascular 
morbidity was proposed as attributable to 
the development of an unfavorable ratio of 
total-to-HDL cholesterol concentrations, 
and activation of inflammation, thrombosis 
and fibrinolysis caused by increased 
viremia upon halting the antiretroviral 
treatment (84).
5.5. Treatment of cART-associated 
lipodystrophy 
5.5.1. Management of lipoatrophy
5.5.1.1. Switch studies
As PIs were originally suspected to 
cause cART-associated lipodystrophy, 
several switch studies were performed 
to replace PIs, either with a NNRTI or 
abacavir. These studies documented 
alleviation of the metabolic disturbances 
following the switch, but little impact 
on IAT accumulation was seen, and 
even a tendency towards worsened 
peripheral lipoatrophy was reported 
(49,244,285,330). These results, however, 
are challenging to compare and interpret 
due to differences in study size and design, 
measurements available and duration of 
follow-up (140). With recognition of NRTI 
toxicity as a key factor in the pathogenesis 
of cART-associated lipodystrophy (25), 
attention has been drawn to switching 
away from NRTIs. Studies have shown 
that substituting tNRTIs (stavudine, 
zidovudine) with less toxic non-thymidine-
based NRTIs (abacavir, tenofovir) or with 
a NRTI-sparing regimen altogether leads 
to a slow reversal of cART-associated 
lipoatrophy (23,56,163,243,251,273,274,381,
382). However, depending on the patients’ 
history of antiretroviral use, issues such 
as HIV-1 drug resistance and tolerability 
may arise, and changes in antiretroviral 
regimens may not always be feasible. 
Furthermore, while switch studies away 
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from tNRTIs result in the gain of peripheral 
SAT, amount of IAT and disturbances 
in glucose and lipid homeostasis remain 
unchanged (56,163,243,251,273,274), if 
not deteriorate (23,382).
 
5.5.1.2.  Thiazolidinediones
Thiazolidinediones are insulin-
sensitizing agents that act as ligands for 
PPARG. Although efficient in improving 
glycemic parameters in diabetic patients 
(440), thiazolidinediones are known 
to have an untoward side effect in this 
predominantly overweight population, 
namely gain of, what has been proposed 
to be subcutaneous, fat mass (41,270,360). 
As inhibition of the PPARG pathway in 
adipocyte differentiation was hypothesized 
to be causative of lipoatrophy (12,53) 
and in vitro PPARG agonists had been 
shown to revert this inhibition (44), 
thiazolidinediones seemed an ideal choice 
for a pharmacological intervention to 
treat cART-associated lipodystrophy. 
This view was further fortified by data 
reporting that troglitazone ameliorated the 
metabolic disturbances and subcutaneous 
lipoatrophy in patients with non-HIV-1-
related lipodystrophies (7). 
Thiazolidinediones have been studied 
extensively for the treatment of cART-
associated lipodystrophy (319,350,368). 
A number of randomized double-blind 
placebo-controlled studies of rosiglitazone 
or pioglitazone, using lipodystrophy/ 
-atrophy as the main inclusion criteria 
and with an objective method for 
measurement of SAT (MRI, CT, DEXA or 
combination thereof) have been performed 
(55,57,135,359,370). Surprisingly, most 
(55,57,359,370), though not all (135), 
have failed to result in improvements of 
subcutaneous lipoatrophy in cART-treated 
patients. Moreover, while effective in 
reducing liver fat and alleviating insulin 
resistance, treatment with rosiglitazone, 
but not pioglitazone, tended to worsen 
proatherogenic dyslipidemia in these 
patients (370). 
The available evidence summarized 
in recent reviews and meta-analyses 
(319,350,368) does not support the use 
of thiazolidinediones for the treatment 
of cART-associated lipoatrophy. 
They may, however, be beneficial in a 
subgroup of lipoatrophic patients that 
have been switched away from the 
most lipotoxic antiretrovirals (55,359). 
Thiazolidinediones are recognized 
to be efficient in improving insulin 
sensitivity in patients with cART-
associated lipodystrophy and can be 
used for that indication in this group 
of patients (319,350,368). Troglitazone 
and rosiglitazone have, however, been 
withdrawn from the market due to severe 
hepatotoxicity (101) and increased risk 
of cardiovascular complications (93), 
respectively. Pioglitazone remains a 
treatment option, although its safety has 
also been recently questioned (94).
5.5.1.3. Leptin
Concentrations of leptin mRNA (12,159) 
and circulating leptin protein (52,281,369) 
have been reported as lower in patients 
with cART-associated lipodystrophy, 
consistent with their reduced adipose tissue 
mass, as compared to non-lipodystrophic 
cART-treated patients (52,281) and 
HIV-1-negative subjects (12,159,369). 
Leptin treatment in hypoleptinemic 
HIV-1-negative lipodystrophic patients 
has resulted in the reversal of insulin 
resistance, dyslipidemia and hepatic 
steatosis (161,303,311). Unfortunately, 
in some (161,303), but not in all (311), 
studies leptin therapy also decreased 
weight and body fat percentage, although 
adipose tissue loss was not specified by 
body compartments. These data prompted 
investigations of leptin substitution 
therapy as a potential treatment also for 
cART-associated lipoatrophy (206,275). 
In these studies, leptin was well-tolerated 
and led to a decrease in intra-abdominal/
truncal fat, but had no effect on peripheral 
or liver fat (206,275). Leptin also improved 
lipid profiles and whole-body insulin 
sensitivity of glucose and lipid metabolism 
(206,275). Thus, while ameliorating several 
metabolic disturbances, administration of 
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leptin provided no solution for lipoatrophy 
in cART-treated patients. 
5.5.1.4. Uridine 
Mitochondrial toxicity caused by 
NRTI-induced inhibition of mtDNA-
replicating POLG has been proposed 
as the basis of the pathophysiology 
of cART-associated lipoatrophy (25). 
De novo synthesis of pyrimidine 
nucleotides, the building blocks of DNA, 
is dependent on an intact mitochondrial 
respiratory chain, a dysfunction of which 
can ultimately lead to a deficiency of 
intracellular pyrimidines, jeopardizing 
DNA synthesis (225). Theoretically, the 
consequences of mitochondrial toxicity 
can be overcome, even in the presence 
of the original toxic agents, by providing 
exogenous pyrimidines to replenish the 
endogenous depleted pyrimidine pool. 
Indeed, in vitro studies with uridine, 
a precursor of pyrimidine nucleotides, 
have demonstrated that uridine increases 
mtDNA concentrations and ameliorates 
signs of mitochondrial toxicity in adipocyte 
cultures (414). Although theoretically 
possible via a mechanism of competitive 
inhibition, uridine has not been shown 
in in vitro studies to compromise the 
antiretroviral efficacy of NRTIs. Prior to 
Study V, uridine had not been used for any 
indication in HIV-1-infected patients. In 
HIV-1-negative subjects, however, uridine 
had been used to prevent and revert 
5-fluorouracil-induced cytotoxicity in the 
treatment of malignancies (177,396,397), 
and as supplementation for hereditary 
orotic aciduria, an inherited disorder of 
pyrimidine metabolism (13,118). Uridine 
was shown to be safe and reasonably 
well-tolerated with diarrhea being the 
dose-limiting side effect. Intravenous 
administration of uridine, however, had 
been associated with febrile reactions and 
phlebitis (177,396,397). 
5.5.1.5. Restorative surgical interventions 
Facial lipoatrophy is, understandably, 
the most stigmatizing element of cART-
associated lipodystrophy. While switch 
studies and other therapeutic strategies 
for the treatment of cART-associated 
lipodystrophy have demonstrated slow 
reversal of SAT (vide supra), restorative 
surgical interventions have emerged as 
a quicker and more satisfactory solution 
(40,127). These interventions have been 
shown to improve the quality of life of 
lipodystrophic patients and to decrease 
depression and anxiety as evaluated by 
validated surveys (127). Studies have also 
proven them to be cost-effective in terms 
of quality-adjusted life years (312).
There are several treatment options 
currently available: i) autologous 
fat transplantation, ii) injection of 
biodegradable (collagen, hyaluronic acid, 
poly-L-lactic acid, calcium hydroxyapatite) 
or non-biodegradable (silicone, 
polymethylmethacrylate, polyacrylamide, 
polyalkylimide) fillers and iii) placement 
of alloplastic implants made of polymeric 
silicone, polytetrafluoroethylene or 
polyethylene (40,127). While implants and 
non-biodegradable fillers are permanent, 
the filling effect of the biodegradable 
products is estimated to be 6-12 months, 
after which the effect wears off, and the 
procedure can be repeated with the same or 
a different agent (127). The data, however, 
are limited to the follow-up period of the 
studies ranging from 6 to 24 months (127). 
The operative risks are greater with 
autologous fat transplantation and implant 
placement than with the use of injectable 
fillers, as the former techniques require 
invasive surgery necessitating anesthesia 
and longer post-procedure recovery time 
(40,127). Injection treatments have their 
risks also in form of acute and delayed 
adverse reactions attributable to either 
the procedure itself or the filling agent 
used. Acute events are mostly transient 
and include injection site reactions such 
as edema, tenderness, pain, erythema, 
pruritus, hematoma and bleeding (40,127). 
Some of the more serious acute adverse 
events are asymmetry, lumps caused by 
uneven filler distribution, infection or 
even tissue necrosis (40,127). Delayed 
events may occur from weeks to years after 
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product application and include filler/
implant migration or, alternatively, rigid 
persistence in their placement while the 
facial contours change with age, scarring 
due to fibrosis and overt collagenization, 
skin discoloration, acute or chronic 
infections, and graft rejection reactions 
(40,127). One should remain cautious 
about the use of permanent fillers/implants 
as cART-associated lipodystrophy can 
resolve or progress over time rendering 
the fillings excessively prominent and 
noticeable. Moreover, from the safety 
point of view, the use of permanent fillers/
implants is not recommended as the long-
term complications of permanent fillers/
implants can prove very difficult to treat 
(367). 
5.5.2. Management of lipohypertrophy
5.5.2.1. Lifestyle modifications
Longitudinal studies assessing the effects 
of aerobic exercise and/or endurance 
training in cART-treated patients with 
and without lipodystrophy have reported 
preferential decreases in IAT (386) and 
waist circumference (79), increases lean 
body mass (438), but no changes in SAT 
(79,386) or body fat percentage (438) 
in the exercise group as compared to 
the observation follow-up group. Some 
studies, however, have documented 
decreases in body fat as a result of 
intensive exercise (167,328), but were not 
designed to specify whether the lost fat 
was IAT or SAT. Exercise was reported to 
improve lipid profiles, especially fasting 
triglyceride concentrations, but had no 
effect on insulin sensitivity (386). The 
combination of a hypocaloric diet low in 
saturated fat with an exercise regime has 
proved effective at reducing both IAT and 
SAT significantly but had no impact on 
glucose or lipids in cART-treated women 
with general obesity (90). Retrospective 
case-control studies have suggested that 
diets rich in protein and fiber are associated 
with a lower risk of accumulation of IAT 
in cART-treated patients (146). Overall, 
a supervised balanced diet and versatile 
exercise programs can be concluded as 
worthwhile and beneficial in managing 
cART-associated lipohypertrophy and 
concomitant metabolic disturbances, 
but may reduce SAT in exceptionally 
lipoatrophic individuals.
5.5.2.2. Growth hormone –related 
treatments 
Administration of components of the 
growth hormone axis (growth hormone, 
insulin-like growth factor, growth hormone 
releasing hormone and recombinant 
human growth hormone releasing factor 
also known as tesamorelin) has been 
investigated as a potential strategy to 
treat hypertrophic IAT in patients with 
cART-associated lipodystrophy (358). The 
basis of this research was data suggesting 
that HIV-1-infected patients with IAT 
accumulation have reduced circulating 
growth hormone concentrations (324) 
along with reports of the lipolytic effect 
of growth hormone analogue therapy 
being associated with reduced abdominal 
obesity, and improved insulin sensitivity 
and lipid profiles in HIV-1-negative obese 
subjects (162). 
A recent meta-analysis of 10 
randomized, double-blinded, placebo-
controlled trials with growth hormone 
axis treatments for cART-associated 
lipodystrophy evaluated the efficacy 
and safety of these interventions (358). 
Although, when pooled together, the 
growth hormone axis treatments exerted 
a beneficial effect on body composition 
by decreasing IAT and improving glucose 
and triglyceride concentrations with no 
concurrent decrease in SAT, individual 
agents had varying effects (358). Of the 
different agents studied, tesamorelin has 
shown the greatest potential for clinical use 
(123). In two large phase III studies (96), 
tesamorelin significantly decreased the 
amount of IAT, triglyceride concentration 
and the ratio of total to HDL cholesterol 
concentrations whilst having no effect on 
fasting plasma glucose and fasting serum 
insulin concentrations, or OGTT results. A 
small, but statistically significant, increase 
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in glycosylated hemoglobin A1c (HbA1c) 
of 0.12% was seen (96). Of particular 
importance in the context of cART-
associated lipodystrophy, the lipolytic 
effect of tesamorelin was limited to IAT 
with no decrease in SAT (96). 
Although promising and having already 
received approval by the U.S. Food and 
Drug Administration (102), tesamorelin 
therapy has a number of concerns 
regarding it use. Firstly, tesamorelin is 
administered by daily subcutaneously 
injections. Secondly, treatment with 
tesamorelin is costly and reimbursement is 
limited. Thirdly, effects of tesamorelin are 
reversed after cessation of the therapy (96) 
while the long-term safety of the therapy 
remains to be established. 
5.5.2.3. Restorative surgical interventions
Suction-, ultrasound- and laser-assisted 
lipectomy techniques have been used 
as treatment options for enlarged 
dorsocervical fat pads (302,349). The 
rate of recurrence after liposuction 
alone, however, is relatively high (349). 
Excisional lipectomy with or without 
concomitant liposuction may give more 
sustainable results (418). 
5.5.3. Management of insulin resistance 
and type 2 diabetes
Metformin has been studied as a treatment 
for insulin resistance in cART-treated 
patients with or without lipodystrophy/ 
-atrophy (131,183,246,277,335,356,403). 
In these studies, while ameliorating insulin 
resistance, this treatment worsened 
lipoatrophy. Nonetheless, metformin 
is currently the drug of choice for the 
treatment of type 2 diabetes in HIV-1-
infected cART-treated patients unless 
contraindications exist (91). Pioglitazone 
can be an alternative, especially for 
lipoatrophic patients (91). Sulfonylureas 
and insulin can be used as mono or add-
on therapy as in the general population 
(91). Newer anti-diabetic agents, such as 
incretin mimetics or gliptins, have yet to 
be studied in HIV-1-infected cART-treated 
patients. If they are used, potential drug-
drug interactions must be kept in mind.
5.5.4. Management of dyslipidemia
Switching the antiretroviral regimen to one 
causing less dyslipidemia is considered the 
best solution if patient’s other conditions 
and drug resistance profile allow the 
switch (367). If lipid-lowering medication 
is needed, its potential interactions with 
the antiretrovirals have to be considered 
(e.g., those mediated by cytochrome P450 
3A4 isoform). Pravastatin and rosuvastatin 
are safe and most widely used, while 
simvastatin is contraindicated with PIs 
(91). Atorvastatin can be used but requires 
close follow-up and careful dose titration 
(91). Fibrates, ezetimibe, plant stanols/
sterols and fish oil supplementation can be 
used as in the general population (91).
5.5.5. Management of other risk factors
Angiotensin-converting enzyme inhibitors 
and angiotensin II receptor blockers 
with and without diuretics are safe with 
regards to drug-drug interactions and 
are recommend for the treatment of 
hypertension in HIV-1-infected cART-
treated patients (91). Some calcium 
channel blockers might interact with PIs 
and NNRTIs and are preferably avoided 
(91). Β-blockers are mostly used in HIV-
1-infected cART-treated patients with 
coronary artery disease (91).
The most important behavioral risk 
factors for cardiovascular disease are 
tobacco use, unhealthy diet and physical 
inactivity (429). Accordingly, HIV-1-
infected patients should be motivated to 
stop smoking, if needed with the support 
of nicotine substitution and bupropion 
or varenicline therapy (91). Varenicline 
appears to be safer than bupropion with 
respect to drug-drug interactions (91). 
Diet recommendations for HIV-1-infected 
patients do not differ from those given for 
the general population (91). Finally, patients 
with cART-associated lipodystrophy 
should be motivated to engage in regular 
moderate-intensity exercise (91). 
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AIMS OF THE STUDY
The present studies were undertaken to answer the following questions:
I. Does the use of antiretroviral therapy or the presence of cART-associated lipodystrophy 
affect arterial stiffness, an independent predictor of cardiovascular mortality, as assessed 
by a technique of pulse wave analysis? 
II. Is gene expression of macrophage markers and inflammatory cytokines upregulated 
in the abdominal SAT of lipoatrophic as compared to non-lipoatrophic cART-treated 
patients? Is adipose tissue inflammation correlated with liver fat content? 
III. Is the amount of mtDNA, adipose tissue inflammation and gene expression involved 
in multiple cellular functions different in SAT of patients with and without cART-
associated lipoatrophy? Is the effect similar between the lipoatrophic users of stavudine 
as compared to those treated with zidovudine? 
IV. How does the abdominal SAT (lipoatrophic in cART-associated lipodystrophy) 
differ from the dorsocervical SAT (unaffected or hypertrophied in cART-associated 
lipodystrophy) in patients with and without cART-associated lipodystrophy? 
V. Can oral uridine supplementation revert lipoatrophy and the associated metabolic 
disturbances without changing current cART?
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SUBJECTS, 
STUDY DESIGNS
AND METHODS
1. SUBJECTS 
All study subjects (n=64) were recruited 
from the HIV outpatient clinic of the 
Helsinki University Central Hospital. 
Subjects had to be older than 18 years of age, 
infected with HIV-1, treated with cART for 
at least 18 months prior to enrollment and 
clinically stable with no signs or symptoms 
of current opportunistic infections. No 
medication changes, either of cART or 
other medications, were allowed within the 
last three months preceding the studies. 
Exclusion criteria included pregnancy and 
signs, symptoms or biochemical evidence of 
active diseases other than HIV-1. Lactation, 
allergy to milk proteins (the uridine 
supplement used in Study V contained milk 
protein) and current use of didanosine (no 
evidence from in vitro studies indicated 
that uridine can abrogate lipotoxicity of 
didanosine which is a purine rather than 
a pyrimidine analogue (414,416)) were 
additional exclusion criteria in Study V. 
None of the study subjects were carriers of 
hepatitis virus B or C. Flow chart of patient 
recruitment to Studies I-V is given in Figure 
4. Characteristics of the study subjects are 
provided in Tables 3a and 3b.
Figure 4. Flow chart demonstrating enrollment of HIV-1-infected patients with (cART+LD+) and without 
(cART+LD-) combination antiretroviral therapy –associated lipodystrophy to Studies I-V. Group 1 was recruited 
in 2001 and Group 2 in 2004-2005. The two groups had seven lipodystrophic and five non-lipodystrophic 
patients in common. In addition to patients from Group 1, eleven lipodystrophic and four non-lipodystrophic 
patients from Group 2 participated in Study I. For purposes of clarity, all study groups in the figure are termed 
as being treated with cART (an up-to-date term that has currently substituted the previously used term “highly 
active antiretroviral therapy, HAART” that, as mentioned in the text, was used in Studies I-III and V).
 
Figure 4.
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Variable
Number of subjects (male/female)
Age (y)
Body composition
Body weight (kg)
BMI (kg/m2)
Waist-to-hip ratio 
Total abdominal adipose tissue (cm3)
Abdominal subcutaneous adipose tissue (cm3)
Intra-abdominal adipose tissue (cm3)
Liver fat (%)
Features of insulin resistance
fP-glucose (mmol/L)
fS-insulin (mU/L)
fS-triglycerides (mmol/L)
fS-HDL cholesterol (mmol/L)
HIV-1-related characteristics
Time since diagnosis (years)
Total duration of cART (years)
Current NRTI (%)
Current NNRTI (%)
Current PI (%)
Most recent CD4+ T-cell count (cells/mm3)
Undetectable HIV-1 viral load (%)
Study IV
cART+LD+
18/3
47 ± 2
73.8 ± 2.8
23.6 ± 0.7
1.00 ± 0.01*
3510 ± 250
1290 ± 250
2220 ± 260**
3.0 (1.5 – 11.3)**
5.1 (4.9 – 5.7)
12.8 ± 2.4*
3.4 ± 0.5*
1.2 ± 0.1**
9.1 ± 1.0
5.9 ± 0.4*
100
20*
95**
545 ± 57
86
Study V
Uridine
9/1
47 ± 2
76.7 ± 4.7
24.4 ± 1.1
1.01 ± 0.02
3740 ± 560
1420 ± 420
2230 ± 300
5.9 ± 2.8
6.2 ± 1.1
12.3 ± 3.8
2.9 ± 0.4
1.3 ± 0.1
11.1 ± 1.4
6.0 ± 0.6
100
20
100
594 ± 81
90
Placebo
8/2
49 ± 5
70.5 ± 3.2
22.6 ± 0.9
0.99 ± 0.02
3420 ± 520
1250 ± 390
2180 ± 470
12.4 ± 4.7
5.4 ± 0.5
13.7 ± 5.7
3.0 ± 0.4
1.2 ± 0.1
8.7 ± 1.4
6.3 ± 0.6
100
20
90
517 ± 88
80
cART+LD-
10/1
44 ± 3
75.4 ± 3.1
23.7 ± 0.8
0.92 ± 0.02
2780 ± 410
1870 ± 270
910 ± 170
1.0 (0.75 – 1.5)
5.3 (5.1 – 5.8)
4.9 ± 0.5
1.6 ± 0.3
1.8 ± 0.1
7.8 ± 1.3
3.8 ± 0.5
100
80
20
522 ± 44
100
Table 3b. Characteristics of the study subjects (Studies IV-V).
Data are shown as mean ± SEM or median (25% percentile – 75% percentile), as appropriate. p-values: *<0.05, 
**<0.005. BMI, body mass index; cART, combination antiretroviral therapy (treatment with three or more 
antiretroviral drugs used concurrently); cART+LA+, HIV-1-infected patients with combination antiretroviral 
therapy –associated lipodystrophy; cART+LA-, HIV-1-infected patients without combination antiretroviral 
therapy –associated lipodystrophy; HDL, high-density lipoprotein; HIV-1, human immunodeficiency virus type 
1; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, 
protease inhibitor. Adapted from Sevastianova et al. Diabetes 2011; 60:1894-900 (Study IV) and Sutinen et al. 
Antiviral Therapy 2007; 12:97-105 (Study V), data are reproduced with permission of the copyright holders.
Classification as a lipodystrophic patient 
(HAART+LD+ in Studies I-III and V; 
cART+LD+ in Study IV) required i) self-
reported symptoms of loss of SAT with or 
without enlargement of abdominal girth, 
increase in breast size or accumulation of 
adipose tissue in the dorsocervical region (also 
known as buffalo hump) and ii) confirmation 
of these findings by a single investigator. 
Patients without lipodystrophy (HAART+LD- 
in Studies I-III and V; cART+LD- in Study 
IV) had received cART without developing 
the aforementioned changes in body fat 
distribution.
The purpose, nature and potential risks 
of the studies were explained to the patients 
before their written informed consent 
was obtained. The study protocols were 
approved by the Ethics Committee of the 
Department of Medicine at the Helsinki 
University Central Hospital. The clinical trial 
involving uridine (Study V) was investigator-
initiated and undertaken independently of 
the manufacturer of the uridine supplement, 
Nucleomaxx® (Pharma Trade Healthcare, 
Spånga, Sweden). Study V was registered in the 
clinical trial registry of the Helsinki University 
Central Hospital and was compliant with 
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the revised CONSORT statement guidelines 
(www.consort-statement.org).
2. STUDY DESIGNS
2.1. Design of Study I
In this cross-sectional study, PWA was 
carried out in order to measure and compare 
arterial stiffness in HIV-1-infected cART-
treated patients with (HAART+LD+, 
n=42) and without (HAART+LD-, n=17) 
cART-associated lipodystrophy. Multiple 
linear regression analysis was performed 
to identify determinants of arterial 
stiffness in the aforementioned patients.
2.2. Design of Study II 
In this cross-sectional study, gene 
expression of macrophage markers (CD68; 
intergrin αM, ITGAM; epidermal growth 
factor –like module-containing, mucin-
like, hormone receptor –like 1, EMR1; a 
disintegrin and metalloproteinase domain 
8, ADAM8) and inflammatory cytokines 
(CCL2; CCL3; TNFA) in a needle aspiration 
biopsy of abdominal SAT was measured by 
real-time reverse transcriptase polymerase 
chain reaction (RT-PCR) and correlated 
with liver fat content, measured by 
1H-MRS, in HIV-1-infected cART-treated 
patients with (HAART+LD+, n=27) and 
without (HAART+LD-, n=13) cART-
associated lipodystrophy.
2.3. Design of Study III
In this cross-sectional study, real-time 
RT-PCR –measured mtDNA content 
and gene expression of genes involved 
in mitochondrial energy metabolism 
(cytochrome c oxidase subunit III, 
COX3; cytochrome c oxidase subunit IV, 
COX4; 16S ribosomal RNA, 16SRNA), 
mitochondrial biogenesis (DNA 
polymerase γ (catalytic subunit), POLG1; 
DNA polymerase γ (accessory subunit), 
POLG2; TFAM; PGC1B), adipogenesis 
(CEBPA; CEBPB; LMNA; lamin B, 
LMNB; PPARG, peroxisome proliferator 
–activated receptor γ subunit 2, PPARG2; 
SREBP1C), lipid and glucose metabolism 
(FASN; PLIN1; GLUT4; hexokinase I, 
HEXOK1), and in apoptosis, inflammation 
and oxidative stress (factor of apoptotic 
stimulus, FAS; proliferating cell nuclear 
antigen, PCNA, tumor protein p53, 
p53; TNFA; IL6; interleukin 1β, IL1B; 
glutathione peroxidase transcript 1, 
GPX1; superoxide dismutase 1, SOD1) 
were compared between HIV-1-infected 
cART-treated patients with (LA+, n=18) 
and without (LA-, n=10) cART-associated 
lipoatrophy. Also, immunohistochemical 
stainings indicative of inflammation 
(CD68) and tissue vitality (PLIN1) were 
compared between the same study 
groups. A subgroup analysis of the same 
parameters was conducted within the 
LA+ group comparing patients receiving 
stavudine (d4T+LA+, n=8) to those 
receiving zidovudine (AZT+LA+, n=10). 
Analyses were carried out in surgical 
adipose tissue biopsy specimens of the 
abdominal SAT.
2.4. Design of Study IV
In this cross-sectional study, surgical biopsy 
specimens of dorsocervical and abdominal 
SAT were compared in HIV-1-infected 
cART-treated patients with (cART+LD+, 
n=21) and without (cART+LD-, n=11) 
cART-associated lipodystrophy using 
histology, microarray and real-time RT-
PCR. MRI technology was utilized to image 
both adipose tissue depots.
2.5. Design of Study V
In this investigator-initiated, double-
blind, placebo-controlled trial, 20 HIV-
1-infected patients with cART-associated 
lipoatrophy were randomized to receive 
either a dietary uridine supplement (36g 
tid for 10 consecutive days/month) or 
placebo for 3 months. Measurements of 
body composition were performed before 
and after the intervention. These included 
quantification of IAT and abdominal SAT 
by MRI, total body, trunk and limb fat by 
DEXA, and liver fat content by 1H-MRS. 
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Secondary aims included evaluation of 
the effects of uridine on features of insulin 
resistance and safety parameters. For the 
purpose of these secondary analyses, blood 
samples were taken at baseline, after each 
10-day course of treatment with uridine 
(days 11, 41 and 71) and at 3 months. 
Adherence to the supplement was verified by 
measuring blood concentrations of uridine 
at baseline, days 41 and 71 and at 3 months. 
Patients were seen by the study physician at 
baseline, day 41 and at 3 months.
3. METHODS
All subjects on all occasions were studied 
after an overnight fast. Unless otherwise 
stated, the methods below have been used 
in Studies I-V.
3.1. BODY COMPOSITION 
3.1.1. Anthropometric indices
Body weight and height were measured 
barefoot in light clothing. Body weight 
was read via a digital scale with a 
precision of measurement of 0.1 kg and 
height via a non-stretchable tape with a 
0.1 cm precision. Body circumferences 
were measured in triplicate using a non-
stretchable tape and recorded to the 
nearest 0.5 cm. Circumferences were 
measured midway between the lower rib 
margin and the iliac crest for the waist, 
and over the greater trochanters for the hip 
(430). Skinfold thickness (mean values of 
triplicate measurements) was determined 
at five sites (triceps, biceps, iliac crest, 
thigh and cheek in Studies I-II and triceps, 
biceps, iliac crest, thigh and scapula in 
Study IV) (442).
3.1.2. Bioelectric impedance analysis 
Body fat free mass and the percentage of 
body fat were determined (Studies I-II) 
using bioelectric impedance (BIA) analysis 
(BioElectrical Impedance Analyzer System 
model #BIA-101A;RJL Systems, Detroit, 
MI) (87,228).
3.1.3. Dual-energy X-ray absorptiometry
Limb, trunk and total body fat as well as 
lean body mass were measured (Studies 
III-V) using a DEXA scanner (Lunar 
Prodigy, Madison, WI). 
3.1.4. Magnetic resonance imaging 
Volumes of IAT and abdominal SAT (Studies 
II-V) were quantified by analyzing 16 T1-
weighted two-dimensional fast low angle 
shot trans-axial MRI scans reaching 8 cm 
above and 8 cm below the 4th and 5th lumbar 
interspace (slice thickness 10 mm, field 
of view 375 x 500 mm2, time of repetition 
138.9 ms, echo time 4.1 ms). In addition, 
in Study IV the dorsocervical SAT volume 
was measured from scans covering the area 
from the interspace between the 2nd and 3rd 
cervical vertebra to the lower edge of the 
scapulae (slice thickness 5 mm, field of view 
315 x 500 mm2, time of repetition 159 ms, 
echo time 4.1 ms). Volumes of adipose tissue 
depots were calculated in a blinded fashion 
using an image analysis software (Alice 3.0, 
Parexel, Waltham, MA). A histogram of the 
pixel intensity of each scan was displayed 
and intensity corresponding to the nadir 
between lean and adipose tissue peaks 
was used as a cut-off threshold. Adipose 
tissue was defined as the area of pixels with 
intensity values above this threshold. In 
case of abdominal scans, this area equaled 
total abdominal adipose tissue. Thereafter, 
pixels corresponding to IAT were manually 
erased and the remaining area, covering 
abdominal SAT, was calculated. IAT volume 
was calculated by subtracting SAT volume 
from the total abdominal adipose tissue 
volume. In the case of dorsocervical SAT, 
additional limits defining the depot were 
set at the lateral-most point of the neck/
shoulders or that of head of humerus, when 
visible, and the lateral-most point of the 
back below the level of armpits. 
3.1.5. Proton magnetic resonance 
spectroscopy
Liver fat content was measured using 
1H-MRS (Studies II, IV-V). In this 
51
Subjects, Study Designs and Methods
procedure, localized single voxel (2 x 2 x 
2 cm3) proton spectra were recorded using 
a 1.5 tesla whole body system (Magnetom 
Vision, Siemens, Erlangen, Germany) that 
consisted of a combination of whole body 
and loop surface coils for radiofrequency 
transmitting and signal receiving. T1-
weighted high-resolution MRI images were 
used for localization of a voxel of interest 
that was carefully positioned in the right 
lobe of the liver, avoiding large vessels, 
bile ducts and the gall bladder. Subjects 
were required to lie on their stomach on 
the surface coil embedded in the mattress, 
in order to ensure a firm contact between 
the chest wall and the coil, and to minimize 
movement artifact due to breathing. The 
single voxel spectra were recorded using the 
stimulated echo acquisition mode sequence 
(echo time of 20 ms, repetition time of 
3000 ms, mixing time 30 ms, 1024 data 
points over 1000 kHz spectral width with 32 
averages). Water-suppressed spectra with 
128 averages were recorded to detect weak 
lipid signals. Long repetition time and short 
echo time were chosen to minimize the 
effects of T1 and T2 relaxations, and ensure 
fully relaxed water signal which was used as 
the internal standard. Chemical shifts were 
measured relative to water at 4.80 parts per 
million. The methylene signal, representing 
triglycerides, was recorded at 1.4 parts per 
million (374). As there is no extrahepatocytic 
fat in the liver, the methylene signal can 
be directly extrapolated to represent the 
intrahepatocytic fat. Signal intensities 
were quantified using an analysis program 
VAPRO-MRUI (www.mrui.uab.es/mrui/). 
Spectroscopic intrahepatocytic triglyceride 
content was expressed as a ratio of the area 
under the methylene peak to that of the 
sum of the areas under the methylene and 
the water peaks (x 100 = percentage of liver 
fat). All spectra were analyzed by a single 
physicist blinded to other research data.
3.2. SUBCUTANEOUS ADIPOSE 
TISSUE BIOPSIES
3.2.1. Needle aspiration biopsy
A small area of skin in the abdominal 
area was anesthetized with 1% lidocaine 
without epinephrine. A biopsy needle 
(14G), attached to a tight-fitting syringe, 
was inserted through the infiltrated skin 
and small samples of adipose tissue were 
aspirated by vacuum suction (Study II). The 
adipose tissue samples were thoroughly 
rinsed with sterile saline and immediately 
thereafter frozen in liquid nitrogen and 
stored in -80ºC until analysis. 
3.2.2. Surgical biopsies 
Following local anesthesia with 1% 
lidocaine without epinephrine, surgical 
adipose tissue biopsies were taken from 
the midway between the iliac crest and 
the umbilicus as well as from the midline 
at the base of the neck (Studies III-V). 
The adipose tissue sample was thoroughly 
rinsed with sterile saline. Part of the 
biopsy was immediately snap-frozen in 
liquid nitrogen and stored in -80ºC until 
analysis. Another part of the tissue sample 
was formalin-fixed and paraffin-embedded 
for subsequent histological (Study IV) 
and immunohistochemical (Study III) 
analyses.
3.3. MITOCHONDRIAL DNA 
CONTENT
In Studies III-IV, mtDNA content of the 
adipose tissue samples was quantified. 
Genomic DNA was extracted from adipose 
tissue with the QIAamp DNA isolation 
kit (Qiagen, Hilden, Germany). MtDNA 
and nuclear DNA (nDNA) copy numbers 
were determined by real-time RT-PCR 
using the ABI 7700 sequence detection 
system (PE Applied Biosystems, Foster 
City, CA). The mtDNA-encoded ATP 
synthase 6 gene was amplified between 
nucleotide positions 8981 and 9061. 
MtDNA was quantified with a FAM 
fluorophore –labeled probe (5´-6FAM-
CCTAACCGCTAACATTACTGCAGGCCACC-
TAMRA-3´). For the detection of nDNA, 
exon number 8 of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) 
gene between nucleotide positions 
4280 and 4342 was selected and a VIC 
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fluorophore –labeled probe (5´-VIC-
C C C T G C C T C T A C T G G C G C T G C C -
TAMRA-3´) used. Amplifications of 
mitochondrial and nuclear products 
were performed separately in optical 
96-well plates (PE Applied Biosystems, 
Foster City, CA) using assays by the same 
manufacturer. All samples were run in 
triplicate. Absolute mtDNA and nDNA 
copy numbers were calculated using serial 
dilutions of plasmids with known copy 
numbers.
3.4. GENE EXPRESSION
3.4.1. RNA extraction and cDNA 
preparation
Frozen adipose tissue (50 - 150 mg) was 
homogenized using either the RNA STAT-
60 (Tel-Test, Friendswood, TX; Study 
II) or the Geneclean kit (Bio101 systems, 
Obiogene Inc., Carlsbad, CA; Studies III-
IV). Total RNA was extracted with the 
RNeasy Lipid Tissue Kit (Qiagen, Hilden, 
Germany) as per the manufacturer’s 
instructions. After the DNase treatment 
(RNase-free DNase set, Qiagen, 
Hilden, Germany), RNA was purified 
using the RNeasy mini kit (Qiagen, 
Hilden, Germany). RNA concentrations 
were measured using the RiboGreen 
fluorescent nucleic acid stain (RNA 
quantification kit, Molecular Probes, 
Eugene, OR) and the quality of RNAs was 
assessed by agarose gel electrophoresis 
(Study II). Alternatively, in Studies III-
IV, quantity and integrity of RNA were 
verified using RNA 6000 nanochips 
(Agilent 2100 Bioanalyzer, Palo Alto, 
CA).  Average yields of total RNA were 
3 ± 1 μg per 100 mg of adipose tissue wet 
weight and did not differ between any 
of the study groups (data not shown). 
Isolated RNA was either transcribed into 
complimentary DNA (cDNA) directly or 
stored at -80°C until further processing. 
Transcription of RNA into cDNA was done 
using Moloney murine leukemia virus 
reverse transcriptase (Life Technologies, 
Paisley, U.K.; Study II), the Superscript II 
(Invitrogen, Carlsbad, CA; Studies III-IV) 
and oligo(dT)12-18 primers (Invitrogen) 
or the SuperScript VILO cDNA synthesis 
kit (Invitrogen). cDNA was stored at 
-80°C until further analysis.
3.4.2. Real-time reverse transcriptase 
polymerase chain reaction
Quantification of messenger RNAs 
(mRNA) of all genes in Study II and of 
homeobox genes in Study IV was performed 
using TaqMan semiquantitative RT-
PCR assays (TaqMan® Gene Expression 
Assays, PE Applied Biosystems, Foster 
City, CA) and commercially available 
primers (vide infra) according to the 
manufacturer’s protocol using the ABI 
PRISM 7000 Sequence Detection System 
instrument and appropriate software (PE 
Applied Biosystems, Foster City, CA). 
Quantification of mRNAs of all genes in 
Study III and of CD68 in Study IV was 
done using the LightCycler 480 (Roche, 
Penzberg, Germany) with SYBR® Green 
assays by Roche. Primer pairs were 
designed in an intron-spanning fashion 
to avoid non-specific amplification of 
contaminating genomic DNA using the 
universal probe library from Roche 
(www.universalprobelibrary.com). The 
conditions of real-time RT-PCR were 
optimized for linearity of amplification 
for all primers in a dilution series. Melting 
curve analysis was done to ensure that all 
investigated genes were represented by a 
single peak, indicating specificity. The 
real-time RT-PCR for UCP1 (Study IV) 
was carried out as a pilot study in a subset 
of samples (n=6) from individuals with 
the largest “buffalo humps” on clinical 
evaluation on the ABI PRISM 7900HT 
instrument and software (PE Applied 
Biosystems, Foster City, CA), using the 
Power SYBR® Green PCR Master Mix by 
the same manufacturer.
All samples were run in duplicate. 
Expression of target genes was quantified 
(arbitrary units) by generating a six-point 
serially diluted standard curve (Studies 
II-IV) (419). The following housekeeping 
genes were used: β2-microglobulin (B2M) 
(Study II), the mean of expression of actin β 
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Gene
16SRNA
36B4*
36B4**
ACTB*
ACTB†
ATP6
B2M*
B2M††
CD68
CEBPA
CEBPB
COX3
COX4
FAS
FASN
GADPH
GLUT4
GPX1
HEXOK1
HOXA10
HOXC9
HOXC8
IL1B
IL6
LMNA
LMNB
p53
PCNA
PGC1B
PLIN1
POLG1
POLG2
PPARG
PPARG2
SHOX2
SOD1
SREBP1C
TFAM
TNFA
UCP1
Forward primer 5’ – 3’
CGATTAAAGTCCTACGTGATCTGA
CTGGAAAACAACCCAGCTCT
CATGCTCAACATCTCCCCCTTCTCC
ATTGGCAATGAGCGGTTC 
GAGCTACGAGCTGCCTGACG
ACCAATAGCCCTGGCCGTAC
TTCTGGCCTGGAGGCTATC
GCCTGCCGTGTGAACCAT
GAATTTTATAAATGTGACGAACTGC
CAACACTTGTATCTGGCCTCTG
AACCTGGAGACGCAGCAC
TCCAAACATCACTTTGGCTTC
CACCGCGCTCGTTATCAT
TGAATCTCCAACCTTAAATCCTG
CTGGTGATGAACGTCTACCG
CGGGGCTCTCCAGAACATC
CTGTGCCATCCTGATGACTG
ATGTGTGCTGCTCGGCTA
GACCAAGTTTCTCTCTCAGATCG
GAGAGCAGCAAAGCCTCGC
GCCTGCTGCCTCAGCACAG
TCTCCAACTCAGGCTACCAG 
CTGTCCTGCGTGTTGAAAGA
GATGAGTACAAAAGTCCTGATCCA
AGCAAAGTGCGTGAGGAGTT
AGCTGGAGTGGTTGTTGAGG
AGGCCTTGGAACTCAAGGAT
TGTCACAGACAAGTAATGTCGATAAA
GAAGAGGAAGAAGGGGAGGA
GGACACAGTGGTGCATTACG
GAGAAGGCCCAGCAGATGTA
CCAGTGGCTTGATTTCTGGT
GGCCCAGATACACTGACTACG
GACCTGAAACTTCAAGAGTACCAAA
TGTTCGTGTGGATGCACGTG
TCATCAATTTCGAGCAGAAGG
GACACACCAGCTCCTCGAC
GTTTCTCCGAAGCATGTGG
CAGCCTCTTCTCCTTCCTGA
CTGGAATAGCGGCGTGCTT
Backward primer 5’ – 3’ 
AGGGAGGAATTTGAAGTAGATAGAAA
GAACACAAAGCCCACATTCC
GGGAAGGTGTAATCCGTCTCCACAG
GGATGCCACAGGACTCCAT
GTAGTTTCGTGGATGCCACAG
GGTGGCGCTTCCAATTAGGT
TCAGGAAATTTGACTTTCCATTC
TTACATGTCTCGATCCCACTTAACTAT
GGAAAACCCCGTCAAAGATT
CCGAGCAAAACCAAAACAAA
CAGCTGCTCCACCTTCTTCT
AACCACATCTACAAAATGCCAGT
TGGCCACCCACTCTTTGT
TGACTCCAGCAATAGTGGTGAT
GGCTCCTCAGGCTTGTCC
ATGACCTTGCCCACAGCCT
CGTAGCTCATGGCTGGAACT
CGAGAAGGCATACACCGACT
CCTAGCTGCTGGAGGATAGC
CCAGTGTCTGGTGCTTCGTG
GAACCCTCCCAAATCGCAAG
TGAGCCCCATAAAGGGACTGT
TTGGGTAATTTTTGGGATCTACA
CTGCAGCCACTGGTTCTGT
AGGTCACCCTCCTTCTTGGT
TTGGATGCTCTTGGGGTTC
CCCTTTTTGGACTTCAGGTG
GAACTGGTTCATTCATCTCTATGG
GGTAGGGGCAGTGGTCAG
GTCCCGGAATTCGCTCTC
ATCCGACAGCCGATACCA
AAGTTAGATGGACTCATGGCAAA
TGGCTTCATACTTGCTTTTCC
TGAGGCTTATTGTAGAGCTGAGTC
GAAACCAAACCTGCACTCGG
CAGGCCTTCAGTCAGTCCTTT
GTAGCAGGAGGCCAGCAG
GCACAGCTCTGCTCCAGAC
GCCAGAGGGCTGATTAGAGA
AATAACACTGGACGTCGGGC
*Used in Studies III and IV. **Used in Study IV as a housekeeping gene in homeobox gene analysis only. 
†Used in Study IV as a housekeeping gene in UCP1 analysis only. ††Used in Study II. For full names of the 
genes, please see text. Adapted from Sievers et al. Journal of Infectious Diseases 2009; 200:252-62 (Study III) 
and Sevastianova et al. Diabetes 2011; 60:1894-900 (Study IV), data are reproduced with permission of the 
copyright holders.
Table 4. Primer sequences of the studied genes.
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3.5. HISTOLOGY
Histological appearance of adipose 
tissue samples was evaluated in Study 
IV. Formalin-fixed, paraffin-embedded 
adipose tissue samples were sectioned 
using a standard protocol. The slides 
were stained with hematoxylin and eosin 
and examined under the light microscope 
(Nikon Eclipse 80i, Nikon Corporation, 
Tokyo, Japan) for the amount of connective 
tissue, vascularization, lipogranulomata 
(i.e., lipid-laden macrophages encircling 
adipocytes), degree of adipocyte size 
variation, and for the presence of non-
intact cells (due to membrane ruptures) 
and brown adipocytes. Images for 
publication were taken using computer 
software compatible with the microscope 
(NIS-Elements 3.0, Nikon Corporation, 
Tokyo, Japan).
3.6. IMMUNOHISTOCHEMISTRY
Adipose tissue biopsies were used for 
immunohistochemical analysis (Study 
III). CD68 served as a marker for 
macrophages and PLIN1 as a marker for 
viable adipocytes (66). Sectioning was 
performed using a standard protocol for 
formalin-fixed paraffin-embedded tissue 
blocks. Consecutive serial sections were 
treated with xylene, descending ethanol 
dilution series and distilled water to dewax 
the tissue samples. Thereafter, sections 
were microwave-treated in 10mM citrate 
buffer (pH 6.0) and washed alternately 
with distilled water, hydrogen peroxide 
and phosphate-buffered saline (PBS) 
with 0.25% Triton X-100 (pH 7.2) to 
inactivate endogenous staining. Non-
specific staining was reduced by applying 
normal goat serum (1:5, Dako, Glostrup, 
Denmark) to the sections for 30 min. 
Samples were then incubated at room 
temperature with mouse monoclonal anti-
CD68 (1:200; Novocastra Laboratories 
Ltd, Newcastle upon Tyne, U.K.) or 
guinea pig polyclonal anti-PLIN1 (1:1000; 
Acris Antibodies GmbH, Hiddenhausen, 
Germany). For negative controls of CD68 
staining, mouse monoclonal isotypic 
(ACTB), acidic ribosomal phosphoprotein 
P0 (36B4) and B2M (Study III and IV) 
and 36B4 or ACTB (Study IV). Gene 
expression was given relative to that of 
B2M (Study II) or calculated from the real-
time RT-PCR efficiency (313) in relation 
to housekeeping genes (Studies III-IV). 
Non-regulation of the housekeeping genes 
was validated by geNorm version 3.4 
(PrimerDesign, Southampton, U.K.; Study 
III) (404).
The assay ID of commercially available 
primers (PE Applied Biosystems, Foster 
City, CA) were: CD68 (Hs00154355_
m1), ITGAM (Hs00355885_m1), and 
EMR1 (Hs00173562_m1), ADAM8 
(Hs00174246_m1), CCL2 (Hs00234140_
m1), CCL3 (Hs00234142_m1), TNFA 
(Hs00174128_m1). The sequences of in-
house primers are provided in Table 4. 
3.4.3. Microarray
1 µg/sample of total RNA was indirectly 
labeled using the T7 amplification 
method (Amino Allyl MessageAmpTM 
II aRNA Amplification Kit, Ambion, 
Austin, TX) according to the 
manufacturer’s instructions. The 
amplified RNA (aRNA, 5 µg/sample) 
was labeled using monoreactive Cy3 
and Cy5 dyes (GE Healthcare, GE Life 
Sciences, Uppsala, Sweden) followed by 
purification according the manufacturer’s 
instructions. Labeled aRNAs were 
hybridized onto Whole Human 
Genome 4x44K microarrays (Agilent 
Technologies, Santa Clara, CA) according 
to the manufacturer’s instructions. The 
slides were then washed according to the 
instructions with buffers from Agilent and 
scanned with the GenePix 4200 AL (Axon 
Instruments, Molecular Devices, Silicon 
Valley, CA) at the resolution of 5 µm/
pixel and at 16 bit depth. The analysis was 
carried out as comparison of dorsocervical 
to abdominal SAT in the cART+LD+ and 
the cART+LD- groups separately. DAVID 
Bioinformatics Resources version 6.7 
(http://david.abcc.ncifcrf.gov) was used 
to select over-represented pathways and 
gene categories (158).
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control (1:200; Abcam, Cambridge, U.K.) 
was used as a primary antibody. For PLIN1 
negative control, the primary antibody 
was omitted. After rinsing in PBS-Triton 
X-100 buffer, sections were incubated 
with biotinylated anti-mouse (1:1500; 
Vector Laboratories Inc., Burlingame, 
CA) or anti-guinea pig (1:1500; Abcam, 
Cambridge, U.K.) secondary antibodies. 
Avidin-biotin peroxidase complexes 
(Vector Laboratories Inc., Burlingame, 
CA) were added followed by visualization 
with 3,3-diaminobenzidine tetrachloride 
(Vector Laboratories Inc., Burlingame, 
CA). Following washes with distilled water, 
ascending ethanol series and xylene, 
sections were counterstained with Harris 
hematoxylin (Histolab, Gothenburg, 
Sweden). For each sample, the number 
of macrophages, crown-like structures 
(CLS) and PLIN1-free adipocytes within 
the entire section were counted using 
light microscopy and normalized for the 
total section area. Macrophages were 
identified as CD68-positive cells and CLSs 
were defined as one PLIN1-free adipocyte 
surrounded by at least three macrophages 
(66). Measurement of total section area 
using arbitrary units was performed using 
Adobe Photoshop Elements version 1.0.1 
(AdobeSystems Inc., San Jose, CA).
3.7. PULSE WAVE ANALYSIS
To determine central aortic pulse pressure 
and the augmentation index, pulse waves 
were recorded from the radial artery, with 
the wrist slightly extended and supported 
on a pillow, by applanation tonometry 
using a Millar tonometer (SPC-301, Millar 
Instruments, Houston, TX). Data were 
collected directly into a desktop computer 
and processed with the SphygmoCor 
Blood Pressure Analysis System (BPAS-1, 
PWV Medical, Sydney, Australia) which 
allows continuous online recording of 
the radial artery pressure waveform. The 
radial waveform was assessed visually to 
ensure that artifacts from movement and 
respiration are minimized. The mean of 
three recordings, each consisting of 15 to 
20 sequential radial artery waveforms, was 
used for subsequent analysis. The integral 
system software was used to generate an 
average radial artery waveform and the 
corresponding central ascending aortic 
pressure waveform applying a previously 
validated transfer factor (58,175,300). 
The aortic waveform was then subject to 
further analysis for calculation of aortic 
augmentation, the aortic augmentation 
index as well as central systolic, diastolic 
and pulse pressure (for definitions of the 
measurements, please see Figure 2). As 
the augmentation index is known to vary 
with heart rate (424), a correction formula 
was used to derive augmentation index 
values corrected for heart rate (AgIHR) 
(424). Aortic, and not radial artery, 
data were used for further analyses as 
aortic characteristics are more predictive 
of cardiovascular morbidity. This is 
because the aorta, an elastic capacitance 
vessel, shows more pronounced changes 
in structure and function with ageing 
and co-morbidities than the muscular 
peripheral conduit vessels. As suggested 
by O’Rourke et al. (300), the radial 
blood pressure was calibrated against 
the sphygmomanometrically determined 
brachial blood pressure, ignoring the 
small degree of amplification between 
the brachial and radial sites. Pulse 
wave analysis and sphygmomanometric 
measurements were conducted after a 
minimum of 15 min of acclimatization and 
prior to blood sampling.
3.8. LABORATORY ANALYSES
Plasma glucose concentrations were 
measured using a hexokinase method 
(Studies I-II, IV-V), serum total (Studies 
I, IV-V) and HDL cholesterol (Studies 
I-II, IV-V) and triglyceride concentrations 
(Studies I-II, IV-V) with respective 
enzymatic kits from Roche Diagnostics 
using an autoanalyzer (Roche Diagnostics 
Hitachi 917, Hitachi Ltd., Tokyo, Japan). 
The concentration of LDL cholesterol 
(Studies I, IV) was calculated using the 
formula of Friedewald (107). Serum 
FFAs (Study II) were measured by 
fluorometric assay (260). Serum free 
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insulin concentrations were determined by 
radioimmunoassay (Phadeseph® Insulin 
RIA, Pharmacia & Upjohn Diagnostics, 
Uppsala, Sweden) after precipitation with 
polyethylene glycol (Study II) and by time-
resolved fluoroimmunoassay (Studies I, 
IV-V) using the Insulin Kit (AUTOdelfia, 
Wallac, Turku, Finland). C-peptide 
concentrations were measured using 
the C-peptide Kits on the AUTOdelfia 
apparatus (Studies I, IV). HbA1c was 
measured on an autoanalyzer (DCA 
2000 Analyzer, Bayer Ames Technicon, 
Tarrytown, NY; Study I) by high pressure 
liquid chromatography (Study V) using the 
fully automated Glycosylated Hemoglobin 
Analyzer System (BioRad, Richmond, 
CA). The homeostasis model assessment 
of insulin resistance (HOMA-IR; Studies 
II, IV-V) was calculated from the formula: 
fasting glucose (mmol/L) x fasting insulin 
(mU/L) / 22.5 (248). Serum ALT activity 
(Studies I, IV-V) was determined according 
to the recommendations of the European 
Committee for Clinical Laboratory 
Standards using the Roche Diagnostics 
Hitachi 917 analyzer. Plasma sodium 
(Studies I and V), potassium (Studies I 
and V), chloride (Study V) and bicarbonate 
(Study V) concentrations were determined 
with indirect ion-selective electrodes and 
plasma creatinine (Studies I and V) with 
an enzymatic kit from Roche Diagnostics 
using an autoanalyzer (Roche Diagnostics 
Hitachi Modulator, Hitachi Ltd., Tokyo, 
Japan). Anion gap (Study V) was calculated 
from the electrolyte concentrations using 
the formula ([sodium ion] + [potassium 
ion]) - ([chloride ion] + [bicarbonate ion]), 
with all units expressed in mmol/L. Venous 
blood gas analysis (Study V) was performed 
using specific electrodes with a blood gas 
analyzer (Ciba Corning 850, Medfield, 
MA). Plasma lactate concentration (Study 
V) was measured using an enzymatic kit 
from Roche Diagnostics which utilized 
an autoanalyzer (Cobas Integra 400/800, 
Roche Instrument Center, Rotkreutz, 
Switzerland). Serum CRP (Studies I-II, 
IV-V) was analyzed using a high sensitivity 
commercial kit (Ultrasensitive CRP Kit, 
Orion Diagnostica, Espoo, Finland). 
CD4+ T-cell count was determined using 
a flowcytometric apparatus (FACSort/
FACSCalibur, Beckton Dickinson, San 
José, CA). HIV RNA load was measured 
using either the Cobas HIV-1 Amplicor 
Monitor version 1.5, normal or ultra 
sensitive (Roche Diagnostics, Branchburg, 
NJ; Studies I-II) or the HPS Cobas TaqMan 
48n HIV-1 Test (Roche Diagnostics, 
Branchburg, NJ; Studies I, III-V), with a 
detection limit of 1.7 log10 copies/mL in 
both assays. Serum uridine concentrations 
(Study V) were measured using high 
performance liquid chromatography as 
previously described (453). 
3.9. STATISTICAL METHODS
All data were tested for normality of 
distribution using a Kolmogorov-Smirnov 
test. In Studies I and II, logarithmic 
transformation was performed on data 
that were not normally distributed, and 
the unpaired t-test was used to assess the 
differences between the study groups. 
In Studies III-V, unpaired and paired 
t-tests, Mann-Whitney test and Wilcoxon 
matched pairs test for continuous variables 
were used, as appropriate. Categorical 
variables were compared using Fisher’s 
exact test (Studies I-III, V) or Chi-square 
test (Study IV), as appropriate. In Study 
V, safety laboratory follow-up data were 
analyzed using ANOVA for repeated 
measures. Microarray (Study IV) results 
were analyzed using Benjamini and 
Hochberg post hoc correction for multiple 
comparisons.
Correlation analyses were performed 
with Pearson product-moment 
correlation coefficient after logarithmic 
transformation, when necessary 
(Studies II-III), or with Spearman’s non-
parametric correlation coefficient (Studies 
I,IV). Multiple linear regression analyses 
(Study I) were performed to identify 
the independent determinants of the 
augmentation index. 
All calculations were carried out using 
Lotus 1-2-3 of Lotus SmartSuite Release 
9.5 (Lotus Development Corporation, 
IBM Corporation, New York City, NY; 
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Studies I-V), SPSS version 11.0.1 (SPSS 
Inc., Chicago, IL; Study I), Sigma Stat for 
Windows software version 3.0 (Jandel 
Corporation, San Rafael, CA; Study III) or 
GraphPad Prism version 3.02 (Studies I, II, 
III, V) or version 4.03 (Study IV) (GraphPad 
Software Inc., San Diego, CA). Data are 
expressed as mean ± standard error of 
mean (SEM) or median (25% percentile 
– 75% percentile), as appropriate. Two-
tailed p-values <0.05 were considered 
statistically significant in all analyses 
except for that of microarray in which the 
statistical significance was set to p≤0.01. 
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RESULTS
1. ARTERIAL STIFFNESS IN 
cART-ASSOCIATED 
LIPODYSTROPHY (STUDY I)
1.1. Study subjects
A total of 59 HIV-1-infected cART-treated 
individuals were studied. The physical and 
biochemical characteristics of the study 
subjects are shown in Table 3a. Both the 
HAART+LD+ and the HAART+LD- groups 
were similar with respect to age, gender and 
BMI. Smoking and alcohol consumption 
habits as well as the use of antihypertensive 
and lipid-lowering medication were 
comparable between the groups (Study 
I, Table 1). The HAART+LD+ group had 
several laboratory and anthropometric 
abnormalities indicative of lipodystrophy 
and insulin resistance. Study subjects 
in the HAART+LD+ group had greater 
central body adiposity as depicted by 
the waist-to-hip ratio (Table 3a), and 
thinner skinfolds indicating less SAT than 
their non-lipodystrophic counterparts 
have (Study I, Table 1). Serum insulin 
and triglyceride concentrations were 
significantly higher and HDL cholesterol 
concentrations significantly lower in 
the HAART+LD+ as compared to the 
HAART+LD- group (Table 3a). Serum 
ALT and hs-CRP concentration were 
significantly higher in the HAART+LD+ 
than in the HAART+LD- group (Study I, 
Table 1). Renal function was normal and 
comparable in both groups (Study I, Table 
1) and, thus, could not be expected to 
influence the augmentation index.
Characteristics related to HIV-1-
infection and antiretroviral treatment of 
the study groups are provided in Table 
3a. The groups were comparable with 
respect to time since diagnosis of HIV-1 
and the most recent viral load and CD4+ 
T-cell count (Table 3a). Total duration of 
treatment with one or more antiretroviral 
drugs (ART) and duration of HAART 
(Table 3a) were slightly, although not 
significantly (p=0.098 and p=0.057, 
respectively), longer in the HAART+LD+ 
than in the HAART+LD- group. 
Cumulative exposure to NRTIs was greater 
in the HAART+LD+ group as compared 
to the HAART+LD- group (3880 ± 242 
vs. 2730 ± 299 consumed daily doses, 
HAART+LD+ vs. HAART+LD-, p<0.01). 
The groups were comparable with regard 
to cumulative exposure to NNRTIs (240 
± 62 vs. 340 ± 98 consumed daily doses, 
HAART+LD+ vs. HAART+LD-, NS). 
Cumulative exposure to PIs tended to be 
longer in the HAART+LD+ than in the 
HAART+LD-, but did not quite reach 
statistical significance (1730 ± 202 vs. 1120 
± 254 consumed daily doses, HAART+LD+ 
vs. HAART+LD-, p=0.096).
1.2. Pulse wave analysis
There were no significant differences 
between the HAART+LD+ and the 
HAART+LD- groups with regards to 
peripheral systolic pressure (126 ± 2 
vs. 124 ± 2 mmHg, HAART+LD+ vs. 
HAART+LD-, NS), diastolic pressure 
(79 ± 1 vs. 78 ± 2 mmHg, HAART+LD+ 
vs. HAART+LD-, NS), pulse pressure 
(47 ± 2 vs. 45 ± 2 mmHg, HAART+LD+ 
vs. HAART+LD-, NS) or mean arterial 
pressure (95 ± 1 vs. 94 ± 2 mmHg, 
HAART+LD+ vs. HAART+LD-, NS). The 
groups were also similar with respect to 
these parameters at the level of the aorta. 
Heart rate was comparable in both groups 
(66 ± 1 vs. 62 ± 2 beats/min, HAART+LD+ 
vs. HAART+LD-, NS). Augmentation 
(6.8 ± 0.8 vs. 5.4 ± 1.1, HAART+LD+ vs. 
HAART+LD-, NS), augmentation index 
(18.2 ± 1.6 vs. 15.6 ± 3.0, HAART+LD+ 
vs. HAART+LD-, NS) and the AgIHR 
(19.2 ± 1.7 vs. 16.2 ± 3.2, HAART+LD+ 
vs. HAART+LD-, NS) did not differ to a 
statistically significant degree between the 
groups.
Simple linear regression analysis 
combining both study groups was carried 
out to identify significant correlates of 
AgIHR (Study I, Table 3). Variables which 
correlated with the AgIHR in simple linear 
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regression analysis to p-value of≤0.20 
were retained for the construction of 
multiple linear regression models. These 
included age, brachial systolic pressure, 
HbA1c, plasma sodium, hs-CRP, time 
since HIV-1 diagnosis, nadir CD4+ T-cell 
count and duration of ART, HAART, 
lamivudine, stavudine, ritonavir and 
saquinavir therapy as well as cumulative 
exposure to NRTIs and PIs. In multiple 
linear regression analysis (Table 
5), duration of ART and cumulative 
exposure to NRTIs and PIs were 
identified as independent predictors 
of the AgIHR. Duration of HAART and 
duration of stavudine therapy showed 
borderline significance in the prediction 
of the AgIHR, while the contribution of 
the other aforementioned HIV-1- and 
treatment-related factors remained 
insignificant.
2. SUBCUTANEOUS ADIPOSE 
TISSUE INFLAMMATION 
IN cART-ASSOCIATED 
LIPODYSTROPHY (STUDY II)
2.1. Study subjects
Characteristics of the HAART+LD+ and 
the HAART+LD- groups are provided in 
Table 3a. The groups were comparable 
with respect to age, gender and BMI. The 
HAART+LD+ group had 2-fold more IAT, 
1.5-fold less SAT and 10-fold more liver 
fat than the HAART+LD- group. The sum 
of means of skinfold thicknesses taken at 
five body sites was significantly smaller in 
the HAART+LD+ than in the HAART+LD- 
group (38 ± 3 vs. 54 ± 5 mm, HAART+LD+ vs. 
HAART+LD-, p<0.01). The HAART+LD+ 
group was also more insulin resistant than 
the HAART+LD- group as determined by 
Variable
Age
Brachial systolic pressure
HbA1c
Sodium
hs-CRP
Time since HIV-1 diagnosis
Nadir CD4+ T-cell count
Duration of ART
Duration of HAART
Cumulative exposure to NRTIs
Cumulative exposure to PIs
Duration of stavudine therapy
Model 1 
(R2=0.20)
0.061
0.171
0.762
0.288
0.737
0.325
N/A
N/A
N/A
N/A
N/A
N/A
Model 2
(R2=0.20)
0.095
0.163
0.935
0.368
0.713
N/A
0.269
N/A
N/A
N/A
N/A
N/A
Model 3 
(R2=0.25)
0.191
0.198
0.875
0.501
0.608
N/A
N/A
0.046
N/A
N/A
N/A
N/A
Model 4 
(R2=0.23)
0.086
0.147
0.649
0.257
0.566
N/A
N/A
N/A
0.087
N/A
N/A
N/A
Model 5 
(R2=0.26)
0.124
0.130
0.704
0.370
0.761
N/A
N/A
N/A
N/A
0.032
N/A
N/A
Model 6 
(R2=0.28)
0.098
0.114
0.789
0.500
0.566
N/A
N/A
N/A
N/A
N/A
0.011
N/A
Model 7 
(R2=0.25)
0.041
0.085
0.287
0.700
0.909
N/A
N/A
N/A
N/A
N/A
N/A
0.051
Table 5. Selected models from multiple linear regression analysis 
explaining variation of the heart rate –corrected augmentation index.
ART, antiretroviral therapy (treatment with at least one antiretroviral drug); HAART, highly active antiretroviral 
therapy (minimum of three antiretroviral drugs used concurrently); HbA1c, glycosylated hemoglobin A1c; HIV-1, 
human immunodeficiency virus type 1; hs-CRP, high sensitivity C-reactive protein; N/A, not applicable; NRTIs, 
nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors. Adapted from Sevastianova et al. Antiviral 
Therapy 2005; 10:925-35 (Study I), reproduced with permission of the copyright holder.
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Figure 5.
Figure 5. Expression of CD68, integrin αM (ITGAM), epidermal growth factor –like module-containing, 
mucin-like, hormone receptor –like 1 (EMR1), a disintegrin and metalloproteinase domain 8 (ADAM8), 
tumor necrosis factor α (TNFA), chemokine (C-C motif) ligand 2 (CCL2) and  chemokine (C-C motif) ligand 3 
(CCL3) mRNA in HIV-1-infected patients with highly active antiretroviral therapy –associated lipodystrophy 
(HAART+LD+; closed bars) vs. those without lipodystrophy (HAART+LD-, open bars). Data are given as 
mean ± SEM. p-values: *p<0.01, **p<0.001, ***p<0.0001, ****p<0.00001. Adapted from Sevastianova et al. 
American Journal of Physiology: Endocrinology and Metabolism 2008; 295:E85-91 (Study II), reproduced 
with permission of the copyright holder.
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Figure 6. The correlation between adipose tissue mRNA expression of CD68, chemokine (C-C motif) 
ligand 2 (CCL2), chemokine (C-C motif) ligand 3 (CCL3) and intergrin αM (ITGAM) with liver fat content. 
Closed circles, HIV-1-infected patients with highly active antiretroviral therapy –associated lipodystrophy; 
open circles, HIV-1-infected patients without highly active antiretroviral therapy –associated lipodystrophy. 
Adapted from Sevastianova et al. American Journal of Physiology: Endocrinology and Metabolism 2008; 
295:E85-91 (Study II), reproduced with permission of the copyright holder.
Figure 6.
(TNFA, CCL2 and CCL3) was significantly 
higher in lipoatrophic abdominal SAT of 
the HAART+LD+ group as compared to the 
HAART+LD- group (Figure 5). There was 
no difference between the study groups with 
respect to mRNA concentrations of B2M, 
the housekeeping gene (data not shown).
2.3. Correlation between adipose 
tissue gene expression and liver fat 
content
Expression of CD68, CCL2, CCL3 and 
ITGAM showed significant positive 
correlation with liver fat content (Figure 6). 
Correlations of expression of TNFA, 
serum insulin concentration (Table 3a) and 
the HOMA-IR index [2.0 (1.5 – 4.2) vs. 1.2 
(1.0 – 1.4), HAART+LD+ vs. HAART+LD-, 
p<0.005]. HIV-1 RNA loads and CD4+ 
T-cell counts were comparable between the 
groups as were the classes of antiretroviral 
drugs used (Table 3a). 
2.2. Expression of cytokines and 
macrophage–related genes
Gene expression analyses were carried 
out on samples from abdominal SAT. 
Expression of macrophage-related genes 
(CD68, ITGAM, EMR1 and ADAM8) and 
those encoding for inflammatory cytokines 
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EMR1 and ADAM8 with liver fat content 
remained non-significant. HOMA-IR 
showed a borderline significant positive 
correlation with CD68 mRNA expression 
(r=0.29, p=0.066). Correlations between 
previously measured serum adiponectin 
concentrations (372) and currently reported 
inflammatory genes were as follows: CD68 
r=-0.61, p<0.0001, CCL2 r=-0.38, p<0.05; 
CCL3 r=-0.65, p<0.0001; ITGAM r=-0.47, 
p<0.005; EMR1 r=-0.49, p<0.001; ADAM8 
r=-0.58, p<0.0001 and TNFA r=-0.26, NS.
3. MITOCHONDRIAL DNA, 
GENE EXPRESSION AND 
IMMUNOHISTOCHEMISTRY 
IN SUBCUTANEOUS ADIPOSE 
TISSUE IN cART-ASSOCIATED 
LIPOATROPHY (STUDY III)
3.1. Study subjects
The LA+ and LA- groups were comparable 
with respect to age, gender, weight, BMI, 
CD4+ T-cell count and HIV-1 RNA load 
(Table 3a), as well as with respect to 
truncal and total body fat (9550 ± 1170 vs. 
9380 ± 1620 g, LA+ vs. LA-, NS and 13220 
± 1750 vs. 15680 ± 2550 g, LA+ vs. LA-, 
NS, respectively). Compared to the LA- 
group, the LA+ group had significantly less 
total limb fat (3240 ± 620 vs. 5750 ± 920 g,
LA+ vs. LA-, p<0.05), a longer history 
of antiretroviral therapy and an almost 
statistically significantly longer duration 
of HIV-1 infection (p=0.092, Table 3a).
Of the 18 patients with lipoatrophy, 
eight received stavudine (d4T+LA+) and 
ten received zidovudine (AZT+LA+). Age, 
gender distribution and HIV-1-related 
characteristics were similar between the 
d4T+LA+ and the AZT+LA+ subgroups 
(Study III, Table 3). The subgroups 
were also similar with respect to use of 
antiretrovirals other than d4T and AZT 
(Study III, Table 3). When compared to 
the AZT+LA+ group, the d4T+LA+ group 
had a significantly lower weight (66.6 ± 3.5 
vs. 79.2 ± 4.2 kg, d4T+LA+ vs. AZT+LA+, 
p<0.05) and lower BMI (21.5 ± 0.9 vs. 
25.1 ± 1.0 kg/m2, d4T+LA+ vs. AZT+LA+, 
p<0.05). It also had less limb fat (1550 ± 520 
vs. 4590 ± 810 g,  d4T+LA+ vs. AZT+LA+, 
p<0.01), less truncal fat (6770 ± 880 vs. 
11770 ± 1710 g, d4T+LA+ vs. AZT+LA+, 
p<0.05) and less total fat (8660 ± 1380 vs. 
16880 ± 2440 g, d4T+LA+ vs. AZT+LA+, 
p<0.05) than the AZT+LA+ group. The 
amount of IAT was similar between the LA 
subgroups (Study III, Table 3).
3.2. Mitochondrial DNA content
The amount of mtDNA was significantly 
lower in the LA+ than in the LA- group (238 
± 129 vs. 585 ± 558 copies/cell, LA+ vs. 
LA-, p<0.01). Furthermore, the d4T+LA+ 
group had a significantly lower mtDNA 
copy number as compared to the AZT+LA+ 
group (139 ± 59 vs. 317 ± 115 copies/cell, 
d4T+LA+ vs. AZT+LA+, p<0.001).
In order to calculate the relative number 
of RNA transcripts per molecule of mtDNA 
template, expression of mtDNA-encoded 
genes was normalized for the amount of 
mtDNA molecules. Relative to the number 
of mtDNA copies per cell, transcription 
of mtDNA-encoded genes, 16SRNA and 
COX3, was significantly higher in the LA+ 
compared to the LA- group (0.34 ± 0.04 
vs. 0.15 ± 0.01, LA+ vs. LA-, p<0.005 for 
16SRNA and 0.42 ± 0.05 vs. 0.25 ± 0.02, 
LA+ vs. LA-, p<0.005 for COX3). This 
effect was more pronounced, albeit not 
quite to the level of statistical significance 
in the case of 16SRNA, in the d4T+LA+ 
than in the AZT+LA+ group (0.52 ± 0.06 
vs. 0.35 ± 0.03, d4T+LA+ vs. AZT+LA+, 
p<0.005 for COX3 and 0.42 ± 0.06 vs. 
0.28 ± 0.02, d4T+LA+ vs. AZT+LA+, 
p=0.07 for 16SRNA).
3.3. Expression of genes involved 
in mitochondrial function and 
biogenesis
COX3, encoded by mtDNA, was slightly, 
but not significantly, lower and the nDNA-
encoded COX4 significantly higher in the 
LA+ compared to the LA- group (Table 6). 
These changes resulted in a significantly 
lower COX3/COX4 ratio in the LA+ than 
in the LA- group (Table 6). The d4T+LA+ 
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Gene
Mitochondrial function and biogenesis
COX3
COX4
COX3/COX4 
16SRNA
POLG1
POLG2
TFAM
PGC1B
Adipogenesis
SREBP1C
CEBPA
PPARG
LMNA
LMNB
Lipid and glucose metabolism
FASN
GLUT4
PLIN1
HEXOK1
Inflammation, oxidative stress and apoptosis
IL1B
SOD1
PCNA
GPX1
FAS
P53
LA+
0.87 ± 0.10
2.53 ± 0.23**
0.33 ± 0.04***
0.70 ± 0.08 
1.21 ± 0.11
1.24± 0.07
1.30 ± 0.12
6.74 ± 1.68*
0.40 ± 0.09*** 
1.96 ± 0.27
1.82 ± 0.25
1.26 ± 0.14
1.39 ± 0.19*
3.64 ± 0.92***
1.42 ± 0.28*
1.03 ± 0.28
1.21 ± 0.13
1.39 ± 0.04***
2.03 ± 0.20*
1.81 ± 0.09*
1.84 ± 0.26
6.01 ± 0.73**
1.02 ± 0.08
LA-
1.28 ± 0.24
1.37 ± 0.14
0.89 ± 0.12
0.72 ± 0.11
1.19 ± 0.04
1.09 ± 0.04
1.22 ± 0.05 
0.95 ± 0.11 
1.98 ± 0.38
2.74 ± 0.41
1.48 ± 0.15
1.05 ± 0.08 
0.61 ± 0.15 
9.67 ± 0.94
2.87 ± 0.56
1.37 ± 0.19 
1.42 ± 0.09 
0.12 ± 0.03
1.36 ± 0.06 
1.49 ± 0.13 
1.31 ± 0.12
2.38 ± 0.39
1.09 ± 0.09
d4T+LA+
0.64 ± 0.08†
2.77 ± 0.33
0.24 ± 0.03†
0.50 ± 0.07†
0.93 ± 0.14†
1.20 ± 0.06
1.38 ± 0.24
6.52 ± 2.60
0.25 ± 0.19†
1.29 ± 0.21†
1.58 ± 0.36
1.09 ± 0.21
1.50 ± 0.32
3.00 ± 1.27
0.90 ± 0.20
0.53 ± 0.27†
0.86 ± 0.18†
0.38 ± 0.06
1.71 ± 0.20
1.94 ± 0.16
1.35 ± 0.15
6.65 ± 1.05
0.97 ± 0.16
AZT+LA+
1.06 ± 0.14
2.29 ± 0.32
0.43 ± 0.06
0.86 ± 0.11
1.41 ± 0.12
1.26 ± 0.11
1.24 ± 0.10
6.90 ± 2.32
0.47 ± 0.10
2.50 ± 0.40
2.01 ± 0.35
1.44 ± 0.16
1.33 ± 0.24
4.22 ± 1.36
1.78 ± 0.42
1.52 ± 0.43
1.48 ± 0.13
0.40 ± 0.05
2.29 ± 0.30
1.70 ± 0.09
2.18 ± 0.40
5.51 ± 1.02
1.05 ± 0.09
Table 6. Relative expression of selected genes in abdominal SAT from 
HIV-1-infected patients with and without cART-associated lipoatrophy.
Gene expression values are calculated from the real-time reverse transcriptase polymerase chain reaction in 
relation to the mean expression of three housekeeping genes (actin β, ACTB; acidic ribosomal phosphoprotein 
P0, 36B4; β2-microglobulin, B2M). Data are shown as mean ± SEM. p-values: *<0.05, **<0.005, ***<0.0005 
for comparison of LA+ vs. LA-; †<0.05 for comparison of d4T+LA+ vs. AZT+LA+. AZT+LA+, lipoatrophic 
HIV-1-infected patients on zidovudine-containing antiretroviral regimen; cART, combination antiretroviral 
therapy; d4T+LA+, lipoatrophic HIV-1-infected patients on stavudine-containing antiretroviral regimen; 
HIV-1,  human  immunodeficiency  virus  type  1;  LA+,  lipoatrophic  HIV-1-infected  patients;  LA-,  non-
lipoatrophic HIV-1-infected patients; SAT, subcutaneous adipose tissue. For full names of the genes, please 
see text. Adapted from Sievers et al. Journal of Infectious Diseases 2009; 200:252-62 (Study III), data are 
reproduced with permission of the copyright holder.
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group had significantly lower expression 
of COX3 and 16SRNA as compared to the 
AZT+LA+ group (Table 6). Also, the COX3/
COX4 ratio was significantly lower in the 
d4T+LA+ compared to the AZT+LA+ group 
(Table 6). Expression of POLG1 and POLG2 
did not differ between the LA+ and the LA- 
groups (Table 6). Expression of POLG1, but 
not of POLG2, was significantly lower in 
the d4T+LA+ compared to the AZT+LA+ 
group (Table 6). Expression of TFAM was 
comparable between all groups (Table 6). 
Expression of PGC1B was 7-fold higher in 
the LA+ compared to the LA- group (Table 
6). There was no significant difference 
between the d4T+LA+ and the AZT+LA+ 
groups with regard to PGC1B (Table 6).
3.4. Expression of genes involved 
in adipogenesis
SREBP1C was significantly lower in the 
LA+ compared to the LA- group (Table 
6). Among all study patients, there was an 
inverse correlation between expression of 
SREBP1C and PGC1B (r=-0.58, p<0.005) 
and a positive correlation between SREBP1C 
expression and mtDNA copy numbers 
(r=0.55, p<0.05). CEBPA and SREBP1C 
transcripts were lower in the d4T+LA+ than 
in the AZT+LA+ group (Table 6). There 
was no statistically significant difference 
between either LA+ vs. LA- or d4T+LA+ 
vs. AZT+LA+ with respect to expression of 
PPARG (Table 6). LMNB expression was 
significantly higher in the LA+ as compared 
to the LA- group (Table 6). Expression of 
LMNA and LMNB was comparable between 
the two LA subgroups (Table 6). 
3.5. Expression of genes involved 
in lipid and glucose metabolism
The LA+ group had lower expression of 
FASN and GLUT4 transcripts than the LA- 
group (Table 6). Expression of GLUT4 was 
not significantly different between the LA 
subgroups, although it tended to be lower in 
the d4T+LA+ than in the AZT+LA+ group 
(p=0.12, Table 6). PLIN1 and HEXOK1 
transcripts were significantly lower in the 
d4T+LA+ than in the AZT+LA+ group 
(Table 6). Among all patients GLUT4 
expression correlated positively with both 
FASN (r=0.73, p<0.001).
3.6. Expression of genes involved 
in inflammation, oxidative stress
and apoptosis
Expression of the inflammatory cytokine 
IL1B was higher in the LA+ than in the 
LA- group (Table 6). Expression of IL1B 
correlated inversely with mtDNA copy 
numbers (r=-0.42, p<0.005). Expression 
of SOD1 and PCNA was higher in the 
LA+ than in the LA- group (Table 6). 
Expression of FAS, but not of p53, was 
increased in the LA+ compared to the LA- 
group (Table 6). There was no statistically 
significant difference in expression of 
markers of inflammation, oxidative stress 
and apoptosis between the d4T+LA+ and 
the AZT+LA+ groups (Table 6).
3.7. Immunohistochemistry 
In abdominal SAT of the LA+ group, there 
were 7-fold more macrophages than in that 
of the LA- group (14.1 ± 13.1 vs. 2.3 ± 1.9 
macrophages per 100 000 arbitrary area 
units, LA+ vs. LA-, p<0.05; Study III, Figure 
1). The number of macrophages did not differ 
between the LA subgroups. The number 
of CLSs and PLIN1-free adipocytes did not 
differ between LA+ and LA- or between the 
LA subgroups (Study III, Figure 2).
4. DORSOCERVICAL 
SUBCUTANEOUS ADIPOSE 
TISSUE IN cART-ASSOCIATED 
LIPODYSTROPHY (STUDY IV)
4.1. Study subjects
Characteristics of the study patients are 
provided in Table 3b. The cART+LD+ and 
the cART+LD- groups were comparable 
with respect to age, gender and BMI. The 
cART+LD+ group had significantly higher 
ratios of dorsocervical to abdominal SAT and 
IAT to abdominal SAT than the cART+LD- 
group [0.8 (0.5 – 1.3) vs. 0.4 (0.4 – 0.6), 
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cART+LD+ vs. cART+LD-, p<0.05 and 2.3 
(0.8 – 4.5) vs. 0.5 (0.5 – 0.7), cART+LD+ 
vs. cART+LD-, p<0.0005]. Fasting insulin 
and triglyceride concentrations were 
significantly higher and HDL cholesterol 
concentrations significantly lower in the 
cART+LD+ compared to the cART+LD- 
group (Table 3b).
4.2. Mitochondrial DNA content
The mtDNA copy number was significantly 
higher in dorsocervical compared to 
abdominal SAT in the cART+LD+ 
group (356 ± 59 vs. 256 ± 44 copies/
cell, dorsocervical vs. abdominal SAT in 
cART+LD+, p<0.05). A similar trend was 
found in the cART+LD- group (930 ± 109 
vs. 563 ± 161 copies/cell, dorsocervical vs. 
abdominal SAT in cART+LD-, p=0.08, 
Figure 7). The mtDNA copy number was 
62% lower in the cART+LD+ than in 
the cART+LD- group in dorsocervical 
(p<0.0001) and 54% lower in abdominal 
SAT (p<0.05, Figure 7).
4.3. Histology
Dorsocervical adipose tissue in both the 
cART+LD+ and the cART+LD- groups 
had significantly less adipocytes (55 ± 6 
vs. 77 ± 5%, dorsocervical vs. abdominal 
SAT in cART+LD+, p<0.05 and 61 ± 5 
vs. 89 ± 4%, dorsocervical vs. abdominal 
SAT in cART+LD-, p<0.00001) and 
more connective tissue (45 ± 6 vs. 23 ± 
5%, dorsocervical vs. abdominal SAT in 
cART+LD+, p<0.05 and 39 ± 5 vs. 11 ± 
4%, dorsocervical vs. abdominal SAT in 
cART+LD-, p<0.00001) than abdominal 
SAT (Study IV, Figure 2). The two depots 
were similar with respect to variation in 
adipocyte size, cell membrane rupture, 
presence of lipogranulomata and cells 
Figure 7.
Figure 7. Number of mitochondrial DNA (mtDNA) copies per cell in dorsocervical (Dc SAT) and abdominal 
subcutaneous (Abd. SAT) adipose tissue of patients on combination antiretroviral therapy (cART) with 
(cART+LD+) and without (cART+LD-) treatment-associated lipodystrophy. Data are given as mean ± SEM. 
p-values: *p<0.05, **p<0.0001. Adapted from Sevastianova et al. Diabetes 2011; 60:1894-900 (Study IV), 
reproduced with permission of the copyright holder.
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morphologically typical of brown adipose 
tissue, irrespective of lipodystrophy status 
(data not shown).
Abdominal, but not dorsocervical, 
SAT from patients in the cART+LD+ 
group contained significantly more 
lipogranulomata (p<0.05) than 
the corresponding tissue from the 
cART+LD- group (Study IV, Figure 2). 
Other histological parameters such as 
adipocyte size, cell membrane rupture 
and the presence of cells morphologically 
typical of brown adipose tissue did 
not differ significantly between the 
cART+LD+ and the cART+LD- groups in 
either depot (data not shown).  
4.4. Microarray
Microarray analysis comparing 
dorsocervical to abdominal SAT within the 
cART+LD+ group identified 27819 probes 
for genes of which 99 were differentially 
expressed. These 99 probes corresponded to 
75 unique Entrez gene IDs. Of these 75 genes, 
61 were downregulated and 14 upregulated 
in dorsocervical as compared to abdominal 
SAT (Study IV, Supplementary Data online 
at http://diabetes.diabetesjournals.org/
lookup/suppl/doi:10.2337/db11-0075/-/
DC1). The differentially expressed genes were 
involved in regulation of gene transcription, 
organ development and regionalization, 
immune response and inflammation, as 
well as in composition and organization of 
the extracellular matrix and cytoskeleton. 
Three of the top six genes downregulated 
in dorsocervical as compared to abdominal 
SAT were homeobox genes (HOX) A10, 
HOXC9 and HOXC8. These genes are known 
to be transcription factors that provide cells 
with specific positional identities on the 
anterior-posterior axis. Among the genes 
upregulated in dorsocervical as compared to 
abdominal SAT was short stature homeobox 
2 (SHOX2), a gene responsible for cranio-
facial lateralization of the embryonic cells. 
Microarray analysis comparing 
dorsocervical to abdominal SAT within the 
cART+LD- group identified 27900 probes 
for genes of which 18 were differentially 
expressed. Of these, 13 corresponded to 
unique Entrez Gene IDs. Of these 13 genes, 
9 were downregulated and 4 upregulated 
in dorsocervical as compared to abdominal 
SAT (Study IV, Supplementary Data online 
at http://diabetes.diabetesjournals.org/
lookup/suppl/doi:10.2337/db11-0075/-/
DC1). The differentially expressed genes 
were involved in regulation of transcription, 
organ development and regionalization. 
The top three downregulated genes were 
also on the top of the list in the cART+LD+ 
group, namely HOXA10, HOXC9 and 
HOXC8. In a similar fashion to the 
cART+LD+ group, SHOX2 was among the 
genes that were upregulated to the greatest 
degree in dorsocervical as compared to 
abdominal SAT.
4.5. Gene expression by real-time 
reverse transcriptase polymerase 
chain reaction
Expression of SHOX2 was 4-fold higher in 
dorsocervical as compared to abdominal 
SAT in the cART+LD+ and 6-fold higher 
for the respective comparison in the 
cART+LD- group. Expression of HOXA10, 
HOXC9 and HOXC8 was 18-, 8- and 11-
fold lower in dorsocervical compared to 
abdominal SAT in the cART+LD+ group 
(Figure 8). In the cART+LD- group, 
expression of HOXA10, HOXC9 and 
HOXC8 were 21-, 9- and 10-fold lower in 
dorsocervical than in abdominal SAT. Fold 
change differences for any of the homeobox 
genes analyzed were not significantly 
different between the cART+LD+ and the 
cART+LD- groups (Figure 8).
UCP1 mRNA was detected in similarly 
minute quantities in some, but not all, of the 
dorsocervical and abdominal SAT samples 
from selected patients with prominent 
lipohypertrophy (“buffalo hump”) in the 
dorsocervical region (data not shown). 
The measured mRNA concentrations, 
however, were approximately 1000 times 
lower than those reported in human BAT 
previously (410).
Expression of CD68 mRNA, used 
as a marker of macrophages and, thus, 
inflammation, was significantly lower in 
dorsocervical as compared to abdominal 
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Figure 8.
Figure 8. Mean fold change in mRNA expression (measured by real-time reverse transcriptase polymerase 
chain reaction) in dorsocervical as compared to abdominal subcutaneous adipose tissue (SAT) in the 
combination antiretroviral therapy (cART) –treated lipodystrophic (cART+LD+ group, closed bars) and non-
lipodystrophic (cART+LD- group, open bars) patients. Positive values on the Y-axis indicate upregulation 
and negative values downregulation of the gene in question in dorsocervical as compared to abdominal SAT. 
Error bars, SEM. Adapted from Sevastianova et al. Diabetes 2011; 60:1894-900 (Study IV), reproduced with 
permission of the copyright holder.
SAT in the cART+LD+ [0.39 (0.08 - 6.63) 
vs. 0.56 (0.19 - 6.48), dorsocervical vs. 
abdominal SAT in cART+LD+, p<0.05]. 
Similar findings were noted in the 
cART+LD- group (p<0.05). Expression of 
CD68 mRNA did not differ between the 
study groups in either adipose tissue depot 
(data not shown).
5. TREATMENT OF cART-
ASSOCIATED LIPOATROPHY 
WITH URIDINE (STUDY V)
5.1. Study subjects
A total of 39 patients were screened for 
the study. Of these, 15 did not meet the 
inclusion criteria and four refused to 
participate. Of the eligible 20 patients, 
ten were randomized to receive uridine 
supplementation and ten to placebo. One 
patient in the uridine group discontinued 
the study after two days due to the taste 
of the product. One patient in the placebo 
group died of myocardial infarction. 
The remaining 18 patients completed 
the study. Antiretroviral and all other 
medications remained unchanged in all 
participants throughout the study. At 
baseline, the uridine and placebo groups 
were similar with respect to age, gender, 
body composition, metabolic parameters 
and HIV-1-related characteristics (Table 
3b). 
5.2. Effect of uridine treatment 
on body composition
Data on the effects of uridine and placebo 
on body composition in patients with 
cART-associated lipodystrophy are 
provided in Table 7. The mean increases 
in limb fat mass, total body fat mass and 
IAT volume were significantly greater 
in the uridine compared to the placebo 
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group (Figure 9). After 3 months of 
treatment with uridine, total limb fat 
mass increased by 29%, truncal fat mass 
by 10%, and total body fat mass by 14% 
(Table 7). In addition, the percentage of 
limb, truncal and total body fat increased 
significantly in the uridine, but not in the 
placebo, group (Table 7). In the uridine 
group, limb fat accounted for 18 ± 3% and 
truncal fat for 78 ± 3% of total fat mass 
at baseline. After 3 months of treatment, 
the proportion of limb fat to total fat mass 
increased to 25 ± 2% (p<0.05), whereas 
Table 7. Effects of uridine and placebo on body composition and metabolic 
parameters.
Variable
Age (years)
Male / female
Weight (kg)
Body mass index (kg/m2)
Total limb fat (g)
Total limb fat (%)
Total truncal fat (g)
Total truncal fat (%)
Total fat (g)
Total fat (%)
Intra-abdominal adipose  tissue (cm3)
Liver fat (%)
Serum insulin (mU/L)
HOMA-IR index
HbA1c (%)
Serum triglycerides (mmol/L)
Serum cholesterol (mmol/L)
Serum HDL cholesterol (mmol/L)
Baseline
(n=10)
47 ± 2
9 / 1
76.7 ± 4.7*
24.4 ± 1.1*
3080 ± 850***
20.6 ± 5.9***
9980 ± 1730***
24.1 ± 3.3**
13490 ± 2580***
17.3 ± 2.9***
2230 ± 300*
5.9 ± 2.8
12.3 ± 3.8
3.2 ± 0.9
5.4 ± 0.4
2.9 ± 0.4
5.6 ± 0.4
1.23 ± 0.09
Baseline
(n=10) 
49 ± 5
8 / 2
70.5 ± 3.2
22.6 ± 0.9
3060 ± 800
24.0 ± 6.0
8660 ± 1350
23.5 ± 2.8
12140 ± 2090
17.4 ± 2.7
2180 ± 470
12.4 ± 4.7
10.8 ± 2.2
2.8 ± 0.7
5.2 ± 0.3
3.4 ± 0.8
4.8 ± 0.3
1.14 ± 0.05
3 months
(n=9)
79.0 ± 5.4
25.1 ± 1.3
4260 ± 940†
28.1 ± 6.0
11570 ± 1910†
27.2 ± 3.5†
16330 ± 2810††
20.6 ± 3.0
2520 ± 370†
7.7 ± 3.9
13.7 ± 5.7
3.2 ± 1.5
5.1 ± 0.1
3.0 ± 0.4
5.7 ± 0.4
1.15 ± 0.08†
3 months
(n=9)
69.8 ± 3.4
22.4 ± 0.9
3340 ± 880
25.7 ± 6.4
8490 ± 1390
23.5 ± 2.9
12280 ± 2250
17.8 ± 2.7
1940 ± 460
8.7 ± 3.1
9.3 ± 2.4
2.0 ± 0.6
4.9 ± 0.3
3.0 ± 0.9
5.3 ± 0.5
1.22 ± 0.09
Uridine group Placebo group
Data are mean ± SEM. p-values:  *p<0.05,  **p<0.01,  ***p<0.001  for  comparison between baseline  vs.  3 
months within the uridine or placebo group; †p<0.05, ††p<0.01 for comparison of change in the uridine vs. 
placebo group. HbA1c, glycosylated hemoglobin A1c; HDL, high-density lipoprotein, HOMA-IR, homeostasis 
model assessment of insulin resistance. Adapted from Sutinen et al. Antiviral Therapy 2007; 12:97-105 
(Study V), reproduced with permission of the copyright holder.
that of truncal fat to total fat mass 
decreased to 72 ± 2% (p<0.05). In the 
uridine group, the increase in total limb 
fat was similar in patients treated with 
both AZT (800 ± 240 g) and d4T (990 
± 110 g). Body weight and IAT increased 
significantly in the uridine group while it 
remained unchanged in the placebo group. 
There was no change in abdominal SAT 
(1350 ± 390 vs. 1480 ± 440 cm3, uridine 
group baseline vs. 3 months, NS; 1250 ± 
390 vs. 1220 ± 440 cm3, placebo group 
baseline vs. 3 months, NS). In contrast 
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Figure 9. Change from baseline in total limb fat mass, intra-abdominal fat volume, total body fat mass and 
lean body mass in the uridine (closed bars) as compared to placebo (open bars) group. Data are mean ± SEM. 
p-values: †p<0.05 and ††p<0.01 for comparison of the change in the uridine vs. placebo group; *p<0.05 and 
**p<0.001 for comparison between baseline and 3 months within the uridine group. Adapted from Sutinen et 
al. Antiviral Therapy 2007; 12:97-105 (Study V), reproduced with permission of the copyright holder.
Figure 9.
excess increased significantly within the 
uridine group (Study V, Table 3). In the 
uridine group, a trend was observed in 
terms of an increase of the bicarbonate 
concentration (24.0 ± 0.3 vs. 24.9 ± 
0.3 mmol/L, baseline vs. 3 months, 
p=0.052). Plasma ALT and lactate as well 
as serum hs-CRP concentrations or anion 
gap did not change significantly in either 
group (Study V, Table 3).
None of the patients, who had an 
undetectable HIV-1 viral load (<50 
copies/mL) at baseline, lost virologic 
control during the study. HIV-1 viral load 
remained unchanged among patients 
with measurable viremia at baseline (one 
patient in the uridine group and two in the 
control group). CD4+ cell counts remained 
stable in both groups (594 ± 81 vs. 613 ± 
92 cells/mm3, baseline vs. 3 months in the 
uridine group, NS; 517 ± 88 vs. 503 ± 
93 cells/mm3, baseline vs. 3 months in the 
placebo group, NS).
to the significant increase in total body 
fat mass in the uridine group, there was 
no significant change in total lean body 
mass in either group (Figure 9). Liver fat 
content did not change significantly in 
either group (Table 7). 
5.3. Effect of uridine treatment 
on metabolic parameters
Uridine or placebo treatment had no 
effect on fasting insulin, total cholesterol 
and triglyceride concentrations, HOMA-
IR and HbA1c (Table 7). Serum HDL 
cholesterol showed a non-significant 
decrease in the uridine group and a 
non-significant increase in the placebo 
group, with the mean difference between 
the groups being, however, statistically 
significant (Table 7). Although there 
were no statistically significant changes 
in blood gas analyses between the study 
groups, venous blood pH and base 
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5.4. Circulating uridine 
concentrations
At baseline, serum uridine concentrations 
did not differ between the groups 
(5.2 ± 0.5 vs. 4.4 ± 0.5 μmol/L, uridine 
vs. placebo group, NS) and were similar 
to those previously described by the same 
laboratory for HIV-1-negative subjects 
(5.6 ± 1.1 µmol/L) (405). On day 71, serum 
uridine concentrations increased to 16.9 ± 
1.9 μmol/L (p<0.001) in the uridine group, 
but remained stable in the placebo group 
(5.0 ± 0.4 μmol/L, NS). The difference 
between the groups was highly significant 
(p<0.001).
5.5. Safety and tolerability
Both uridine and placebo were well 
tolerated. One patient in the uridine 
group discontinued the study due to the 
taste of the product and one patient on 
placebo died of myocardial infarction. 
No other side effects were reported 
in either group during the 3 months 
of treatment. Total blood count, ALT, 
creatinine, sodium and potassium 
concentrations, which were measured 
additionally on days 11, 41 and 71 to 
assess the safety of the intervention, 
remained unchanged in both groups 
(data not shown).
71
Discussion
DISCUSSION
1. SUBJECTS AND METHODS
1.1. Subjects
All of the patients in Studies I-V were 
infected with HIV-1 and treated with 
antiretroviral agents, but differed with 
respect to the presence or absence of 
cART-associated lipodystrophy. While 
this set-up allowed for an analysis of 
the effects of lipodystrophy on the 
parameters evaluated, the separate impact 
of the HIV-1 infection or cART on these 
parameters could not be determined. 
This is particularly important in the 
context of interpretation of expression of 
proinflammatory genes, as HIV-1 infection 
per se is known to induce expression of 
inflammatory cytokines (85,125,201). 
Furthermore, human preadipocytes have 
been shown in vitro to express receptors 
used by HIV-1 for cell entry (143). If this 
applies also to (pre)adipocytes in vivo in 
humans, HIV-1 may be able to influence 
directly the transcription of genes, 
including proinflammatory genes, in 
these cells. However, as the study groups 
in Studies I-V were highly similar with 
respect to time since the diagnosis of HIV-
1 and the severity of immunodeficiency, as 
depicted by the nadir CD4+ T-cell count 
as well as the most recent CD4+ T-cell 
count and HIV-1 viral load, it can only 
be assumed that the potential effect of 
the HIV-1 infection, if present, is similar 
between the lipodystrophic/-atrophic 
study groups. 
The majority of the study subjects were 
male. This does not represent the normal 
gender distribution among the HIV-1-
infected patients in the HIV outpatient 
clinic of the Helsinki University Central 
Hospital or worldwide. Potentially, 
this aspect may have an impact on the 
generalizability of the results to the greater 
HIV-1-infected population. However, in 
the present studies, the proportion of 
males to females was similar between the 
study groups compared. Furthermore, in 
Study I, the data analysis was repeated 
after omitting female study subjects, and 
no change in the outcome occurred. 
Although case definitions have 
been proposed (48,50,54), at present 
there is no universal consensus on the 
diagnostic criteria for cART-associated 
lipodystrophy. Therefore, in the present 
studies, like in most others, allocation of 
study patients to either the lipodystrophic 
or the non-lipodystrophic group relied on 
the clinical definition of cART-associated 
lipodystrophy, i.e., self-reported and 
investigator-confirmed symptoms of loss 
of SAT with or without accumulation of 
adipose tissue intra-abdominally or in the 
dorsocervical upper-trunk.
1.2. Methods
1.2.1. Pulse wave analysis
In Study I, PWA was used for the first time to 
assess arterial compliance in HIV-1-infected 
cART-treated patients. PWA is a rapid, 
non-invasive, technically simple, relatively 
inexpensive and highly reproducible 
technique (355,423). It has the advantage 
of reflecting changes not only in an isolated 
artery, but also in the entire vascular 
tree (355,423). In PWA, a commercially 
available software uses a generalized 
transfer function to calculate aortic blood 
pressure from the applanation tonometry 
measurements from the radial artery. The 
transfer function has been validated and 
the results proven comparable with those 
of catheterization studies (58,175) and 
perioperational blood pressure recordings 
(309). No mathematical model is perfect, 
however, and it should be noted that the 
augmentation index is influenced not only 
by arterial stiffness/elasticity, but also by 
ventricular ejection and arterial reflecting 
sites (288).
1.2.2. Body composition analyses
In Studies I-V, body composition was 
measured by several independent 
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non-invasive methods including 
anthropometry, measurement of 
skinfold thickness, BIA, DEXA, MRI and 
1H-MRS. Of these methods, the first three 
mentioned are readily available, portable, 
inexpensive and easy to operate. They 
are, however, prone to considerable inter-
observer variation (392). In the present 
studies, a single investigator performed 
all measurements in an attempt to 
optimize the reproducibility of data. The 
BIA method has been validated in HIV-
1-infected patients before the cART era 
(187), but although it is known to be more 
reliable in lean subjects with sparse SAT 
than in obese subjects (392), it has not 
been validated in lipodystrophic cART-
treated patients. In fact, BIA might be 
particularly unsuitable in patients with 
uneven body fat distribution, as is the case 
in cART-associated lipodystrophy (344), 
for more than 90% of the measured whole-
body impedance arises from the limbs that 
represent only <50% of fat free mass (103) 
and might particularly poorly represent 
the rest of the body.
DEXA was used to measure total body 
fat (in both absolute and percentage 
equivalents) as well as that of limbs 
and trunk separately. DEXA is a highly 
accurate method for the assessment 
of body composition, but its limited 
availability and cost makes it unpractical 
for wide-spread clinical use. The 
precision of body fat and lean body mass 
measurement by DEXA has been validated 
in animal models and by comparison with, 
e.g., neutron activation analysis (87). 
The reproducibility of repeated DEXA 
measurements is good if conducted on the 
same instrument, while inter-instrument 
difference may be substantial, presumably 
due to differences in device calibration 
(87). 
As DEXA does not differentiate between 
SAT and IAT, MRI technology was needed 
to complement it in the present studies. 
With the 16 slices covering the area from 
8 cm above to 8 cm below the 4th and 
5th lumbar interspace, this approach can 
be estimated to capture approximately 
60% of the total IAT volume. Accuracy of 
measurements of adipose tissue mass by 
MRI has been validated against human 
cadaver dissection and has proved very 
precise (average difference of 0.076 kg) 
(3). The reproducibility of repeated 
measurements of IAT and SAT in our 
laboratory is 5% and 3%, respectively 
(369). The reproducibility data from our 
laboratory are also available for repeated 
measurements of liver fat using 1H-MRS, 
with reproducibility of 11% (369). 1H-MRS 
data have also been validated against 
histologically determined lipid content 
(190) and against estimates of fatty 
infiltration in the liver by CT (332) and 
MRI (229), and have proven to be highly 
accurate. 
1.2.3. Real-time reverse transcriptase 
polymerase chain reaction
Real-time RT-PCR is the most sensitive 
method for quantification of mRNA (31). 
It should, however, be emphasized that 
mRNA concentration does not necessary 
reflect protein expression due to factors 
like post-transcriptional regulation and 
protein’s secondary/tertiary structure 
assembly. It should also be remembered 
that gene expression detected in adipose 
tissue does not originate from adipocytes 
only, but also from preadipocytes, 
fibroblast, endothelial cells, macrophages 
and leukocytes, all of which reside in 
the adipose tissue and, thus, contribute 
to the observed mRNA and protein 
concentrations. Furthermore, a sufficient 
sample size is critical for the reliability 
of studies of gene expression in adipose 
tissue, as RNA yields from adipose tissue 
are up to 200-fold lower per weight of 
tissue than in, e.g., liver or muscle (240). 
This can be particularly challenging in the 
case of severely lipoatrophic individuals.
1.2.4. Microarray
Microarray analysis covering the whole 
human genome (20000 - 25000 genes) 
generates a vast amount of data. In 
order to avoid false positive findings, it 
is important to utilize stringent filtering 
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criteria on the acquired data (correction 
for multiple comparisons, using lower 
p-value as a “threshold” of statistical 
significance) and performing validation 
analyses (histology and real-time RT-
PCR) on the findings.
1.2.5. Histology and 
immunohistochemistry
One considerable limitation of 
histological and immunohistochemical 
analyses is the requirement of a surgical 
biopsy specimen. This limited analyses 
in Study II, in which only needle 
aspiration biopsies of adipose tissue were 
available. In addition, histological and 
immunohistochemical analyses are prone 
to sampling error and are more robust 
in their sensitivity than, e.g., real-time 
RT-PCR. In Study IV, we encountered 
a discrepancy between the histological 
and the gene expression data. While an 
increased number of lipogranulomata (a 
histological indication of the presence of 
macrophages) was found in abdominal 
SAT from the cART+LD+ group in 
comparison to the corresponding 
tissue in the cART+LD- group, there 
was no such difference between the 
study groups in mRNA expression of 
CD68, a gene that is widely used as a 
marker for macrophages. This could 
be due to a limited sensitivity of the 
analytical methods, i.e., a type 2 error or, 
alternatively, the discrepancy between 
histological and real-time RT-PCR 
results may be a consequence of different 
macrophage phenotypes being detected 
by each method. While all macrophages 
are recognized by a CD68 antibody, only 
some macrophages are known to be 
proinflammatory and secrete cytokines 
such as TNFA and IL6 that were presently 
measured by real-time RT-PCR (22,120). 
Indeed, it is possible that macrophages 
resident in adipose tissue, and detected 
by the histological analysis of Study 
IV, are anti-inflammatory, functioning 
mainly in engulfment of cellular debris 
and tissue reparation, and do not secrete 
inflammatory cytokines (22,120).
2.  VASCULAR 
COMPLICATIONS IN 
cART-ASSOCIATED 
CIPODYSTROPHY
2.1. Arterial stiffness
Cumulative exposure to cART has been 
associated with an increased incidence 
of myocardial infarction (108,109). The 
increment in the relative risk of myocardial 
infarction seen in these studies could only 
partially be explained by conventional risk 
factors (108,109). The augmentation index, 
a surrogate of systemic arterial stiffness 
measured by PWA technique, is known to 
predict cardiovascular events and mortality 
independent of dyslipidemia and other 
confounders in HIV-1-negative subjects 
(227,420,421). Prior to Study I, its value 
in explaining increased cardiovascular risk 
beyond that attributable to conventional 
risk factors had not been assessed in HIV-
1-infected cART-treated patients with and 
without cART-associated lipodystrophy. 
Despite the representativeness of the 
lipodystrophic and the non-lipodystrophic 
study groups in Study I, the presence of 
cART-associated lipodystrophy was not 
seen to have any effect on parameters 
measured by PWA. Following the 
publication of Study I, only one study has 
readdressed the issue of arterial stiffness 
in cART-associated lipodystrophy (401). 
This study, comparing 55 cART-treated 
non-lipodystrophic and 23 cART-treated 
lipodystrophic patients, confirmed the 
findings of Study I that there are, indeed, 
no differences between these groups with 
respect to arterial stiffness as depicted by 
pulse wave velocity (401). 
In Study I, antiretroviral therapy 
per se, both in terms of duration of ART 
(treatment with at least one antiretroviral 
drug) and in terms of cumulative exposure 
to NRTIs and PIs, was found to be 
associated with the AgIHR independent 
of age and brachial blood pressure. 
Duration of HAART (minimum of three 
antiretroviral drugs used concurrently, 
i.e., contemporary cART) and d4T therapy 
were notably, albeit only borderline 
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significantly, predictive of the AgIHR. Age, as 
anticipated, was a strong, but not the sole, 
predictor of the AgIHR, whereas laboratory 
and anthropometric measures related 
to the cART-associated lipodystrophy 
were not predictive of the AgIHR. The 
association of cumulative exposure to 
cART and measures of arterial stiffness, 
e.g., pulse wave velocity and the aortic 
augmentation index, has been confirmed 
by some (209,342,401), though not all 
(151,202) subsequent studies by other 
groups. It should be noted, however, 
that the patients in the studies with 
discrepant results were notably different 
from those assessed in Study I: i) cART 
was initiated at a significantly higher 
CD4+ T-cell count, thus, underestimating 
the detrimental effects that active HIV-1 
infection and immunodeficiency can have 
on the vasculature (vide infra) (151) and 
ii) exposure to cART was significantly 
shorter, which may not have permitted 
its full impact to become evident (202). 
Of importance, the results of Study I 
have been supported by large cohort 
studies which have established that HIV-
1-infected cART-treated patients are at 
notable cardiovascular risk due to their 
medication (68,74,110,181,389) with up 
to 26% increase in the rate of myocardial 
infarction per year of exposure to cART, 
even independent of cART-associated 
lipodystrophy (109).
The mechanisms by which 
antiretroviral agents may cause 
cardiovascular complications independent 
of lipodystrophy are not, at present, 
completely understood. Atherogenic 
dyslipidemia, which may be seen in cART-
treated patients also without adipose 
tissue redistribution, is hypothesized 
to occur due to PI-induced increase of 
the hepatic production of triglyceride-
rich particles (211), increased lipolysis 
in mature adipocytes (15,212,320,329), 
and decreased activity of endothelial 
LPL (211,320), therefore, representing 
a plausible link between cardiovascular 
disease and cART. Mechanisms 
independent of dyslipidemia, however, 
are also believed to exist. For example, a 
study exposing HIV-1-negative subjects 
to four weeks of monotherapy with the 
PI indinavir reported the development of 
significant endothelial dysfunction without 
any concurrent changes in blood lipids 
(348). In a similar fashion, PI-induced 
inhibition of proteasomal degradation 
of apolipoprotein B in the liver (218) 
has been proposed to contribute to the 
development of endothelial dysfunction, 
even in the absence of dyslipidemia (402). 
Furthermore, it has been suggested that PIs 
promote CD36-dependent accumulation 
of cholesteryl esters in monocyte-derived 
macrophages, thereby contributing to the 
formation of foam cells and, consequently, 
of atherosclerosis (82). Finally, PIs have 
been demonstrated to damage mtDNA and 
cause necrosis (450), impair vasomotor 
function, and decrease nitric oxide 
synthase gene and protein expression (111) 
in endothelial cells in vitro.
Although no association between HIV-
1-related characteristics and markers of 
arterial stiffness were found in Study I, 
a number of other studies have reported 
increased arterial stiffness in untreated 
HIV-1-infected patients compared to HIV-
1-negative controls (11,343). The literature 
on this topic indicates several possible 
pathways by which HIV-1 infection per 
se could cause vascular complications. 
Firstly, it has been suggested that HIV-1 
infects endothelial cells in vitro, causing 
their enhanced adhesiveness, disrupted 
proliferation and apoptosis (60). This, in 
turn, leads to secretion of proinflammatory 
cytokines that have been suggested to act 
in synergy with viral proteins to induce 
further endothelial injury and dysfunction 
(60). Secondly, HIV-1 may contribute 
to endothelial damage and premature 
atherosclerosis by sustaining low-degree 
inflammation, in a manner similar to that 
of other infections such as Chlamydia 
pneumoniae and cytomegalovirus 
(384,451). Thirdly, immunodeficiency 
likewise immune reconstruction following 
initiation of cART are both associated with 
enhanced T-lymphocyte proliferation 
and activation (144), which could 
potentiate any pre-existing atherogenic 
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inflammation. Chronic inflammation, in 
turn, through the release of cytokines and 
growth factors, has been documented to 
stimulate migration and proliferation of 
smooth-muscle cells, and elaboration of 
the extracellular matrix of tunica media, 
resulting in thickened, poorly compliant 
arterial walls (327). Finally, infections 
in general can induce atherogenic 
changes in lipid profile, along with a 
pro-coagulant state of blood (77), and 
HIV-1 is no exception (86,125,133). The 
various detrimental effects of infection 
with HIV-1 are evident from clinical 
studies identifying low CD4+ T-cell 
count as a robust risk factor for arterial 
stiffness (151) and the development 
of atherosclerotic lesions (157,174). A 
further indicator of this detrimental 
relationship was reported in the SMART 
Study, in which the interruption, as 
opposed to continuous use, of cART was 
associated with an increased incidence 
of myocardial infarction (85). Recently, 
the effect of chronic inflammation 
on arterial structure was elegantly 
demonstrated in HIV-1-infected cART-
untreated “elite controllers” (156). 
The term “elite controllers” refers to 
patients with undetectable viral load 
and preserved CD4+ T-cell count despite 
the long-term HIV-1 infection and no 
antiretroviral treatment. When compared 
to age-matched HIV-1-infected cART-
treated patients and to HIV-1-negative 
subjects, the “elite controllers” were 
reported to have an increased intima 
media thickness, an important structural 
marker of atherosclerosis, most likely as a 
consequence of their permanent immune 
activation and inflammatory response 
(156).
2.2. Hypertension
As cART-associated lipodystrophy has 
a close resemblance with the metabolic 
syndrome, and hypertension is part of 
the international diagnostic criteria for 
the metabolic syndrome (5), it would be 
reasonable to expect a high prevalence 
of hypertension also in patients with 
cART-associated lipodystrophy. In Study 
I, however, there were no differences 
between the lipodystrophic and the non-
lipodystrophic groups in either brachial 
or aortic blood pressure, even in the 
presence of substantial differences in 
body composition, lipid profiles and 
measures of insulin resistance between 
the groups. Previous data regarding 
the link between cART-associated 
lipodystrophy and hypertension are 
controversial (16,63,115,170,338). It 
is interesting to note that the status of 
hypertension as a component of the 
metabolic syndrome has also become 
an area of controversy in recent years. 
Compelling epidemiological evidence 
suggests that obesity, or more specifically, 
accumulation of IAT may be the link 
between features of insulin resistance 
and hypertension (136,160). In fact, an 
insulin-independent, leptin-melanocortin 
pathway –mediated activation of 
sympathetic nervous system has been 
proposed as the mechanism by which 
obesity causes hypertension (137). In light 
of these findings, it seems comprehensible 
than lipodystrophic patients, typically 
lean and hypoleptinemic, may remain 
normotensive despite their marked 
insulin resistance.
Another plausible explanation for 
the absence of an association between 
high blood pressure and the presence of 
cART-associated lipodystrophy is the fact 
that changes in blood pressure may take 
longer to develop than the other features 
of cART-associated lipodystrophy. In 
HIV-1-negative subjects, alterations 
in arterial elasticity are known to 
precede the onset of clinically relevant 
hypertension by a substantial period of 
time (288,300). Therefore, a technique 
of PWA non-invasively evaluating the 
augmentation index, a measure of 
arterial elasticity (287,289,300,424) 
and a strong independent predictor of 
risk (298,420) and mortality (227) of 
cardiovascular disease, is a valuable tool 
in detecting arterial hardening before 
any sphygmomanometrically detectable 
changes in blood pressure occur.
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3. BODY COMPOSITION 
IN cART-ASSOCIATED 
LIPODYSTROPHY
3.1. Adipose tissue compartments
Although the cART-treated lipodystrophic 
and non-lipodystrophic patients had 
similar BMI, the former group had 
significantly greater waist-to-hip ratio 
and thinner skinfolds, indicative of IAT 
accumulation in combination with the 
loss of SAT (Studies I-II, IV). Total body 
fat (assessed by BIA in Studies I-II and 
by DEXA in Studies III-IV) tended to be 
lower in the cART-treated lipodystrophic/ 
-atrophic than in the non-lipodystrophic/ 
-atrophic patients, although the difference 
did not reach statistical significance 
(Studies I-IV). In Studies II-IV, MRI was 
used to quantify the abdominal SAT and 
IAT. The cART-treated lipodystrophic/ 
-atrophic patients had up to 2.5-fold more 
IAT and 1.4-fold less SAT than their non-
lipodystrophic/-atrophic counterparts, even 
though they were comparable with respect 
to age, gender and BMI. This in line with 
previous data and the lipodystrophy-
defining criteria (48,50). 
3.2. Liver fat
Liver fat was measured using 1H-MRS that 
showed the cART-treated lipodystrophic 
patients to have up to 10-fold more liver fat 
than the cART-treated non-lipodystrophic 
patients (Studies II and IV). Study V, 
including only lipoatrophic cART-treated 
patients, further supported the concept 
of pathologically high liver fat content in 
these patients. Liver fat content at study 
baseline averaged 9.1 ± 2.7% in all study 
participants, which is above the upper 
limit of normal (5.56%) (375). Yet, plasma 
ALT concentrations were 38.6 ± 6.0 U/L, 
i.e., within the normal range (10-70 U/L 
for men and 10-45 U/L for women). 
Uridine or placebo treatment had no effect 
on liver fat content or ALT concentrations 
in the study subjects. In Study I, in which 
liver fat content was not available, plasma 
ALT concentrations were higher in the 
cART-treated lipodystrophic as opposed 
to the non-lipodystrophic group, likely 
also reflecting increased liver fat in the 
context of cART-associated lipodystrophy 
as described previously (122).
4. SUBCUTANEOUS ADIPOSE 
TISSUE IN cART-ASSOCIATED 
LIPODYSTROPHY
4.1. Histology
In cART-treated patients, lipoatrophic, 
as compared to non-lipoatrophic 
adipose tissue, is characterized by 
smaller adipocytes, greater cell size 
variation, disruption of cell membranes 
and signs of apoptosis as determined 
by immunohistochemical staining 
(80,159,224). On histological analysis of 
Study IV, irrespective of lipodystrophy 
status, less adipocytes and more 
connective tissue were seen in the 
dorsocervical than in the abdominal 
SAT. Thus, these characteristics seem to 
be intrinsic to the dorsocervical depot. 
Prior to Study IV, light microscopy data 
and the ultrastructural characteristics 
of adipose tissue from lipohypertrophic 
areas of HIV-1-infected patients on 
cART were reported only in one small 
study (n=4) (224). This study did not 
specify the anatomical location of the 
lipohypertrophic areas, and reported to 
have used as controls ten skin biopsies 
from patients with pigmented or bullous 
skin lesions, all of them containing 
SAT. The authors reported that in the 
lipohypertrophic samples, occasional 
adipocytes exhibited changes similar 
to those seen in the lipoatrophic SAT, 
although the changes were generally of 
milder degree than would be seen in a 
lipoatrophic depot (224). These changes 
could not be quantitated because of the 
small sample size. Although the ratio of 
adipocytes to connective tissue was not 
reported in the cited study, the finding 
of the lipohypertrophic adipose tissue to 
be “more normal” than the lipoatrophic 
one is in line with the present data on 
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lower CD68 expression and greater 
preservation of mtDNA copy number 
in the dorsocervical as compared to the 
abdominal SAT (vide infra).
4.2. Adipose tissue inflammation 
In Study II, gene expression of 
macrophage markers (CD68, ITGAM, 
EMR1, ADAM8) and cytokines (CCL2, 
CCL3, TNFA) was found to be significantly 
higher in the lipoatrophic as compared 
to the non-lipoatrophic abdominal SAT 
from cART-treated patients. Accordingly, 
Study III showed upregulation of IL1B 
in the lipoatrophic compared to the 
non-lipoatrophic SAT, with TNFA and 
IL6 showing a similar trend towards 
upregulation, but failing to reach statistical 
significance, possibly due to a large 
variation within the study groups. Studies 
III and IV further confirmed a greater 
degree of adipose tissue inflammation, 
in terms of lipogranulomata (lipid-laden 
macrophages encircling adipocytes) 
and number of immunohistochemically 
detected CD68-positive cells 
(macrophages), in the abdominal SAT 
from lipoatrophic cART-treated patients 
as compared that of those without cART-
associated lipodystrophy/-atrophy. These 
findings are in line with previous gene and 
protein expression data as well as with 
histological and immunohistochemical 
detection of adipose tissue –resident 
macrophages indicative of increased 
adipose tissue inflammation in SAT from 
patients with as compared to those without 
cART-associated lipodystrophy/-atrophy 
(165,222) or HIV-1-negative subjects 
(12,80,159,165,224). 
With regards to the comparison of 
two anatomically separate adipose tissue 
depots (preserved dorsocervical and 
atrophied abdominal SAT), expression 
of CD68 was found to be significantly 
lower in the dorsocervical than in the 
abdominal SAT in both lipodystrophic and 
non-lipodystrophic patients (Study IV). 
Furthermore, microarray data suggested 
that genes involved in inflammatory 
processes are downregulated in the 
dorsocervical as compared to the abdominal 
SAT in the lipodystrophic group. These 
findings are in keeping with previous 
reports indicating that inflammation, as 
judged by mRNA expression of, e.g., TNFA 
and CD68 (126) and tissue release of TNFA 
(165), is more severe in the lipoatrophic 
abdominal than in the dorsocervical SAT. 
These studies, however, were small (n=8-10) 
and samples of both dorsocervical and 
abdominal SAT were not available from 
the same individuals. 
The antiretroviral drugs most frequently 
associated with the development of 
lipodystrophy (tNRTIs such as d4T and 
AZT) are known to increase the release 
of proinflammatory CCL2 and IL6 from 
adipocytes in vitro (200), and incite 
increased macrophage infiltration of 
supra-iliac SAT in vivo in HIV-1-infected 
patients started on antiretroviral treatment 
(291,292). Study III was specifically 
designed to compare the effects of d4T 
and AZT on the abdominal SAT from 
lipoatrophic patients. No differences in the 
degree of inflammation were seen between 
the lipoatrophic abdominal SAT from 
users of d4T compared to those of AZT, 
implying that the differences observed 
in inflammatory status of lipoatrophic 
as compared to non-lipoatrophic group 
are not due to the individual tNRTIs, but 
rather are associated with lipodystrophy 
per se.
It cannot be determined from a cross-
sectional study whether adipose tissue 
inflammation precedes cART-associated 
lipoatrophy or vice versa. Data from 
studies performed in settings outside 
HIV-1 imply that macrophage-secreted 
proinflammatory cytokines exert a number 
of effects on adipose tissue. The cytokines 
inhibit expression of genes involved in 
adipocyte differentiation (365), decrease 
lipogenesis due to disrupted activity of 
LPL (106) and poor synthesis of FATP 
and ACS (331), increase adipose tissue 
lipolysis via upregulation of HSL activity 
(305), and increase apoptosis (317). As a 
net effect, adipocyte size, number and total 
adipose tissue mass tend to decrease (317). 
Intriguingly, adipose tissue inflammation 
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has been implicated in the pathogenesis 
of insulin resistance (448), also a feature 
of cART-associated lipodystrophy 
(54,122,138).
4.3. Adipose tissue inflammation 
and liver fat
Study II reported a significant, positive 
correlation between expression of several 
inflammatory markers (CD68, ITGAM, 
CCL2 and CCL3) in abdominal SAT and 
liver fat content. Such correlations, in 
isolation, do not prove causality, but 
there are data on potential molecular 
mechanisms linking adipose tissue 
inflammation to liver fat content and vice 
versa. Overexpression of CCL2 in murine 
adipocytes has been shown to enhance 
macrophage infiltration into adipose tissue, 
increase concentrations of circulating 
FFAs, cause hepatic and intramyocellular 
triglyceride accumulation, and increase 
insulin resistance despite unchanged 
body weight (172). In contrast, induction 
of hepatic steatosis in mice by high fat 
diet or by transgenic manipulations was 
shown to lead to subacute hepatocellular 
inflammation, featuring increased number 
of CD68-positive cells within the liver, 
and cause both hepatic and peripheral 
insulin resistance (32). This pathway 
was postulated to involve NFKB, a 
transcriptional factor mediating induction 
of inflammatory cytokine expression (32). 
Similar associations seem to exist 
in humans, as gene expression of both 
CD68 and ITGAM have been shown to be 
increased in SAT of obese as compared 
to non-obese subjects, and have been 
positively correlated with liver fat content 
independent of obesity (235). Yet another 
study has reported that expression of 
CD68, CCL2 and CCL3 in SAT of subjects 
with high liver fat content is higher than in 
SAT of carefully weight-matched subjects 
with normal liver fat content (184). In the 
latter study, gene expression of CD68 was 
also positively and significantly correlated 
with liver fat content (184). 
One possible link between adipose 
tissue inflammation and liver fat in 
subjects with and without cART-associated 
lipodystrophy is serum FFA concentration. 
These were noted to be comparable 
between the HAART+LD+ and the 
HAART+LD- groups in Study II. However, 
fasting insulin concentrations have been 
consistently shown to be significantly 
higher in the cART-treated lipodystrophic 
patients relative to the cART-treated non-
lipodystrophic ones (Studies I-II, IV). 
Since lipolysis mobilizing FFAs into the 
circulation is suppressed by even small 
increases in insulin concentration (297), 
the finding of similar FFA concentrations 
in both study groups suggests resistance 
to insulin-induced suppression of lipolysis 
in the lipodystrophic group. Indeed, 
increased FFAs, through activation of 
the NFKB pathway, are known, on one 
hand, to trigger adipose tissue-resident 
macrophages to produce auxiliary 
inflammatory mediators further inflaming 
the adipose tissue (351,448) and, on the 
other hand, most likely via FFA-derived 
ceramides (223,366) and DAGs (169,445), 
to induce insulin resistance in the liver and 
peripheral tissues (195,254). 
IAT has been proposed to be an 
important source of inflammatory 
cytokines and to have a higher rate of 
lipolysis than SAT (8,406). Moreover, 
inflammatory changes in IAT are more 
closely correlated with liver fat than those 
in SAT (36). Furthermore, in morbidly 
obese subjects macrophage accumulation 
in omental, but not in subcutaneous, 
adipose tissue has been reported to 
associate significantly with the severity of 
steatotic and fibroinflammatory lesions 
in the liver (36,388). However, gene 
and protein expression of inflammatory 
markers in IAT could not have been 
studied in Studies II-IV as it is ethically 
unacceptable to obtain samples from IAT 
for research purposes only. Moreover, in 
terms of fatty acid metabolism, there is 
evidence in favor of studying SAT and not 
IAT as the catheterization studies have 
shown the liver to receive most of its FFAs 
from the upper-body SAT rather than 
IAT even in abdominally obese subjects 
(290). However, since cART-associated 
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lipodystrophy encompasses simultaneous 
loss of SAT and gain of IAT, it is possible 
that the intra-abdominal depot of these 
patients contributes proportionally more 
to the hepatic FFA supply than it does in 
the non-lipodystrophic subjects. 
Another potential mediator between 
inflamed adipose tissue and liver fat 
is adiponectin. Adiponectin is anti-
inflammatory and has been shown to 
reduce liver fat and improve hepatic insulin 
sensitivity in mice (436). Recent data have 
suggested that adiponectin conveys its 
beneficial effects on insulin sensitivity by 
lowering the content of intrahepatocytic 
ceramides, molecules implicated 
causative of insulin resistance (223,366), 
by activating ceramidase, an enzyme 
catalyzing degradation of ceramides (153). 
In multiple human studies, changes in 
serum adiponectin induced by anti-diabetic 
agents from the thiazolidinedione class 
have been closely and inversely correlated 
with changes in liver fat (440). Patients 
with cART-associated lipodystrophy have 
been shown to have low adiponectin gene 
expression in SAT and low circulating 
adiponectin concentrations (126,372,387). 
Furthermore, low adiponectin has been 
shown to correlate inversely with liver 
fat in these patients (372). Study II is in 
line with these findings and extends them 
further reporting, on one hand, a positive 
correlation between liver fat and expression 
of proinflammatory genes in lipoatrophic 
abdominal SAT and, on the other hand, 
an inverse correlation between serum 
adiponectin concentration and expression 
of proinflammatory genes in lipoatrophic 
abdominal SAT. Thus, it can be speculated 
that low adiponectin may contribute to 
the inflammatory changes in lipoatrophic 
adipose tissue and to the accumulation of 
liver fat seen in this patient group.
4.4. Mitochondrial DNA content
In keeping with other studies 
(126,139,291,415), mtDNA copy numbers 
were significantly lower in abdominal 
adipose tissue of the lipoatrophic as 
compared to the non-lipoatrophic 
cART-treated patients (Study III). Also 
confirming previous data (59,291), 
the mtDNA depletion was found to be 
more severe among the lipodystrophic 
users of d4T than among those using 
AZT. The dorsocervical adipose tissue 
had significantly more mtDNA than the 
abdominal SAT in the cART+LD+ group, 
with difference close to significance 
(p=0.08) also in the cART+LD- group. 
This is discordant with previous reports 
of a trend (p=0.051) towards lower 
mtDNA content in the lipohypertrophic 
dorsocervical than in the lipoatrophic 
abdominal SAT from cART-treated 
patients (126). One potential explanation 
for this controversy could be the fact that 
the aforementioned study compared SAT 
from different anatomic locations taken 
from different subjects, while in Study IV 
samples of dorsocervical and abdominal 
SAT from the same individual were 
available.
Mitochondrial toxicity of cART 
manifesting as mtDNA depletion has been 
suggested, in a similar fashion to what 
occurs in obesity, to contribute to impaired 
adipocyte differentiation, increased 
inflammation, and activation of apoptosis 
in adipose tissue (408). Supporting this 
theory, a positive correlation between 
mtDNA copy numbers and gene 
expression of an adipogenic transcription 
factor SREBP1C in SAT, and an inverse 
correlation between mtDNA copy number 
and expression of cytokine IL1B is SAT 
were found in Study III.
The most significant finding of Study 
IV, namely that mtDNA content is highly 
significantly lower (by 62%) in the 
dorsocervical SAT in the cART+LD+ as 
compared to the corresponding tissue in 
the cART+LD- group, although the two 
depots are phenotypically comparable, 
contradicts the prevailing theory 
that mtDNA depletion per se causes 
lipoatrophy. The improbability of simple 
linear association between mtDNA 
depletion and development of lipoatrophy 
is further supported by report of up to 17% 
of samples from the lipoatrophic adipose 
tissue from cART-treated patients having 
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normal mtDNA content while, on the 
contrary, some samples from the non-
lipodystrophic cART-treated controls 
have subnormal mtDNA content (352). 
Moreover, if inhibition of mitochondrial 
POLG is proposed to be induced exclusively 
by NRTIs (25,171), and if lipoatrophy is 
caused directly by mtDNA depletion, then 
lipoatrophy would have only been found in 
NRTI-treated patients, which has not been 
the case (362,394). Although the mtDNA 
depletion theory has been challenged in a 
research letter as early as in 2001 (271), no 
study prior to Study IV has had a design 
that would have allowed it to compare the 
preserved SAT of otherwise lipoatrophic 
cART-treated patients to their lipoatrophic 
SAT and, thereby, perhaps to support or 
refute this challenge.
From inherited mitochondrial diseases 
it has been learned that the mitochondrial 
genome exhibits a considerable degree 
of redundancy, so that reductions in 
functional mtDNA to <15% of original are 
often required for diseases to manifest 
(61). Thus, it is also possible that in cART-
associated lipodystrophy there is a certain 
threshold of cellular mtDNA content 
beyond which adipose tissue starts to 
atrophy. Based on the findings of Study IV, 
such a threshold could be suggested to lie at 
~30% of the original mtDNA content. This 
could also explain the different phenotypes 
of dorsocervical and abdominal SAT: 
notwithstanding both depots are affected 
by the loss of mtDNA, the dorsocervical 
SAT simply has not yet reached the 
threshold required for the development of 
visible atrophy. It does not seem possible 
that the ultimate reason for this can be 
determined from mtDNA measurements 
alone. What can be concluded from the 
findings of Study IV, however, is that once 
the lipodystrophy syndrome develops, the 
derangements observed in adipose tissue 
seem to be systemic and not restricted to 
the lipoatrophic regions.
4.5. Mitochondrial function and 
biogenesis
In Study III, expression of selected genes 
involved in mitochondrial function 
and biogenesis were quantified and 
compared between the lipoatrophic 
and the non-lipoatrophic cART-treated 
patients, and within the lipodystrophic 
group between the users of d4T and AZT. 
Gene expression of mtDNA-encoded 
mitochondrial respiratory chain subunit 
COX3 as well as its ratio to that of nDNA-
encoded COX4 (COX3/COX4) was found 
to be significantly lower in cART-treated 
patients with as opposed to those without 
lipoatrophy. This is in keeping with data 
from other investigators reporting a lower 
ratio of expression of mitochondrial to 
nuclear respiratory chain subunit genes in 
cART-treated patients with as compared to 
those without cART-associated lipoatrophy 
(168,291). Furthermore, Study III not only 
confirmed, but also extended the previous 
findings of greater mtDNA depletion 
among the lipoatrophic patients using 
d4T as opposed to those on AZT (59,291), 
by showing decreased COX3 expression 
and low COX3/COX4 ratio to be more 
pronounced among the former than in 
the latter group of patients. Detection of 
decreased expression of POLG1, a key 
enzyme involved in replication of mtDNA, in 
the d4T+LA+ as compared to the AZT+LA+ 
group might offer an explanation for the 
more severe mtDNA depletion consistently 
seen in SAT of the d4T users. Increased 
expression of mitochondrial genes relative 
to the number of mtDNA copies per cell, 
along with increased gene expression of 
PPARG (326) and PGC1B, an activator of 
mitochondrial gene transcription (434), in 
the lipoatrophic as compared to the non-
lipoatrophic cART-treated patients may 
be reflective of an attempt to compensate 
for the mtDNA depletion (Study III). Some 
previous publications agree with this theory 
(126,291), although contradictory data also 
exist (173). Compensatory upregulation of 
transcription of mitochondrial genes could 
serve as an alternative and/or an addition 
to the aforementioned “mtDNA threshold 
theory” in explaining why dorsocervical 
SAT is non-lipoatrophic despite is mtDNA 
depletion. Perhaps dorsocervical SAT 
has sufficient copy numbers of mtDNA in 
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order to support a compensatory effort 
via the upregulation of transcription, 
while the lipoatrophic abdominal SAT is 
so badly depleted of mtDNA that even the 
compensatory mechanisms are no longer 
enough.
Unlike other SAT depots in cART-
associated lipodystrophy, dorsocervical 
SAT has been noted to remain unaffected 
by lipoatrophy, and can even accumulate 
in this region. Prior to Study IV, it 
was unknown how the preserved 
dorsocervical SAT differs from the 
abdominal SAT, both obtained from 
the same HIV-1-infected cART-treated 
lipodystrophic patient. Based on its 
anatomical location, the dorsocervical 
depot has been suggested to represent 
BAT (126,409). Hallmarks of BAT include 
ample mitochondria featuring high 
metabolic activity and high expression 
of UCP1 (37,65,284). Previous studies 
reported significant amounts of UCP1 
mRNA in the “buffalo hump” of patients 
with cART-associated lipodystrophy, but 
not in healthy or lipoatrophic abdominal 
SAT (126,325). In the cited study, 
however, protein levels of UCP1 were 
not quantified. In the dorsocervical SAT 
from the lipodystrophic patients in Study 
IV, increased copy numbers of mtDNA 
(suggestive of BAT) when compared to 
dorsocervical and abdominal SAT from 
the non-lipodystrophic individuals, could 
not be detected. Furthermore, no evidence 
of biologically significant UCP1 mRNA 
expression was found using the same assay 
as previously used to verify the presence 
of UCP1 in BAT in human supraclavicular 
adipose tissue studied by FDG PET (410). 
Finally, no typical BAT morphology was 
seen in the dorsocervical SAT samples, 
even in those from the clinically most 
prominent “buffalo humps”. This is in 
line with a recent study in subjects with 
cART-associated lipodystrophy reporting 
that their dorsocervical SAT lacked BAT 
morphology and was not activated by cold 
exposure like true BAT would (89). Thus, 
the present data support the view that 
dorsocervical SAT in cART-associated 
lipodystrophy is not BAT.
4.6. Adipogenesis
Study III confirms previous data on 
decreased SREBP1C mRNA expression in 
the lipoatrophic as compared to the non-
lipoatrophic SAT in cART-treated patients 
(12,173). Also in line with previous data 
(168), this was found to be equally true for 
both d4T and AZT users. Low expression 
of SREBP1C gene detected is, however, 
discrepant with some (12,286,323), 
although not all (43,44), data on SREBP1C 
protein concentrations in cART-associated 
lipodystrophy/-atrophy. One possible 
explanation for the discrepancy between 
the gene and protein expression data could 
be sequestration of mature SREBP1C 
protein in the endoplasmic reticulum due 
to its retarded degradation by proteasome, 
whereby total cellular SREBP1C 
concentration is high and SREBP1C 
transcription autodownregulated (6,12). 
With regards to expression of other 
adipogenic genes, PPARG was unchanged 
as in some (117), but not all (12,173,241), 
previous studies. Expression of CEBPB 
was significantly lower in lipodystrophic 
as compared to non-lipodystrophic cART-
treated patients. CEBPA followed the same 
trend, although the difference was not 
statistically significant. Downregulation of 
CEBPA and CEBPB was more prominent 
among users of d4T than AZT. These 
findings are in accordance with previous 
reports of decreased expression of CEPBA 
and CEBPB in SAT from patients with 
cART-associated lipoatrophy (12,197).
LMNA and LMNB expression was 
analyzed because it has previously 
been proposed that PI treatment may 
alter LMNA maturation, inhibiting 
translocation of SREBP1C from the 
cytoplasm to the nucleus, and contributing 
to deranged adipogenesis in cART-
associated lipodystrophy/-atrophy (43). 
Study III could not confirm this hypothesis 
as no difference in LMNA expression and 
upregulation in LMNB, an alternatively 
spliced lamin gene, was seen in abdominal 
SAT of lipoatrophic as compared to that of 
non-lipoatrophic cART-treated patients. 
However, the relationship between altered 
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lamin maturation and stability, and 
disrupted SREBP1C translocation through 
nuclear pores has been challenged (199).
4.7. Glucose and lipid metabolism
In Study III, GLUT4 gene expression was 
found to be decreased in cART-treated 
lipoatrophic patients as compared to those 
on cART but without lipoatrophy. This 
was in keeping with our own previous 
findings (173) and with those of others 
(12). Furthermore, the finding is in line 
with data from Studies I, II and IV as 
well as with the generally accepted notion 
(54,122,138) that lipodystrophic cART-
treated patients have higher fasting 
concentrations of insulin, C-peptide and 
HOMA-IR than the non-lipodystrophic 
similarly treated patients. Although not 
necessarily associated with decreased 
gene expression, impaired assembly, 
translocation and transport activity of 
GLUT4 protein have been implicated in 
the pathogenesis of PI-induced insulin 
resistance (15,278,329). 
Concordant with the presence of 
lipoatrophy, FASN, an enzyme involved 
in triglyceride synthesis, was found to be 
significantly lower in abdominal SAT of 
patients with as compared to those without 
cART-associated lipoatrophy. Furthermore, 
expression of FASN was significantly 
positively correlated with that of GLUT4, 
underpinning that both lipogenesis, 
represented by FASN expression, and 
glucose uptake, represented by GLUT4 
expression, share a common nominator such 
as sensitivity/resistance to insulin action. 
Gene and protein expressions of PLIN1 
were also assessed in Study III. PLIN1 is 
a molecule that normally prevents HSL 
phosphorylation and, thereby, excessive 
lipolysis in adipocytes (433). Indeed, 
increased lysosome-mediated proteolysis 
of PLIN1 has been documented to result 
in increased lipolysis in PI-treated 
cultured adipocytes (196). Thus, PLIN1 
is considered as a marker of viable lipid-
storing adipocytes (66). No differences 
were observed in PLIN1 gene expression 
or in the number of PLIN1-free adipocytes 
in the lipoatrophic as compared to the 
non-lipoatrophic SAT from cART-treated 
patients. Lower mRNA concentrations 
of PLIN1, were, however, seen in the 
d4T+LA+ as compared to the AZT+LA+ 
group. This is in line with the suggested 
differences in lipotoxicity between the 
drugs (83,142), although it should be noted 
that the immunohistological analysis did 
not confirm differences of similar degree. 
The contradiction between results of real-
time RT-PCR and immunohistochemistry 
can, perhaps, be attributed to the limited 
study group size, unrepresentative 
sampling or the intrinsic differences in the 
sensitivity of the methods in question.
4.8. Oxidative stress and apoptosis
Upregulation of SOD1 and GPX1, indicators 
of oxidative stress (28,242), evident in 
the lipoatrophic as compared to the non-
lipoatrophic cART-treated group is in 
keeping with reports of increased oxidative 
stress in cell cultures treated with PIs 
(14,200) and NRTIs (45,200), drugs 
inextricably associated with the development 
of lipodystrophy (220). Expression of 
SOD1 and GPX1 tended to be higher in the 
AZT+LA+ group when compared to the 
d4T+LA+ group. This finding may reflect 
the particular propensity of AZT to induce 
production of reactive oxygen species (435).
FAS, a key regulator of apoptosis in response 
to extrinsic stress stimuli, was found to be 
increased in the lipoatrophic as compared to 
the non-lipoatrophic cART-treated patients 
in keeping with previous reports of apoptosis 
in the context of cART-associated lipoatrophy 
both in vitro (42,81,414) and in vivo in 
humans (80,159,251). Expression of p53 did 
not differ between the study groups, which 
is consistent with its predominantly post-
transcriptional stress-induced activation 
(62) and confirmatory of stress-related pro-
apoptotic mRNA alterations such as those 
seen in FAS. 
4.9. Homeobox genes
The microarray data suggested that the 
dorsocervical and the abdominal SAT are 
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largely similar. Using stringent criteria to 
avoid false positive data, out of all genes in 
the genome less than 100 were differentially 
expressed between the two depots. The 
genes differentially expressed in both the 
cART+LD+ and the cART+LD- groups are 
most likely to be genes which are different 
due to the anatomic location of the tissues 
irrespective of lipodystrophy status. The 
number of genes differentially expressed 
in the dorsocervical as compared to the 
abdominal SAT was markedly greater in 
the cART+LD+ than the cART+LD- group. 
Keeping in mind that the dorsocervical SAT 
in the cART+LD+ group was preserved 
and, at least seemingly, unaffected by the 
lipoatrophy present elsewhere in SAT 
(e.g. abdominal region), and that both 
SAT depots in the cART+LD- group were 
equally normal, one could hypothesize that 
the genes found to be discrepant between 
the dorsocervical and abdominal SAT only 
within the cART+LD+ group, would, in fact, 
reflect the abnormality in the abdominal 
lipoatrophic SAT, rather than anything in 
the preserved dorsocervical depot. 
The foremost difference between 
the dorsocervical and the abdominal 
SAT in Study IV was in expression of 
the homeobox genes. The difference 
was observed in both the lipodystrophic 
and the non-lipodystrophic SAT using 
microarray analysis, and was confirmed 
by real-time RT-PCR. Homeobox genes 
are highly conserved genes from the 
evolutionary point of view (347). They 
serve as transcription factors guiding 
cells of the embryonal neural tube to 
migrate to their destined locations, and 
determining the distinctive traits inherit to 
the tissues being formed (347). There are 
4 homeobox gene clusters in mammals, 
HOXA, HOXB, HOXC and HOXD 
(347). Each cluster has several members 
numbered in ascending order starting 
from the anterior boundary of the central 
nervous system (347). Thus, the lower the 
“order number” of a homeobox gene, the 
greater its quantities in dorsocervical as 
compared to abdominal SAT (347). The 
findings of Study IV are in line with this, 
as “rostral” SHOX2 was overexpressed 
in the dorsocervical compared to the 
abdominal SAT. The reverse was true for 
the “caudal” homeobox genes HOXA10, 
HOXC9 and HOXC8. This underscores 
the validity of the present microarray data. 
Depot-specific expression of homeobox 
genes has been previously reported in 
adipose tissue from HIV-1-negative 
subjects (38,75,116,413), and in human 
adipose tissue –derived preadipocytes 
(380) and stromal cells (214). These 
differences were hypothesized to reflect 
the differentiation stages and the different 
adipogenic potential of individual adipose 
tissue depots, as suggested also by work in 
murine models and cell cultures (72). Of 
interest, HOXC4, reported as exclusive for 
BAT (38), was not differentially expressed 
between the two adipose tissue depots in 
the microarray analysis of Study IV. This 
fortifies the premise that dorsocervical 
adipose tissue in cART-associated 
lipodystrophy is not BAT.
5. TREAMENT OF cART-
ASSOCIATED LIPOATROPHY 
WITH URIDINE 
Study V is the first randomized, double-
blind, placebo-controlled trial to evaluate 
uridine supplementation as a potential 
means of preventing adipose tissue loss 
during unchanged concurrent cART. In 
this study, a significant increase in limb 
fat mass was observed after 3 months of 
uridine supplementation in HIV-1-infected 
cART-treated patients with lipoatrophy on 
unchanged cART. The average increase 
in total limb fat with uridine in Study 
V (890 g in 3 months) was greater than 
the increases (an average of 400-500 g 
after 6-12 months) described in switch 
studies (56,163,274,367,381,382). Despite 
these encouraging results, a randomized, 
double-blind, placebo-controlled study 
with 165 subjects that was carried out after 
the completion of Study V reported that 
uridine supplementation failed to have 
a significant and sustained effect with 
regards to increasing limb fat mass (252). 
Of note, the dropout rate in the cited study 
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was 41%, which was mainly attributed to 
the bad taste of uridine supplementation 
or diarrhea associated with its use. Yet 
another recent study has reported that 
uridine supplementation alongside 
concurrent tNRTI-based treatment 
was inferior to a switch from tNRTIs to 
tenofovir in a 48-week follow-up analysis 
with the primary aim of evaluating 
limb fat changes (250). Thus, switching 
away from tNRTIs remains to date the 
best documented treatment for cART-
associated lipoatrophy (56,274,381,382).
Regardless of the significant beneficial 
effects uridine had on body composition, 
it did not change laboratory markers of 
insulin resistance, nor did it change liver fat 
content. This is discordant with data from 
murine models suggesting that uridine 
attenuates NRTI-induced steatohepatitis 
(204). It is widely recognized, however, 
that translation of murine data to humans 
is not always possible. As peripheral 
lipoatrophy in HIV-1-infected cART-
treated patients has been associated 
with insulin resistance (279), one would 
expect the amelioration of lipoatrophy to 
translate to an improvement in insulin 
sensitivity. In Study V, however, despite 
the statistically significant increase in 
limb fat, no change in insulin sensitivity 
was seen. Potential reasons for this 
discrepancy could be insufficient sample 
size and duration of treatment, or too 
small gain in SAT. Of note, the power 
calculations for Study V were done for its 
primary aim, i.e., change in total limb fat, 
by extrapolating the effect size of uridine 
from switch study data on SAT gain after 
cART changes. Prior to Study V, uridine 
had never been used in HIV-1-infected 
cART-treated patients, and switch study 
data had not focused on insulin sensitivity, 
therefore it was not possible to estimate the 
effect size of uridine on insulin sensitivity 
and make accurate power calculations in 
this regards. Alternatively, the untoward 
200 cm3 increase in IAT observed in the 
uridine group after 3 months of uridine 
supplementation therapy could have 
counteracted any beneficial changes in 
insulin sensitivity due to partial resolution 
of lipoatrophic features. This, along with 
the trend for a decrease of HDL cholesterol, 
could, ultimately, have a harmful effect on 
the cardiovascular risk of the patients.
In keeping with the presumed 
mechanism of action, i.e., improvement 
of mitochondrial function, there were a 
statistically significant increases from 
baseline in both venous pH and base excess 
in the uridine group. The changes in acid-
base balance seen with uridine contrast 
with switch studies in which no such 
changes were observed (56,163). It should, 
however, be kept in mind that venous blood 
gas analysis and lactate concentration are 
only surrogate markers of mitochondrial 
function, and no direct measurements of 
mitochondrial function in tissue biopsies 
were performed in Study V.
Theoretically, supplementation with 
uridine could compromise the antiretroviral 
efficacy of pyrimidine NRTIs (i.e., 
tNRTIs) by increasing the concentration 
of intracytoplasmic natural pyrimidine 
triphosphates that compete with tNRTIs 
for the viral reverse transcriptase enzyme. 
However, phenotypic HIV-1-resistance 
assays, animal models and limited human 
data did not indicate that uridine or its 
metabolites interfere with tNRTIs at HIV-1 
reverse transcriptase and, thus, with their 
antiretroviral efficacy (33,182,361). No 
adverse effect of uridine on the antiviral 
activity of tNRTIs was observed in Study V 
as none of the patients with undetectable 
viral load at baseline lost virological 
control.
Limitations of the Study V include 
its small sample size and fairly short 
duration, which were dictated by its nature 
as a pilot study in administering uridine to 
HIV-1-infected cART-treated patients. An 
important inclusion criterion of the present 
study was current use of pyrimidine-based 
NRTIs (d4T or AZT) based on the inability 
of uridine, a precursor of pyrimidine 
nucleotides, to mitigate cellular toxicity 
induced by purine analogue antiretrovirals 
(414,416). Therefore, it must be kept in 
mind that these results cannot be extended 
to patients who are not currently receiving 
tNRTIs. 
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SUMMARY 
The results of Studies I-V can be summarized as follows:
I. Duration of antiretroviral therapy and cumulative exposure to NRTIs and PIs, but not 
lipodystrophy itself or duration and severity of HIV-1 infection, are, independently of 
age and blood pressure, associated with increased arterial stiffness. 
II. Expression of macrophage markers and inflammatory cytokines is increased in 
abdominal SAT of lipodystrophic as compared to non-lipodystrophic cART-treated 
patients. Expression of inflammatory genes is positively correlated with liver fat content.
III. mtDNA is depleted in abdominal SAT of patients with as compared to those without 
cART-associated lipoatrophy. Expression of mtDNA-encoded genes relative to template is 
significantly higher in patients with cART-associated lipoatrophy, perhaps in an attempt 
to compensate for mtDNA loss. Lipoatrophic SAT is inflamed as judged from increased 
numbers of adipose tissue –resident macrophages and expression of proinflammatory 
genes. Expression of adipogenic genes is lower, and that of apoptotic genes, higher in 
abdominal SAT of lipoatrophic as compared to non-lipoatrophic patients. The observed 
changes are more pronounced in patients treated with d4T than with AZT.
IV. Depletion of mtDNA is observed even in the non-lipoatrophic dorsocervical SAT 
of otherwise lipoatrophic individuals. This challenges the prevailing hypothesis that 
mtDNA depletion per se causes lipoatrophy. In lipodystrophic patients, non-lipoatrophic 
dorsocervical SAT is less inflamed than lipoatrophic abdominal SAT. Dorsocervical 
SAT bears no features of BAT. The most marked difference in gene expression between 
dorsocervical and abdominal SAT, irrespective of lipodystrophy status, lies in expression 
of homeobox genes involved in organogenesis and regionalization. 
V. Uridine significantly increases SAT in patients with cART-associated lipoatrophy 
during unchanged tNRTI-based cART. Uridine does not improve features of insulin 
resistance or lead to a decrease in liver fat content, and may have the untoward effect of 
increasing IAT and decreasing HDL cholesterol. Uridine is well-tolerated and does not 
jeopardize the virological control of cART-treated patients. 
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Conclusions
CONCLUSIONS
Despite disparate phenotypes in terms 
of amounts of SAT, several features 
of patients with cART-associated 
lipodystrophy, namely accumulation of 
intra-abdominal and liver fat, adipose 
tissue inflammation, insulin resistance, 
dyslipidemia and arterial stiffness, 
resemble those of HIV-1-negative subjects 
with the metabolic syndrome. The risk of 
myocardial infarction in HIV-1-infected 
cART-treated patients increases with 
cumulative exposure to cART. Most, but 
not all, of the risk increase can be attributed 
to conventional cardiovascular risk factors. 
The augmentation index, a surrogate 
marker of systemic arterial stiffness, 
increases with the cumulative exposure 
to antiretroviral agents, representing an 
additional risk factor that contributes to 
the cardiovascular hazard burden of HIV-
1-infected cART-treated patients. 
Although multiple derangements of 
gene and protein expression have been 
described to characterize cART-associated 
lipodystrophy, the exact pathogenetic 
mechanisms underlying this condition 
remain elusive. Lipoatrophy has been 
hypothesized as being caused by NRTI-
induced depletion of mtDNA. The present 
studies challenge this hypothesis, as 
mtDNA content is significantly decreased 
even in the non-lipoatrophic dorsocervical 
SAT of otherwise lipoatrophic patients as 
compared to the corresponding depot of 
non-lipodystrophic cART-treated patients. 
Instead, the observed disparate expression 
of homeobox genes in dorsocervical 
compared to abdominal SAT may contribute 
to different susceptibility of these adipose 
tissue depots to cART-induced toxicity.
Uridine significantly increases SAT in 
patients with cART-associated lipoatrophy, 
despite concurrent treatment with 
stavudine or zidovudine –containing cART. 
In the present day, with the introduction of 
newer, less toxic antiretroviral agents, use 
of stavudine/zidovudine can be avoided, 
thereby alleviating or even preventing the 
development of lipoatrophy. Therefore, the 
need for uridine or any other lipoatrophy-
targeting treatment has significantly 
decreased.
To conclude, cART-associated 
lipodystrophy is as a complex syndrome 
with multiple metabolic and cardiovascular 
aspects. While its detailed pathophysiology 
remains a mystery, it is of the utmost 
importance to recognize the contribution 
of individual antiretroviral agents to the 
side effects of treatment, avoid the use of 
those causing particular harm, and seek 
for alternative, less toxic agents whenever 
possible. Since cART is life-long, even the 
smallest increment in cardiovascular risk 
is of significance. Therefore, monitoring 
and treatment of conventional modifiable 
risk factors is warranted in HIV-1-infected 
cART-treated patients in order to improve 
their prognosis and quality of life.   
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